Serum free light chain publications

From Wikilite

Chapter 31	SECTION 6 - Appendices
	Serum free light chain publications

1999

Bradwell AR, Drew R, Showell PJ, Carr-Smith HD, Mead GP. Clinical potential of free immunoglobulin light-chain measurements. Clin Chem 1999;45(6):181a
Tang LX, Showell PJ, Mead GP, Carr-Smith HD, Drew R, Bradwell AR. An automated nephelometric immunoassay for quantification of free light-chains in human serum and urine. Clin Chem 1999;45(s6):179a

2000

Bradwell AR, Tang LX, Drayson MT, Drew RL. Immunoassays for detection of free light chains in sera of patients with nonsecretory myeloma. Blood 2000;96(16):4906a
Carr-Smith HD, Edwards J, Showell P, Drew R, Tang LX, Bradwell AR. Preparation of an immunoglobulin free light-chain reference material. Clin Chem 2000;46(6):699a
Harris J, Tang LX, Showell PJ, Carr-Smith HD, Drew R, Bradwell AR. Assays for immunoglobulin free light chains in serum on the Beckman IMMAGE™. Clin Chem 2000;46(6):A180a
Tang LX, Showell P, Carr-Smith HD, Mead GP, Drew R, Bradwell AR. Evaluation of F(ab)2-based latex enhanced nephelometric reagents for free immunoglobulin light-chains on the Behring Nephelometer II. Clin Chem 2000;46(6):705a

2001

Abraham RS, Bergen RH, Naylor S, Katzmann JA, Bradwell AR, Kyle RA, Fonseca R. Characterisation of free immunoglobulin light chains (LC) by mass spectroscopy in light chain-associated (AL) amyloidosis. Blood 2001;98(11):3772a
Abraham RS, Katzmann J, Clark RJ, Lymp JF, Dispenzieri A, Lust JA, Bradwell AR. Light chain myeloma: Correlation of serum nephelometric analysis for the quantitation of immunoglobulin free light chain with urine Bence Jones protein. Clin Chem 2001;47(6):108a
Abraham RS, Katzmann JA, Clark RJ, Dispenzieri A, Lust JA, Bradwell AR, Kyle RA. Detection of serum immunoglobulin free light chains in primary amyloidosis and light chain deposition disease by nephelometry. Clin Chem 2001;47(6):107a
Bradwell AR, Drayson MT, Mead GP. Measurement of free light chains in urine (letter - reply). Clin Chem 2001;47(11):2069-70
Bradwell AR, Smith L, Drayson MT, Mead GP, Carr Smith HD. Serum free light chain measurements for identifying and monitoring patients with nonsecretory myeloma. Clin Chem Lab Med 2001;39:PO-F038a
Bradwell AR, Mead GP, Carr Smith HD, Drayson MT. Detection of Bence Jones myeloma and monitoring of myeloma chemotherapy using serum immunoassays specific for free immunoglobulin light chains. Blood 2001;98:633a
Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, Drew R. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47(4):673-80 PMID: 11274017
Bradwell AR, Carr-Smith HD, Smith L, Mead GP. Detection and monitoring of nonsecretory myeloma using an assay for free light chains in serum. Clin Chem 2001;47(6):142a
Carr-Smith HD, Smith L, Showell P, Mead GP, Drayson MT, Bradwell AR. Detection and monitoring of nonsecretory myeloma using assay for free light chains in serum. Hematol J 2001;1:71a
Carr-Smith HD, Smith L, Showell P, Mead GP, Drayson MT, Bradwell AR. Development of serum free immunoassays for the detection and monitoring of patients with Bence Jones myeloma. Hematol J 2001;1:70a
Clark RJ, Katzmann JA, Abraham RS, Lymp JF, Kyle RA, Bradwell AR. Detection of monoclonal free light chains by nephelometry: Normal ranges and relative sensitivity. Clin Chem 2001;47(6):90a
Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001;97(9):2900-2 PMID: 11313287
Graziani MS, Merlini G. Measurement of free light chains in urine. Clin Chem 2001;47(11):2069-70 PMID: 11673389
Hansson LO, Dijlai-Merzog R, Danielsson O, Bradwell AR. Quantitation of the free light chain kappa and lambda serum, urine and cerebrospinal fluid (CSF) using The Binding Site F(ab)2-based nephelometric method on the IMMAGE® system. Clin Chem 2001;47(6):106a
Katzmann JA, Clarke RJ, Abraham RS, Lymp JF, Carr-Smith HD, Kyle RA, Bradwell AR. Detection of monoclonal free light chains in serum by nephelometry: Normal ranges and relative sensitivity. Presented at Monoclonal Gammopathies and the Kidney 2001;OC1a
Mead GP, Carr-Smith HD, Drayson MT, Hawkins PN, Bradwell AR. Serum free light chain immunoassays as an aid in the diagnosis and monitoring of light chain monoclonal gammopathies. J Bone Miner Metab 2001;19:44a
Smith L, Mead GP, Carr-Smith HD, Drayson MT, Bradwell AR. Development of serum free light chain immunoassays for the detection and monitoring of patients with Bence Jones myeloma. Clin Chem 2001;47(6):141a
Smith L, Mead GP, Carr-Smith HD, Drayson MT, Bradwell AR. Detection and monitoring of Bence Jones myeloma using serum free light chain measurements. Clin Chem Lab Med 2001;39:F039a

2002

Abraham RS, Clark RJ, Bryant SC, Lymp JF, Larson T, Kyle RA, Katzmann JA. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chem 2002;48(4):655-7 PMID: 11901068
Abraham RS, Charlesworth MC, Owen BA, Benson LM, Katzmann JA, Reeder CB, Kyle RA. Trimolecular complexes of lambda light chain dimers in serum of a patient with multiple myeloma. Clin Chem 2002;48(10):1805-11 PMID: 12324506
Bradwell AR, Carr-Smith HD, Mead GP, Drayson MT. Serum free light chain immunoassays and their clinical application. Clin Appl Imm Rev 2002;3:17-33
Bradwell AR, Mead GP, Drayson MT, Carr-Smith HD. Serum immunoglobulin free light chain measurement in intact immunoglobulin myeloma. Blood 2002;100(11):5054a
Bradwell AR, Drayson MT, Mead GP, Galvin G, Gasparetto C. Serum free light chain immunoassay for monitoring patients with light chain producing and nonsecretory myeloma. Blood 2002;100(11):5091a
Bradwell AR, Carr-Smith H, Mead G, Harvey T. Management of patients with light chain myeloma using serum free light chain immunoassays. Clin Chem 2002;48(6):A51a
Carr-Smith HD, Showell P, Bradwell AR. Development and evaluation of turbidimetric reagents for measuring free immunoglobulin light-chains on the Hitachi 911/912. Clin Chem Lab Med 2002;s:43a
Carr-Smith HD, Showell PJ, Matters DJ, Long JM, Bradwell AR. Development and evaluation of nephelometric reagents for measuring free immunoglobulin light-chains on a modified Minineph™ Clin Chem Lab Med 2002;s:44a
Carr-Smith HD, Mead GP, Drayson MT, Hawkins PN, Bradwell AR. Detection and monitoring of light chain monoclonal gammopathies using serum free light chain immunoassays. Clin Chem Lab Med 2002;s:42a
Carr-Smith HD, Showell P, Bradwell AR. Antigen excess assessment of free light chain assays on the Dade-Behring BNII nephelometer. Clin Chem 2002;48(6):23a
Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002;99(12):4276-82 PMID: 12036853
Hermsen D, Bradwell AR, Reinaauer H. Evaluation of an automated nephelometric immunoassay for quantification of free light chains in serum. J Lab Med 2002;26:Q18a
Hofmann W, Guder WG, Bradwell AR, Garbrecht M. Detection of free kappa and lambda light chain in serum and urine in patients with monoclonal gammopathy. Onkologie 2002;25:752a
Hofmann W, Guder WG, Bradwell AR, Garbrecht M. Kappa and lambda light chain in serum and urine in patients with monoclonal gammopathy. J Lab Med 2002;26:19a
Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, Kyle RA. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48(9):1437-44 PMID: 12194920
Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Hawkins PN. Changes in the concentration of circulating free immunoglobulin chains and outcome in systemic AL Amyloidosis. Blood 2002;100(11):5090a
Lachmann HJ, Gallimore R, Gillmore JD, Smith L, Bradwell AR, Hawkins PN. Correlation of changes in nephelometric quantification of serum monoclonal free light chains following chemotherapy and outcome in systemic AL amyloidosis. Clin Chem 2002;48:E46a
Lachmann HJ, Gallimore R, Gillmore JD, Smith L, Bradwell AR, Hawkins PN. Detection of monoclonal free light chains by nephelometry in systemic AL amyloidosis. Clin Chem 2002;48:E45a
Le Bricon T, Bengoufa D, Benlakehal M, Bousquet B, Erlich D. Urinary free light chain analysis by the Freelite immunoassay: a preliminary study in multiple myeloma. Clin Biochem 2002;35(7):565-7 PMID: 12493586
Marien G, Oris E, Bradwell AR, Blanckaert N, Bossuyt X. Detection of monoclonal proteins in sera by capillary zone electrophoresis and free light chain measurements. Clin Chem 2002;48(9):1600-1 PMID: 12194945
Marien G, Bradwell AR, Blanckaert N, Bossuyt X. Detection of monoclonal proteins in sera by capillary zone electrophoresis and free light-chain measurements. Clin Chem 2002;48(6):E52a
Mead GP, Stubbs PD, Carr-Smith HD, Drew R, Drayson MT, Bradwell AR. Nephelometric measurement of serum free light chains in nonsecretory myeloma. Clin Chem 2002;48(s6):70a
Mead GP, Carr-Smith HD, Drayson MT, Bradwell AR. Detection of Bence Jones myeloma and monitoring of myeloma chemotherapy using immunoassays specific for free immunoglobulin light chains. Br J Haematol 2002;117(s1):195a
Showell PJ, Matters DJ, Long JM, Carr-Smith HD, Bradwell AR. Evaluation of latex-enhanced nephelometric reagents for measuring free immunoglobulin light-chains on a modified Minineph™. Clin Chem 2002;48(s6):A67a
Showell PJ, Long JM, Carr-Smith HC, Bradwell AR. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light-chains on the Hitachi 911/912. Clin Chem 2002;48(s6):A66a
Sirohi B, Powles R, Kulkarni S, Carr-Smith HD, Sankpal S, Patel G et al. Serum free light chain assessment in myeloma patients who are in complete remission by immunofixation. Blood 2002;100(11):5095a
Tate JR, Grimmett K, Mead GP, Cobcroft R, Gill D. Free light chain ratios in the serum of myeloma patients in complete remission following autologous peripheral blood stem cell transplantation. Clin Chem 2002;48(s6):E50a

2003

Abraham RS, Katzmann JA, Clark RJ, Bradwell AR, Kyle RA, Gertz MA. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003;119(2):274-8 PMID: 12579999
Alyanakian MA, Abbas A, Delarue R, Arnulf B, Bradwell AR, Aucouturier P. Free immunoglobulin light chains serum levels in the follow-up of patients with monoclonal gammopathies: correlation with the 24H urinary light-chain excretion. Clin Chem 2003;49:D54a
Arneth B, Fischer C, Birklein F, Lackner KJ. The suitability of kappa free light chains in cerebrospinal fluid diagnostics. Clin Chem Lab Med 2003;41(10):P7.85a
Bradwell AR, Mead G, Carr-Smith H, Galvin G, Pratt G. Efficacy of high dose myeloma treatment and response to individual chemotherapy agents in myeloma is indicated by changes in serum free light chain concentrations. Blood 2003;102(11):2547a
Bradwell AR, Carr-Smith HD, Mead GP. Clinical utility of serum free light chain assays. Clin Chem Lab Med 2003;41(Special supplement)
Bradwell AR, Mead GP, Drayson MT, Kyle RA, Katzmann JA. Role of serum free light chain measurements in disease diagnosis and monitoring. Haematologica 2003;4(s1):P7.4a
Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003;361(9356):489-91 PMID: 12583950
Bradwell AR, Galvin GP, Mead GP, Carr-Smith HD. Practical use of serial measurements of serum free light chains to monitor response to treatment of multiple myeloma. Blood 2003;102(11):5234a
Bradwell AR. Clinical applications of serum free light chain immunoassays. Clin Lab Int 2003;November
Carr-Smith HD, Mead GP, Smith L, Drayson MT, Bradwell AR. Serum free light chain levels in patients with intact immunoglobulin myeloma. Br J Haematol 2003;121(s1):198a
Carr-Smith HD, Smith LJ, Bradwell AR. Serum free light chain assay development - specificity, sensitivity, standardisation and protocols. Clin Chem Lab Med 2003;41(Special supplement)
Cohen AD, Zhou P, Xiao Q, Fleisher M, Kalakonda N, Akhurst T et al. An unusual clinicopathologic association: Systemic AL amyloidosis due to non-Hodgkin's lymphoma. Blood 2003;102(11):4838a
Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003;4(6):379-98 PMID: 14671610
Graziani M, Merlini G, Petrini C. Guidelines for the analysis of Bence Jones protein. Clin Chem Lab Med 2003;41(3):338-46 PMID: 12705344
Helmke KH, Oppermann MO, Teuber WT, Michels HM, Ventur YV, Welcker MW, Landenberg PL. Freie immunglobulin-leichtketten im serum bei rheumatischen erkrankungen. Z Rheumatol 2003;62(s1):Fr40a
Hermsen D, Bradwell AR. Nephelometric detection of free kappa and lambda light chains in serum in patients with suspected monoclonal gammopathy. Onkologie 2003;26:697a
Herzog W, Hofmann W. Detection of free kappa and lambda light chains in serum and urine in patients with monoclonal gammopathy. Blood 2003;102(11):5190a
Hoffman U, Opperman M, Kuchler S, Ventur Y, Teuber W, Michels H et al. Free immunoglobulin light chains in patients with rheumatic diseases. Z Rheumatol 2003;62(s1):Fr40a
Hofmann W, Herzog W. Detection of free kappa and lambda light chain in serum and urine in patients with monoclonal gammopathy. Onkologie 2003;26:694a
Hunter HM, Peggs K, Powles R, Apperley J, Mahendra P, Canenagh J et al. A comparison of outcome for patients undergoing non-myeloablative stem cell transplantation compared to conventional conditioning for multiple myeloma. Blood 2003;102(11):2705a
Jaccard A, Moreau P, Aucouturier P, Ronco P, Fermand JP, Hermine O. Amylose immunoglobulinique. Hematologie 2003;9(6):485-95
Katzmann JA, Clark RJ, Rajkumar VS, Kyle RA. Monoclonal free light chains in sera from healthy individuals: FLC MGUS. Clin Chem 2003;49:A74a
Keren DF. Techniques to measure free kappa and free lambda light chains in serum and/or urine. Protein electrophoresis in clinical diagnosis. Arnold (Hodder Headline), 2003
Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, Hawkins PN. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122(1):78-84 PMID: 12823348
Martin W, Clark RJ, Shanafelt T, Katzmann JA, Bradwell AR, Abraham R et al. Detection of serum free light chains in patients with B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Blood 2003;102(11):4827a
Mead GP, Carr-Smith H, Drayson M, Bradwell AR. Serum free light chain concentrations and their use for disease monitoring in multiple myeloma patients with intact immunoglobulin monoclonal proteins. Haematologica 2003;4(s1):170a
Mead GP, Carr-Smith HD, Drayson MT, Bradwell AR. Serum free light chain levels in patients with intact immunoglobulin myeloma. Clin Chem 2003;49:D61a
Mead GP, Carr-Smith HD, Drayson MT, Bradwell AR. Diagnosis and monitoring of multiple myeloma using serum free light chain concentrations. Onkologie 2003;26:695a
Mead GP, Carr-Smith HD, Drayson MT, Bradwell AR. Elevated serum free light chain concentrations in multiple myeloma patients with intact immunoglobulin monoclonal proteins; their use for disease monitoring. Hematol J 2003;4(2):407a
Mead GP, Carr-Smith HD, Drayson MT, Bradwell AR. Serum free light chain assays provide improved monitoring of myeloma therapy. Br J Haematol 2003;121(s1):205a
Mead GP, Drayson MT, Carr-Smith HD, Bradwell AR. Measurement of immunoglobulin free light chains in serum. Clin Chem 2003;49(11):1957-8 PMID: 14578337
Mead GP, Pratt G, Bradwell AR. Frequent measurement of total immunoglobulin and serum free light chains in myeloma patients during peripheral blood stem cell transplantation. Haematologica 2003;4(s1):171a
Myers B, Lachmann H, Russell NH. Novel combination chemotherapy for primary (AL) amyloidosis myeloma: clinical, laboratory and serum amyloid-P protein scan improvement. Br J Haematol 2003;121(5):816-7 PMID: 12780799
Myers B, Russell NH, McMillan AK. Use of a novel combination chemotherapy for AL-Amyloidosis: cyclophosphamide, thalidomide and dexamethasone - serum free light chain (SFLC) and serum amyloid protein P (SAP) scan results. Blood 2003;102(11):5249a
Nowrousian MR, Brandhorst D, Daniels R, Sammet C, Schuett P, Ebeling P et al. Free light-chain measurement in serum compared with immunofixation of urine in patients with multiple myeloma. Blood 2003;102(11):5197a
Nowrousian MR, Brandhorst D, Daniels R, Sammet C, Schuett P, Ebeling P, Seeber S. Comparison between free light chain measurement in serum and immunofixation of urine in patients with multiple myeloma. Onkologie 2003;26(s5):696a
Ong S, Sethi S. Assessment of free light chain assay in serum on the Beckman Immage™. Clin Chem 2003;49(s6):D59a
Overton J, Goodier D, Carr-Smith HD, Bradwell A. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light-chains on the Roche Modular P. Clin Chem 2003;49(s6):D60a
Patten PE, Ahsan G, Kazmi M, Fields PA, Chick GW, Jones RR et al. The early use of the serum free light chain assay in patients with relapsed refractory myeloma receiving treatment with thalidomide analogue (CC-4047). Blood 2003;102(11):1640a
Rajkumar SV, Kyle RA, Therneau TM, Bradwell AR, Melton J, Katzmann JA. Presence of monoclonal free light chains in serum predicts risk of progression in monoclonal gammopathy of undetermined significance (MGUS). Blood 2003;102(11):3481a
Showell P, Matters D, Bradwell AR. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light-chains on the Olympus AU400. Proceedings of ACB National Meeting 2003;13a
Showell PJ, Matters DJ, Long JM, Carr-Smith HD, Bradwell AR. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light-chains on the Olympus AU400. Clin Chem 2003;49(s6):D55a
Sirohi B, Powles R, Kulkarni S, Carr-Smith HD, Patel G, Das M et al. Serum free light chain assessment in myeloma patients who are in complete remission (CR) by immunofixation predicts early relapse. Blood 2003;102(s11):5195a
Smith L, Showell P, Matters D, Carr-Smith HD, Bradwell AR. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light-chains on the Olympus AU400. Clin Chem Lab Med 2003;41(s):W497a
Smith LJ, Long H, Matters DJ, Carr-Smith HD, Bradwell AR. Sample storage and stability for serum free light chain assays. Clin Chem 2003;49(6):D57a
Smith LJ, Long J, Carr-Smith HD, Bradwell AR. Measurement of immunoglobulin free light chains by automated homogeneous immunoassay in serum and plasma samples. Clin Chem 2003;49(s6):D58a
Smith LJ, Mead GP, Bradwell AR. Comparative sensitivity of serum and urine assays for free light chains. Clin Chem Lab Med 2003;41(Special supplement)
Smith LJ, Long J, Matters DJ, Carr-Smith HD, Bradwell AR. Sample storage and stability for free light chain assays. Proceedings of ACB National Meeting 2003;2a
Tate JR, Gill D, Cobcroft R, Hickman PE. Practical considerations for the measurement of free light chains in serum. Clin Chem 2003;49(8):1252-7 PMID: 12881439
Tate JR, Mollee P, Gill D. Measurement of immunoglobulin free light chains in serum: Response. Clin Chem 2003;49(11):1958
Terpos E, Politou M, Szydio R, Nadal E, Avery S, Olavarria E et al. Autologous stem cell transplantation normalises abnormal bone resorption through the reduction of RANK/OPG ratio in multiple myeloma. Blood 2003;102(11):3658a
Wands C, Powell M, Jupp R. The development of serum free light chain immunoassay on Bayer Advia. Proceedings of ACB National Meeting 2003;2:3a

2004

Alyanakian MA, Abbas A, Delarue R, Arnulf B, Aucouturier P. Free immunoglobulin light-chain serum levels in the follow-up of patients with monoclonal gammopathies: correlation with 24-hr urinary light-chain excretion. Am J Hematol 2004;75(4):246-8 PMID: 15054820
Augustson BM, Reid SD, Mead GP, Drayson MT, Child JA, Bradwell AR. Serum free light chain levels in asymptomatic myeloma. Blood 2004;104(11):4880a
Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E et al. Treatment of multiple myeloma. Blood 2004;103(1):20-32 PMID: 12969978
Berard A, Bouabdallah K. Chaines legeres libres: interet pour le diagnostic et le suivi des gammapathies monoclonales. Infos Biologiste Tribune 2004;8:12-3
Bergen HR, Abraham RS, Johnson KL, Bradwell AR, Naylor S. Characterization of amyloidogenic immunoglobulin light chains directly from serum by on-line immunoaffinity isolation. Biomed Chromatogr 2004;18(3):191-201 PMID: 15103706
Bird JM, Cavenagh J, Samson D, Mehta A, Hawkins P, Lachmann H. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol 2004;125(6):681-700 PMID: 15180858
Bouabdallah K. Interet des chaines legeres libres dans la prise en charge des patients atteints de myelome. Biologiste infos 2004;8:12-3
Bradwell AR, Garbincius J, Holmes EW. Serum free kappa to free lambda ratios as an adjunct to serum protein electrophoresis for the detection of monoclonal proteins in the serum. Blood 2004;104(11):4856a
Carr-Smith HD, Harland B, Anderson J, Overton J, Wieringa G, Bradwell AR. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light chains on the Bayer Advia 1650. Clin Chem 2004;50(6):C44a
Carr-Smith HD, Harland B, Anderson J, Overton J, Wieringa G, Bradwell AR. The effect on laboratory organisation of introducing serum free light chain assays. Clin Chem 2004;50(6):A76a
Chou PP, Praither JD, Grainger A, Knight R. Serum free light chain assays. Clin Chem 2004;50:C24a
Cohen AD, Zhou P, Xiao Q, Fleisher M, Kalakonda N, Akhurst T et al. Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association. Br J Haematol 2004;124(3):309-14 PMID: 14717777
Cohen AD, Zhou P, Reich L, Quinn A, Fircanis S, Drake L et al. Risk-adapted intravenous melphalan followed by adjuvant dexamethazone (D) and Thalidomide (T) for newly diagnosed patients with systemic AL amyloidosis (AL): Interim results of a phase II study. Blood 2004;104(11):542a
Dispenzieri A, Gertz MA, Kyle RA. To the editor: Determining appropriate treatment options for patients with primary systemic amyloidosis. Blood 2004;104(9):2992-3
Engelhardt M, Rapple D, Weis A, Bisse E, Thorst G. Serum free light chain (FLC) measurement in multiple myeloma (MM) patients (pts) correlate with known monoclonal paraprotein, disease stage and therapy response. Blood 2004;104(11):4907a
Fischer C, Arneth B, Koehler J, Lotz J, Lackner KJ. Kappa free light chains in cerebrospinal fluid as markers of intrathecal immunoglobulin synthesis. Clin Chem 2004;50(10):1809-13 PMID: 15271859
Fischer CB, Arneth B, Koehler J, Lackner K. The suitability of kappa free light chains in cerebrospinal fluid diagnostics. Clin Chem 2004;50(6):B47a
Gertz M, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN et al. Definition of organ involvement and treatment response in primary systemic amyloidosis (AL): A consensus opinion from the 10th International Symposium on amyloid and amyloidosis. Blood 2004;104(11):754a
Gertz MA, Lacy MQ, Dispenzieri A. Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Rev 2004;18(1):17-37 PMID: 14684147
Gertz MA. Freelite immunoglobulin free light chain assay diagnostic: Serum test enables identification and monitoring of MM. Myeloma Today 2004;6(2):5-6
Gertz MA, Merlini G, Treon SP. Amyloidosis and Waldenstrom's macroglobulinemia. Hematology Am Soc Hematol Educ Program 2004;257-82 PMID: 15561687
Goodman HJB, Lachmann HJ, Bradwell AR, Hawkins PN. Intermediate dose intravenous melphalan and dexamethasone treatment in 144 patients with systemic AL amyloidosis. Blood 2004;104(11):755a
Grateau G, Kyle RA, Skinner M. Amyloid and amyloidosis. CRC Press, 2004
Guis L, Diemert MC, Ghillani P, Choquet S, Leblond V, Vernant JP, Musset L. The quantitation of serum free light chains: Three case reports. Clin Chem 2004;50(6):F38a
Hermsen D, Herzog W. Nephelometric detection of serum free kappa and lambda light chains in patients with suspected monoclonal free light chain gammopathies. Clin Chem 2004;50(6):C19a
Herzum I, Heinz R, Bruder-Burzlaff B, Renz H, Wahl HG. Reliability of the new Freelite assay for quantification of free light chains in urine. Clin Chem 2004;50(6):C36a
Hofmann W, Garbrecht M, Bradwell AR, Guder WG. A new concept for detection of Bence Jones proteinuria in patients with monoclonal gammopathy. Clin Lab 2004;50(3-4):181-5 PMID: 15074473
Katzmann JA, Dispenzieri A, Abraham R, Kyle R. Performance of free light chain assays in clinical practice. Blood 2004;104(11):757a
Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351(18):1860-73 PMID: 15509819
Mead GP, Reid SD, Augustson BM, Drayson MT, Bradwell AR, Child JA. Correlation of serum free light chains and bone marrow plasma cell infiltration in multiple myeloma. Blood 2004;104(11):4865a
Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004;126(3):348-54 PMID: 15257706
Mead GP, Carr-Smith HD, Galvin G, Pratt G, Bradwell AR. Efficacy of high dose treatment and response to individual chemotherapy agents in myeloma is indicated by changes in serum free light chain concentrations. Clin Chem 2004;50(6):C20a
Mead GP, Bradwell AR, Lovell R, Pratt G. Changes in serum free light chain concentrations after high-dose melphalan and autologous stem cell transplant in myeloma patients. Bone Marrow Transplant 2004;33(s1):380a
Merlini G, Palladini G, Bosoni T, Lavatelli F, Melzi d'Eril G, Bradwell AR, Moratti R. Circulating free light chain concentration correlates with degree of cardiac dysfunction in AL amyloidosis. Clin Chem 2004;50(s6):B113a
Merlini G. Editorial: Sharpening therapeutic strategy in AL amyloidosis. Blood 2004;104(6):1593-4
Nakano T, Nagata A, Takahashi H. Ratio of urinary free immunoglobulin light chain kappa to lambda in the diagnosis of Bence Jones proteinuria. Clin Chem Lab Med 2004;42(4):429-34 PMID: 15147154
Palladini G, Perlini S, Vezzoli M, Perfetti V, Lavatelli F, Ferrero I et al. The reduction of the serum concentration of the amyloidogenic light-chain in cardiac AL results in prompt improvement of myocardial function and prolonged survival despite unaltered amount of myocardial amyloid deposits. In: Grateau G, Kyle RA, Skinner M, eds. Amyloid and Amyloidosis. CRC Press, 2004:73-5
Pratt G, Mead G, Lovell R, Bradwell AR. Changes in serum-free light chain concentrations as a marker of disease response in myeloma patients after autologous stem cell transplantation. Br J Haematol 2004;125(s1):94a
Rajkumar SV, Kyle RA, Therneau TM, Melton LJI, Bradwell AR, Clark RJ et al. Presence of an abnormal serum free light ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS). Blood 2004;104(11):3647a
Rajkumar SV, Kyle RA, Therneau TM, Clark RJ, Bradwell AR, Melton LJ, III et al. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance. Br J Haematol 2004;127(3):308-10 PMID: 15491291
Räpple D, Weis A, Deschler B, Bisse E, Ihorst G, Englehardt M. Lambda (λ)- and kappa (κ)- free light chains in multiple myeloma (MM) patients correlate with known monoclonal paraprotein, disease stage and therapy response. Onkologie 2004;27(s3):771a
Reid SD, Mead GP, Drayson MT, Bradwell AR. Comparison of immunofixation electrophoresis with serum free light chain measurement for determining complete remission in light chain multiple myeloma. Bone Marrow Transplant 2004;33(s1):632a
Reid SD, Drayson MT, Mead GP, Augustson B, Bradwell AR. Serum free light chains are a more sensitive marker of serological remission in multiple myeloma patients. Clin Chem 2004;50(s6):C34a
Sanchorawala V, Wright DG, Magnani B, Skinner M, Seldin DC. Serum free light chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) Amyloidosis. Blood 2004;104(11):942a
Sanchorawala V, Seldin DC, Wright DG, Skinner M, Finn KT, Falk RH. Pulsed low dose intravenous melphalan in patients with AL amyloidosis, ineligible for aggressive treatment with high-dose melphalan and stem cell transplantation. Blood 2004;104(11):2393a
Showell PJ, Lynch EA, Carr-Smith H, Bradwell AR. Evaluation of latex-enhanced nephelometric reagents for measuring free immunoglobulin light-chains on the Radim Delta. Clin Chem 2004;50(s6):C40a
Sirohi B, Powles R, Kulkarni S, Carr Smith HD, Patel G, Das M et al. Serum free light chain ratio is predictive of early relapse in patients who are in complete remission by immunofixation. Bone Marrow Transplant 2004;33(s1):649a
Soutar R, Lucraft H, Jackson G, Reece A, Bird J, Low E, Samson D. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol 2004;124(6):717-26 PMID: 15009059
Tate JR, Mollee P, Gill D. Serum free light chain ratios do not detect relapse in some patients with intact immunoglobulin myeloma post autologous peripheral blood stem cell transplantation. Clin Chem 2004;50:B54a
Thompson EJ. Editorial: Quality versus quantity: Which is better for cerebrospinal fluid IgG? Clin Chem 2004;50:1721-2
Urban S, Oppermann M, Reucher SW, Schmolke M, Hoffmann U, Hiefinger-Schindlbeck R, Helmke KH. Free light chains (FLC) of immunoglobulins as parameter resembling disease activity in autoimmune rheumatic diseases. Ann Rheum Dis 2004;63(s1):141a

2005

Abdalla S. The use of serum free light chain assay in clinical practice. Haematologica 2005;90(s1):PO405a
Abdalla S, Goodman HJB, Hawkins PN. Thalidomide alone and in combination with other agents in the treatment of patients with AL amyloidosis. Haematologica 2005;90(s1):PO1411a
Ahsan G, Streetly M, Fields PA, Bradwell AR, Schey SA, Kazmi M. The thalidomide analogue (Actimid) induces T-cell activation at day 28 in patients with relapsed refractory myeloma but does not correlate with improved outcome. Blood 2005;106:3473a
Akar H, Seldin DC, Magnani B, O'Hara C, Berk JL, Schoonmaker C et al. Quantitative serum free light-chain assay in the diagnostic evaluation of AL amyloidosis. In: Grateau G, Kyle RA, Skinner M, eds. Amyloid and Amyloidosis. CRC Press, 2005
Akar H, Seldin DC, Magnani B, O'Hara C, Berk JL, Schoonmaker C et al. Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis. Amyloid 2005;12(4):210-5 PMID: 16399645
Augustson BM, Katsavara H, Reid SD, Mead GP, Shirfield M, Bradwell AR. Monoclonal gammopathy screening: Improved sensitivity using the serum free light chain assay. Haematologica 2005;90(s1):PO1302a
Augustson BM, Reid SD, Mead GP, Drayson MT, Child JA, Bradwell AR. Serum free light chain levels in asymptomatic myeloma. Haematologica 2005;90(s1):PO1303a
Augustson BM, Reid SD, Cohen D, Hawkins K, Mead G, Drayson M et al. Normalisation of serum free light chains and negative immunofixation electrophoresis may be predictive of progression free survival and overall survival following high dose melphalan. Haematologica 2005;90(s1):PO403a
Bakshi NA, Gulbranson R, Garstka D, Bradwell AR, Keren DF. Serum free light chain (FLC) measurement can aid capillary zone electrophoresis in detecting subtle FLC-producing M proteins. Am J Clin Pathol 2005;124(2):214-8 PMID: 16040291
Beetham R, Howie N, Soutar R. Can opportunistic case-finding of paraproteins be clinically justified? Ann Clin Biochem 2005;42(Pt 4):245-53 PMID: 15989724
Berard A. Quelques notions de rappel sur le myelome? Biologists Infos 2005;15:1-3
Bergon E, Miravalles E, Miranda I, Bergon M. The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma. Clin Chem Lab Med 2005;43(1):32-7 PMID: 15653439
Bradwell AR. Serum free light chain measurements move to center stage. Clin Chem 2005;51(5):805-7 PMID: 15855664
Bradwell AR, Evans ND, Chappell MJ, Cockwell P, Reid SD, Harrison J et al. Rapid removal of free light chains from serum by hemodialysis for patients with myeloma kidney. Blood 2005;106(11):3482a
Bradwell AR, Mead GP, Chappell MJ, Evans ND. Model for assessing free light chain kinetics when monitoring patients with multiple myeloma. Haematologica 2005;90(s1):PO411a
Brockhurst I, Harris KP, Chapman CS. Diagnosis and monitoring a case of light-chain deposition disease in the kidney using a new, sensitive immunoassay. Nephrol Dial Transplant 2005;20(6):1251-3 PMID: 15784642
Carr-Smith HD, Abraham R, Mead GP, Goodman HJ, Hawkins PN, Bradwell AR. Measurement of serum free light chains in AL amyloidosis. In: Grateau G, ed. Amyloid and Amyloidosis. CRC Press, 2005:154-6
Carr-Smith HD, Mead GP, Bradwell AR. Serum free light chain assays as a replacement for urine electrophoresis. Haematologica 2005;90(1):PO404a
Cavallo F, Rasmussen E, Zangari M, Tricot G, Fender B, Fox M et al. Serum free-lite chain (sFLC) assay in Multiple Myeloma (MM): Clinical correlates and prognostic implications in newly diagnosed MM patients treated with Total Therapy 2 or 3 (TT2/3). Blood 2005;106(11):3490a
Chapuis-Cellier C, Foray V, Chazaud A, Troncy J. Contribution of the quantification of free light chains in 273 patients presenting with a newly discovered monoclonal gammopathy. Haematologica 2005;90(s1):PO408a
Chapuis-Cellier C, Foray V, Chazaud A, Troncy J. Apparent discrepancies in the quantitation of free light chains in serum of patients presenting with a monoclonal gammopathy. Haematologica 2005;90(s1):PO409a
Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 2005;143(11):777-84 PMID: 16330788
Cohen AD, Zhou P, Reich L, Ford A, Hedvat C, Teruya-Feldstein J et al. Interim analysis of a Phase II study of risk-adapted intravenous melphalan followed by adjuvant dexamethasone (D) and thalidomide (T) for newly diagnosed patients with systemic AL Amyloidosis (AL). Haematologica 2005;90(s1):PO1407a
Comenzo RL, Zhou P, Wang L, Nimer SD, Olshen AB. Plasma cell gene-expression profiles in patients with systemic AL amyloidosis: Responses to melphalan and stem cell transplant are associated with differential expression of genes involved in translation, protein degradation and detoxification. Blood 2005;106:3405a
Comenzo RL, Zhou P, Reich L, Costello S, Quinn A, Fircanis S et al. Prospective evaluation of the utility of the serum free light chain assay (FLC), Clonal Ig VLR gene identification and troponin 1 levels in a phase II trial of risk-adapted intravenous melphalan with adjuvant Thalidomide and Dexamethasone for newly diagnosed untreated patients with systemic AL amyloidosis. In: Grateau G, Kyle RA, Skinner M, eds. Amyloid and Amyloidosis. CRC Press, 2005:167-9
Comenzo RL. Light chains ahoy: Pirating Thal/Dex for AL too. Blood 2005;105(7):2625
Comenzo RL, Zhou P, Reich L, Costello S, Quinn A, Fircanis S et al. Risk-adapted intravenous melphalan with adjuvant Thalidomide and Dexamethasone for newly diagnosed untreated patients with systemic AL amyloidosis: interim report of a phase II trial. In: Grateau G, Kyle RA, Skinner M, eds. Amyloid and Amyloidosis. CRC Press, 2005:112-5
Das M, Mead GP, Sreekanth V, Anderson J, Blair S, Howe T et al. Serum free light chain (sFLC) concentration kinetics in patients receiving Bortezomib: Temporary inhibition of protein synthesis and early biomarker for disease response. Blood 2005;106(11):5094a
Dellerba MP, James M, Butler SJ, Kelsey PR. Serum free light chain measurement in patients with multiple myeloma and Amyloidosis AL. Clin Chim Acta 2005;355(s1):MP4.35a
Desplat-Jego S, Feuillet L, Pelletier J, Bernard D, Cherif AA, Boucraut J. Quantification of immunoglobulin free light chains in cerebrospinal fluid by nephelometry. J Clin Immunol 2005;25(4):338-45 PMID: 16133990
Dingli D, Kyle RA, Rajkumar VS, Nowakowski GS, Larson DR, Bida JP et al. Immunoglobulin free light chains at diagnosis: Predictors of progression and survival in solitary plasmacytoma of bone. Blood 2005;106(11):5080a
Dispenzieri A, Lacy MQ, Zeldenrust SR, Geyer SM, Lust JA, Hayman SR et al. Lenalidomide has activity in a Phase II trial in patients with primary systemic amyloidosis. Blood 2005;106(11):252a
Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR et al. Absolute values of serum immunoglobulin free light chains predict for survival in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplant. Blood 2005;106(11):422a
Foray V, Chapuis-Cellier C. Contribution of serum free light chain immunoassays in diagnosis and monitoring of free light chain monoclonal gammopathies. Immuno-analyse et Biologie Specialisee 2005;20:385-93
Forsyth JM, Hill PG, Rai BS, Mayne S, Mead GP. Serum free light chain measurement can replace urine electrophoresis in the detection of B cell proliferative disorders. Blood 2005;106(11):5081a
Forsyth JM, Hill PG, Rai BS, Mayne S, Mead GP. Serum free light chains in screening for B cell proliferative disorders. Clin Chim Acta 2005;355(s1):WP18.30a
Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Ansell SM et al. Role of second stem cell transplant in patients with amyloidosis who are refractory or relapsing. Blood 2005;106(11):5469a
Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79(4):319-28 PMID: 16044444
Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN et al. Definition of organ involvement and treatment response in primary systemic amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Haematologica 2005;90(s1):PO1405a
Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR. Amyloidosis: diagnosis and management. Clin Lymphoma Myeloma 2005;6(3):208-19 PMID: 16354326
Giarin MM, Di Bello C, Battaglio S, Falco P, Giaccone L, Boccadoro M. Serum free light chains: a new tool for diagnosis and management of multiple myeloma. Haematologica 2005;90(s3):P235a
Gillmore JD, Wechalekar AD, Goodman HJB, Lachmann HJ, Offer M, Joshi J, Hawkins PN. Cardiac followed by autologous stem cell transplantation for systemic AL Amyloidosis. Blood 2005;106(11):1158a
Goodman HJ, Bridoux F, Lachmann HJ, Gilbertson JA, Gallimore R, Joshi J et al. Localised amyloidosis: Clinical features and outcomes in 235 cases. Haematologica 2005;90(s1):PO1413a
Goodman HJB, Wechalekar AD, Lachmann HJ, Bradwell AR, Hawkins PN. Clonal disease response and clinical outcome in 229 patients with AL amyloidosis treated with VAD-like chemotherapy. Haematologica 2005;90(s1):PO1408a
Gupta S, Comenzo RL, Hoffman BR, Fleisher M. National Academy of Clinical Biochemistry guidelines for the use of tumor markers in monoclonal gammopathies. Online publication [2005;http://www.aacc.org/sitecollectiondocuments/nacb/lmpg/tumor/chp3k_gammopathies.pdf]
Hammer F, Rolinski B, Scherberich JE. Impact of chronic renal failure on serum concentrations of free polyclonal immunoglobulin light chains. Nephro-News, Proceedings of Congress of Nephrology 2005;(September):5a
Hassoun H, Reich L, Klimek VM, Dhodapkar M, Cohen A, Kewalramani T et al. The serum free light chain ratio after one or two cycles of treatment is highly predictive of the magnitude of final response in patients undergoing initial treatment for Multiple Myeloma. Blood 2005;106(11):972a
Hazenberg BPC, Bijzet J, de Wit H, van Steijn J, Vellenga E, van Rijswijk MH. Diagnostic value of free kappa and lambda light chains in fat tissue of patients with systemic AL Amyloidosis. In: Grateau G, Kyle RA, Skinner M, eds. Amyloid and Amyloidosis. CRC Press, 2005:107-8
Henon KT, Dispenzieri A, Katzmann JA, Lacy MQ, Ramirez-Alvarado M, Gertz MA et al. Circulating soluble light chain oligomers in sera of patients with light chain amyloidosis. Haematologica 2005;90(s1):PO1406a
Herzog W, Mead GP, Reid SD, Hewins P, Cockwell P, Bradwell AR. The effect of renal impairment and dialysis on serum free light chain measurement. Nephro-News, Proceedings of Congress of Nephrology 2005;(September):P8.03a
Herzog W, Mead GP, Drayson MT, Bradwell AR. Serum free light chain immunoassays in the diagnosis of monoclonal gammopathies. Nephro-News, Proceedings of Congress of Nephrology 2005;(September):P12.04a
Hill PG, Forsyth JM, Mayne S, Mead GP. Comparison of serum free light chain measurement and urine electrophoresis for detection of B cell proliferative disorders. Haematologica 2005;90(s1):PO406a
Hill PG, Forsyth JM, Rai BS, Mayne S, Mead GP. Serum free light chain measurement can replace urine electrophoresis for detecting B cell proliferative disorders. Clin Chem 2005;51(6):B6a
Ihenetu KU, Abudu N, Miller J, Elin RJ. Free light chain assay shows greater clinical sensitivity than electrophoresis for detecting plasma cell dyscrasias. Clin Chem 2005;51(6):B157a
Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129(6):776-83 PMID: 15953004
Kang SY, Suh JT, Lee HJ, Yoon HJ, Lee WI. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma. Ann Hematol 2005;84(9):588-93 PMID: 15883850
Katsavara H, Reid SD, Augustson BM, Mead GP, Shirfield M, Drayson MT et al. Screening for monoclonal gammopathy: Improved sensitivity using serum free light chain assays. Clin Chim Acta 2005;355:TP4.06a
Katzmann JA, Dispenzieri A, Abraham RS, Lust JA, Kyle RA. Diagnostic Performance of Free Light Chain Assays in Clinical Practice. Clin Chem 2005;51(6):D16a
Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 2005;51(5):878-81 PMID: 15774572
Katzmann JA. Quantitative free light chain assays for the diagnosis and monitoring of monoclonal gammopathies. J Ligand Chem 2005;27(4):246-55
Keren DF. Serum protein electrophoresis evaluation of monoclonal gammopathies (M-proteins). J Ligand Chem 2005;27(4):218-26
Kumar S, Gertz MA, Hayman SR, Lacy MQ, Dispenzieri A, Zeldenrust SR et al. Use of the serum free light chain assay in assessment of response to therapy in multiple myeloma: Validation of recently proposed response criteria in a prospective clinical trial of lenalidomide plus dexamethasone for newly diagnosed multiple myeloma. Blood 2005;106(11):3479a
Kühnemund A, Liebisch P, Bauchmüller K, Haas P, Kleber M, Bisse E et al. Secondary light chain multiple myeloma with decreasing IgA paraprotein levels correlating with renal insufficiency and progressive disease: Clinical course of two patients and review of the literature. Onkologie 2005;28(s3)
Kyrtsonis MC, Sachanas S, Vassilakopoulos TP, Kafassi N, Tzenou T, Papadogiannis A et al. Bortezomib in patients with relapsed-refractory multiple myeloma (MM). Clinical observations. Blood 2005;106(11):5193a
Leleu X, Moreau AS, Coiteux V, Guieze R, Hennache B, Facon T et al. Serum free light chain assays in solitary bone plasmacytoma. Clin Chim Acta 2005;355:TP4.02a
Leleu X, Moreau AS, Coiteux V, Guieze R, Hennache B, Facon T et al. Serum free light chain assays in solitary bone plasmacytoma. Br J Haematol 2005;129(s1):186a
Leleu X, Moreau AS, Hennache B, Dupire S, Faucompret JL, Facon T et al. Serum free light chain immunoassays measurement for monitoring solitary bone plasmacytoma. Haematologica 2005;90(s1):PO410a
Lorenz EC, Gertz MA, Fervenza FC, Leung N. Long-term renal outcome of autologous stem cell transplantation in light chain deposition disease. Blood 2005;106(11):5518a
Matsuda M, Yamada T, Gono T, Shimojima Y, Ishii W, Fushimi T et al. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis. Intern Med 2005;44(5):428-33 PMID: 15942088
Mead GP, Reid SD, Cockwell P, Hewins P, Bradwell AR. The effect of renal impairment and dialysis on serum free light chain measurement. Haematologica 2005;90(s2):PO237a
Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child AJ. Response to: Serum free light chains for monitoring multiple myeloma. Br J Haematol 2005;128:406-7
Mead GP, Reid S, Augustson B, Drayson MT, Bradwell AR, Child JA. Comparison of serum and urine free light chain measurements with bone marrow assessments in multiple myeloma. Haematologica 2005;90(s1):PO407a
Merkel S, Peest D, Witte T, Haller H, Schwarz A. Rekurrenz einer Leichtkettennephropathie im Transplantat - Therapiemöglichkeiten. Nephro-News, Proceedings of Congress of Nephrology 2005;(September):P3.08a
Mollee P, Tate J, Dimeski G, Gill D. Falsely low serum free light chain concentration in patients with monoclonal light chain diseases. Blood 2005;106(11):5077a
Mösbauer U, Schieder H, Renges H, Ayuk F, Zander A, Kroger N. Serum free light chain [FLC] assay in multiple myeloma patients who achieved negative immunofixation after allogeneic stem cell transplantation. Blood 2005;106(11):2023a
Munshi NC. Editorial: Determining the undetermined. Blood 2005;106(3):767-8
Myers B. To the editor: Cardiac amyloidosis. Clin Med 2005;5(6):661-2 PMID: 16411369
Nowrousian MR, Brandhorst D, Sammet C, Kellert M, Daniels R, Schuett P et al. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res 2005;11(24 Pt 1):8706-14 PMID: 16361557
Nowrousian MR, Brandhorst D, Sammet C, Kellert M, Daniels R, Schuett P et al. Relationship between serum concentrations and urinary excretions of monoclonal free light chains (mFLC) detectable as Bence Jones proteins (BJP) by immunofixation electrophoresis (IFE) in patients with multiple myeloma (MM). Blood 2005;106(11):5060a
Offer M, Wechalekar AD, Goodman HJB, Gillmore JD, Lachmann HJ, Bradwell AR, Hawkins PN. Standard oral melphalan chemotherapy for AL amyloidosis revisited using the serum free light chain assay. Blood 2005;106(11):3495a
Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005;105(7):2949-51 PMID: 15572585
Peterson MR, Sumabat F, Nesbet L, Mullaney S, Smith D, Herold DA. Analysis of serum immunoglobulin free light chains in chronic hemodialysis patients. Am J Clin Path 2005;124(s):23a
Pietrantuono A. Que sont les tests Freelite™. Bulletin des Syndicat National des Biologistes des Hopitaux 2005;11(2)
Pratt G, Mead G, Bradwell A. Changes in serum free light chain concentrations as a marker of chemosensitivity after high-dose melphalan and autologous stem cell transplant in myeloma patients. Haematologica 2005;90(s1):PO413a
Rajkumar SV. MGUS and smoldering multiple myeloma: Update on pathogenesis, natural history and management. Hematology Am Soc Hematol Educ Program 2005;340-5 PMID: 16304401
Rajkumar SV, Kyle RA, Therneau TM, Melton JL, Bradwell AR, Clark RJ et al. Abnormal serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS). Haematologica 2005;90(s1):PO1301a
Rajkumar SV, Kyle RA, Therneau TM, Melton LJ, III, Bradwell AR, Clark RJ et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005;106(3):812-7 PMID: 15855274
Rajkumar SV, Kyle RA. Conventional therapy and approach to management. Best Pract Res Clin Haematol 2005;18(4):585-601 PMID: 16026739
Ramasamy I. Free immunoglobulin light chain serum levels in B cell dyscrasias. Clin Chem 2005;51(s6):B122a
Reid SD, Cockwell P, Hewins P, Millard JL, Mead GP, Bradwell AR. Haemodialysis removes free light chains from serum. Clin Chem 2005;51(6):D12a
Reid SD, Leleu X, Moreau AS, Coiteux V, Guieze R, Hennache B et al. Serum free light chain assays in solitary bone plasmacytoma. Clin Chem 2005;51(s6):D13a
Reid SD, Cockwell P, Hewins P, Mead GP, Bradwell AR. Efficient removal of serum free light chains by haemodialysis. Haematologica 2005;90(s1):PO512a
Reid SD, Augustson BM, Katsavara H, Mead GP, Shirfield M, Drayson MT et al. Screening for monoclonal gammopathy: Improved sensitivity using serum free light chain assays. Br J Haematol 2005;129(s1):81a
Reid SD, Augustson BM, Katsavara H, Drayson MT, Mead GP, Shirfield M et al. Monoclonal gammopathy screening: Improved sensitivity using serum free light chain assays. Clin Chem 2005;51(6):B20a
Reid SD, Hewins P, Cockwell P, Millard JL, Mead GP, Bradwell AR. Haemodialysis removes free light chains from serum. Clin Chim Acta 2005;355:MP10.5a
Romeril KR, White G, Ritchie D. Thalidomide therapy in relapsed/refractory light chain myeloma. Haematologica 2005;90(s1):PO708a
Sanchorawala V, Seldin DC, Magnani B, Skinner M, Wright DG. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant 2005;36(7):597-600 PMID: 16044137
Sanchorawala V, Wright DG, Quillen K, Fisher C, Skinner M, Sedlin DC. Early serum free light chain responses following high-dose melphalan and stem cell transplantation for AL Amyloidosis predict treatment outcomes. Blood 2005;106(s11):1160a
Scudla V, Minarik J, Schneider M, Kouril M, Kapsustova M, Vytrasova M et al. Význam sérových hladin volnýh lehkých retezcu imunoglobulinu v diagnostice a hodnocení aktivity mnohocetného myelomu a vybraných monoklonálních gamapatií. Vnitr Lék 2005;51(11):1249-59
Shimojima Y, Matsuda M, Gono T, Ishii W, Fushimi T, Hoshii Y et al. Correlation between serum levels of free light chain and phenotype of plasma cells in bone marrow in primary AL amyloidosis. Amyloid 2005;12(1):33-40 PMID: 16076609
Showell PJ, Lynch EA, Overton J, Carr-Smith HD, Bradwell AR. Evaluation of latex-enhanced nephelometric reagents for measuring free immunoglobulin light chains on the Dade Behring ProSpec. Clin Chem 2005;51(s6):B38a
Smith DE, Bradwell AR, Mead GP, Carr-Smith HD. Serum free light chain assay in diagnosis and monitoring of multiple myeloma. Warde Report 2005;16(1)
Smith DE, Abadie J, Bankson D, Mead G. Assessment of serum free light chain assay for screening for plasma cell disorders. Blood 2005;106(s11):2563a
Szarka C. Serum free light chain ratio predicts outcome in MGUS. Clin Lab Int 2005;December
Tanenbaum ND, Howell DN, Middleton JP, Spurney RF. Lambda light chain deposition disease in a renal allograft. Transplant Proc 2005;37(10):4289-92 PMID: 16387099
Tate J, Mollee P, Gill D. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2005;128(3):405-6 PMID: 15667546
Tate JR, Mollee P, Dimeski G, Gill D. Falsely low serum free light chain concentrations in patients with monoclonal light chain diseases. Clin Chem 2005;51(s6):B31a
Tate JR, Mollee P, Gill D. Utility of serum free light chains for monitoring myeloma post autologous stem cell transplantation. Haematologica 2005;90(s1):PO412a
van Steijn J, Bijzet J, de Wit H, Hazenberg BPC, van Gameren II, van de Belt K, Vellenga E. Serum levels of free kappa and lambda light chains in patients with systemic AL, AA and ATTR Amyloidosis. In: Grateau G, Kyle RA, Skinner M, eds. Amyloid and Amyloidosis. CRC Press, 2005:105-6
Walker R, Rasmussen E, Cavallo F, Jones-Jackson L, Anaissie E, Alpe T et al. Correlation of suppression of FDG PET uptake with serum free light chain levels - both FDG PET-CT and serum clonal free light chain response precede and predict the likelihood of subsequent complete remission in newly diagnosed multiple myeloma. Blood 2005;106(s11):3493a
Walker SA, Roddie PH, Ashby JP. Evaluation of serum free light chain (FLC) measurements as an alternative to urine Bence Jones (BJP) analysis in a routine laboratory setting. Clin Chim Acta 2005;355:WP18.32a
Wechalekar AD, Goodman HJB, Gillmore JD, Lachmann HJ, Offer M, Bradwell AR, Hawkins PN. Clinical profile and treatment outcome in 92 Patients with AL amyloidosis associated with IgM paraproteinaemia. Blood 2005;106(s11):3498a
Wechalekar AD, Lachmann HJ, Goodman HJB, Bradwell AR, Hawkins PN. Role of serum free light chains in diagnosis and monitoring response to treatment in light chain deposition disease. Haematologica 2005;90(s1):PO1414a
Wechalekar AD, Goodman HJB, Gillmore JD, Lachmann HJ, Offer M, Bradwell AR, Hawkins PN. Efficacy of risk adapted cyclophosphamide, thalidomide and dexamethasone in systemic AL amyloidosis. Blood 2005;106(s11):3496a
Yagmur E, Mertens PR, Gressner AM, Kiefer P. Free light chain kappa/lambda ratios are also of diagnostic value for patients with renal insufficiency. Nephro-News, Proceedings of Congress of Nephrology 2005;(September):P12.04a

2006

Abadie JM, Bankson DD. Assessment of serum free light chain assays for plasma cell disorder screening in a Veterans Affairs population. Ann Clin Lab Sci 2006;36(2):157-62 PMID: 16682511
Arendt BK, Ahmann GJ, Mulvihill EM, Sikkink LA, Dispenzieri A, Ramirez-Alvarado M et al. Establishment and characterization of an Ig lambda secreting cell line from a patient with AL Amyloidosis. Blood 2006;108(11):1004a
Blade J. Clinical practice. Monoclonal gammopathy of undetermined significance. N Engl J Med 2006;355(26):2765-70 PMID: 17192542
Bradwell AR, Harding SJ. Paraprotein management: Response to Smellie WSA, Spickett GP: BMJ 2006;333:185-187. BMJ, 7th August 2006
Bradwell AR. Serum free light chain analysis, 4th ed. 2006:285pp
Campbell P, Murdock C. Cardiac amyloidosis - sustained clinical and free light chain response to low dose thalidomide and corticosteroids. Intern Med J 2006;36(2):137-9 PMID: 16472271
Catarini M, Pieroni S, Monachesi A. Serum free light chains: A potential marker for diagnosis, early assessment of response to treatment and relapse in plasma cell disorders. Haematologica 2006;91(s3):PO153a
Chang-Ki M, Ki-Seong E, Seok L, Jong-Wook L, Woo-Sung M, Chong-Won P et al. Changes in serum free light chain and biochemical markers in patients with multiple myeloma receiving bortezomib treatment. Blood 2006;108(11):5028a
Comenzo RL. Amyloidosis. Curr Treat Options Oncol 2006;7(3):225-36 PMID: 16615878
Dingli D, Kyle RA, Rajkumar SV, Nowakowski GS, Larson DR, Bida JP et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood 2006;108(6):1979-83 PMID: 16741249
Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006;107(8):3378-83 PMID: 16397135
Dispenzieri A, Rajkumar SV, Plevak MF, Katzmann JA, Kyle RA, Larson D et al. Early immunoglobulin free light chain (FLC) response post autologous peripheral blood stem cell transplant predicts for hematologic complete response in patients with multiple myeloma. Blood 2006;108(11):3097a
Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20(9):1467-73 PMID: 16855634
Franke DD, Gousha N, Levinson SS. Analysis of immunoglobulin free light chains in urine: A sensitive assay to characterize Bence Jones proteinuria. Clin Chem 2006;52(6):E9a
Friedman JF, Al-Zoubi A, Kaminski M, Kendall T, Jakubowiak A. A new model predicting at least a very good partial response in patients with multiple myeloma (MM) after 2 cycles of bortezomib-based therapy. Haematologica 2006;91(s1):PO741a
Gertz MA. Monitoring organ response in amyloidosis. Blood 2006;107(10):3814a
Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Gastineau DA. Extent of hematologic response is important in determining outcome in transplanted patients with primary amyloidosis AL. Importance of achieving CR. Blood 2006;108(11):611a
Giarin MM, Giaccone L, Caracciolo D, Bruno B, Falco P, Omedè P et al. Serum free light chains (SFLC) assay: a suggestive new criteria for evaluating disease response, progression and relapse in plasma-cell disorders (PD) and a prognostic factor in monoclonal gammopathy of undetermined significance (MGUS). Haematologica 2006;91(s3):PO151a
Giarin MM, Giaccone L, Bruno B, Omedè P, Battaglio S, Falco P et al. Serum free light chains: a potential useful marker for diagnosis and early assessment of response to treatment and relapse in plasma cell disorders. Haematologica Reports 2006;2(7):4a
Gillmore JD, Goodman HJ, Lachmann HJ, Offer M, Wechalekar AD, Joshi J et al. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 2006;107(3):1227-9 PMID: 16210334
Goodman HJ, Gillmore JD, Lachmann HJ, Wechalekar AD, Bradwell AR, Hawkins PN. Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol 2006;134(4):417-25 PMID: 16822290
Hajdu SI. A note from history: the first biochemical test for detection of cancer. Ann Clin Lab Sci 2006;36(2):222-3 PMID: 16682523
Hassoun H, Reich L, Klimek VM, Dhodapkar M, Cohen A, Kewalramani T et al. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br J Haematol 2006;132(2):155-61 PMID: 16398649
Hill PG, Forsyth JM, Rai B, Mayne S. Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies. Clin Chem 2006;52(9):1743-8 PMID: 16858075
Hutchison C, Chandler K, Mead G, Cockwell P, Bradwell AR. Free light chain removal from serum by haemofiltration and haemodialysis: a comparison of dialysis membranes in vitro. J Am Soc Nephrol 2006;17:PUB237a
Hutchison C, Cockwell P, Chandler K, Harper J, Mead G, Barnett AH, Bradwell AR. Light chain abnormalities in diabetic patients with and without microalbuminuria. J Am Soc Nephrol 2006;17:TH-PO231a
Hutchison C, Cockwell P, Hatersley J, Evans N, Chappell MJ, Mead G, Bradwell A. Simulations of free light chain removal by extended haemodialysis using a mathematical model. J Am Soc Nephrol 2006;17:PUB238a
Hutchison C, Townend J, Mead GP, Chandler K, Harper J, Bradwell AR et al. Monoclonal gammopathy as a determinant of adverse outcomes in patients with chronic kidney disease. Blood 2006;108(11):5053a
Hutchison C, Cockwell P, Reid S, Chandler K, Mead G, Bradwell A. Removal of serum free light chains by haemodialysis in patients with multiple myeloma. Nephrol Dial Transplant 2006;21(s4):SP675a
Hutchison C, Cook M, Bradwell AR, Cockwell P. Renal recovery following light chain removal by extended hemodialysis in a patient with cast nephropathy from multiple myeloma. J Am Soc Nephrol 2006;17:TH-PO268a
Hutchison C, Cockwell P, Reid C, Chandler K, Mead GP, Harrison J et al. Efficient removal of immunoglobulin free light chains by hemodialysis in multiple myeloma: In-vitro and in-vivo studies. Blood 2006;108(11):5112a
Hutchison C, Bradwell AR, Mead G, Chandler K, Harper J, Cook M et al. Free light chain removal by extended hemodialysis in patients with cast nephropathy from multiple myeloma. J Am Soc Nephrol 2006;17:TH-FC102a
Hutchison C, Cook M, Bradwell AR, Cockwell P. Renal recovery following light chain removal by extended haemodialysis in a patient with cast nephropathy. Blood 2006;108(11):5115a
Hutchison C, Cockwell P, Reid S, Chandler K, Mead G, Bradwell AR. Removal of serum free light chains by hemodialysis in patients with multiple myeloma. Haematologica 2006;92(s1):1420a
Hutchison CA, Townend J, Mead G, Chandler K, Harper J, Bradwell AR et al. Serum free light chains as a determinant of adverse outcomes in patients with chronic kidney disease. J Am Soc Nephrol 2006;17:PUB391a
Hutchison CA, Mead G, Harper J, Chandler K, Bradwell AR, Cockwell P. Free light chain abnormalities in patients with renal transplants. J Am Soc Nephrol 2006;17:TH-PO060a
Hutchison CA, Mead G, Chandler K, Harper J, Bradwell AR, Cockwell P. Free light chain abnormalities in patients with chronic kidney disease. J Am Soc Nephrol 2006;17:PUB393a
Itzykson R, Garff-Tavernier M, Katsahian S, Diemert MC, Guis L, Choquet S et al. Serum free light chain (SFLC) elevation is associated with high 2-microglobulin and with a shorter time to treatment in Waldenstrom's Macroglobulinemia (WM). Blood 2006;108(11):2419a
Jaskowski TD, Litwin CM, Hill HR. Detection of kappa and lambda light chain monoclonal proteins in human serum: automated immunoassay versus immunofixation electrophoresis. Clin Vaccine Immunol 2006;13(2):277-80 PMID: 16467338
Katzmann JA, Dispenzieri A, Kyle RA, Snyder MR, Plevak MF, Larson DR et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc 2006;81(12):1575-8 PMID: 17165636
Katzmann JA, Dispenzieri A, Kyle RA, Snyder MR, Plevak MF, Larson DR et al. Elimination of the need for urine studies during diagnostic studies of monoclonal gammopathies by the combined use of serum immunofixation and serum free light chain assays. Blood 2006;108(11):5011a
Katzmann JA. Serum free light chains - quantitation and clinical utility in assessing monoclonal gammopathies. Clinical Lab News 2006;June:12-4
Katzmann JA. Serum free light chain specificity and sensitivity: a reality check. Clin Chem 2006;52(9):1638-9 PMID: 16940461
Korbet SM, Schwartz MM. Multiple myeloma. J Am Soc Nephrol 2006;17(9):2533-45 PMID: 16885408
Kostakoglu L, Niesvizky R, Liu M, Goldsmith SJ, Christos P, Jayabalan DS, Coleman M. FDG-PET predicts disease burden in multiple myeloma. J Clin Oncol 2006;24(18S):7619a
Kumar S, Rajkumar VS, Plevak M, Kyle RA, Katzmann JA, Dispenzieri A. Comparison of serum free light chain levels and 24 hour urinary monoclonal protein secretion in patients with myeloma: Concordant changes with response to therapy. Blood 2006;108(11):5064a
Kumar S, Fonseca R, Dispenzieri A, Katzmann JA, Kyle RA, Clark R, Rajkumar SV. High incidence of IgH translocations in monoclonal gammopathies with abnormal free light chain levels. Blood 2006;108(11):3514a
Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354(13):1362-9 PMID: 16571879
Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol 2006;134(6):573-89 PMID: 16938117
Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, Sachanas S, Tzenou T, Papadogiannis A et al. Serum free light chain ratio (FLCR) at diagnosis constitute a powerful prognostic factor of survival in multiple myeloma (MM). Blood 2006;108(11):3522a
Lachmann HJ, Hawkins PN. Systemic amyloidosis. Curr Opin Pharmacol 2006;6(2):214-20 PMID: 16483845
Lopez J, Dauwalder O, Joly P, Dimet I, Bienvenu J, Bernon H. [Interest and limit of a free light chain immunoassay in serum and urine for the diagnosis and the follow-up of monoclonal dysglobulinemia]. Ann Biol Clin (Paris) 2006;64(3):287-97 PMID: 16698567
Lueck N, Agrawal YP. Lack of utility of free light chain-specific antibodies in the urine immunofixation test. Clin Chem 2006;52(5):906-7 PMID: 16638965
Mayo Medical Laboratories. Monoclonal gammopathy of undetermined significance, Waldenström Macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Communique 2006;November
Mazumder A, Jagannath S. Use of free light chain measurements in clinical trials of novel agents in multiple myeloma. Blood 2006;108(11):3584a
Mead G, Beardsmore C, Reid S, Hattersley J, Moss P, Pratt G et al. Kinetics of tumour kill during induction chemotherapy for multiple myeloma using frequent free light chain measurements. Haematologica 2006;92(s1):PO1219a
Mehta AB. Practice: Paraprotein management. Reply to Smellie WSA, Spickett GP. BMJ 2006;333(7560):185-7
Mehta J, Stein R, Vickrey E, Resseguie W, Singhal S. Significance of serum free light chain estimation with detectable serum monoclonal protein on immunofixation electrophoresis. Blood 2006;108(s11):5048a
Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006;108(8):2520-30 PMID: 16794250
Min CK, Eom KS, Lee S, Lee JW, Min WS, Park CW et al. Changes in serum free light chain and biochemical markers in patients with multiple myeloma receiving bortezomib treatment. Blood 2006;108(11):5028a
Moreau AS, Leleu X, Manning R, Coiteux V, Darre S, Hatjiharisi E et al. Serum free light chains in Waldenstrom Macroglobulinemia. Blood 2006;108(11):2420a
Nakano T, Miyazaki S, Shinoda Y, Inoue I, Katayama S, Komoda T, Nagata A. Proposed reference material for human free immunoglobulin light chain measurement. J Immunoassay Immunochem 2006;27(2):129-37 PMID: 16711251
Nakano T, Miyazaki S, Takahashi H, Matsumori A, Maruyama T, Komoda T, Nagata A. Immunochemical quantification of free immunoglobulin light chains from an analytical perspective. Clin Chem Lab Med 2006;44(5):522-32 PMID: 16681419
Offidani M, Polloni C, Corvatta L, Marconi M, Piersantelli MN, Scortechini I et al. Usefulness of serum free light chain assay (sFLC) in predicting response to chemotherapy in patients affected by multiple myeloma. Haematologica Reports 2006;2(7):7a
Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006;107(10):3854-8 PMID: 16434487
Palladini G, Russo P, Lavatelli F, Nuvolone M, Bosoni T, D'Eril GM et al. Diagnostic performance of the quantitative assay for free light chains (Freelite™) in AL amyloidosis. Clin Chem 2006;52(s6):D123a
Palladini G, Perfetti V, Merlini G. Therapy and management of systemic AL (primary) amyloidosis. Swiss Med Wkly 2006;136(45-46):715-20 PMID: 17183435
Polloni C, Offidani M, Corvatta L, Marconi M, Piersantelli MN, Amoroso B, Leoni P. Role of serum free light chain (sFLC) level and ratio (FLCr) as early predictors of response in multiple myeloma. Haematologica 2006;91:PO152a
Pratt G, Mead GP, Godfrey KR, Hu Y, Evans ND, Chappell MJ et al. The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chains. Leuk Lymphoma 2006;47(1):21-8 PMID: 16321823
Presslauer S, Milosavljevic D, Hubl W, Brucke T, Bayer P. Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis. Multiple Sclerosis 2006;12(s1):783a
Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenstrom Macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc 2006;81(5):693-703 PMID: 16706268
Rajkumar SV, Kyle RA, Plevak M, Clark RJ, Larson D, Therneau T et al. Prevalance of light-chain monoclonal gammopathy of undetermined significance (LC-MGUS) among Olmsted Country, Minnesota residents aged 50 years or greater. Blood 2006;108(s11):5060a
Reid S, Cockwell P, Chandler K, Hutchison CA, Mead G, Bradwell AR. MGUS incidence in a chronic kidney disease population. Nephrol Dial Transplant 2006;21(s4):MP287a
Reid S, Chandler K, Hutchison C, Harrison J, Cockwell P, Mead G, Bradwell A. Free light chain removal from serum by haemofiltration and haemodialysis: a comparison of dialysis membranes in vitro. Nephrol Dial Transplant 2006;21(s4):SP676a
Reid SD, Katsavara H, Augustson BM, Hutchison CA, Mead GP, Shirfield M et al. Screening for monoclonal gammopathy: inclusion of serum free light chain immunoassays produce an increased detection rate. Clin Chem 2006;52(s6):E37a
Reid SD, Cockwell P, Millard JL, Chandler KL, Hutchison CA, Mead GP, Bradwell AR. MGUS incidence in a chronic kidney disease population. Clin Chem 2006;52(6):E38a
Rinker JR, Trinkaus K, Cross AH. Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis. Neurology 2006;67(7):1288-90 PMID: 17030770
Rolinski B, Hammer F, Scherberich JE. Serum concentrations of kappa and lambda free light chains in chronic renal failure. Clin Chem Lab Med 2006;44(9):118a
Rolinski B, Hammer F, Scherberich J. Clearance of kappa and lambda free light chains during hemodialysis. Clin Chem Lab Med 2006;44(9):117a
Ronco P, Plaisier E, Mougenot B, Aucouturier P. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol 2006;1(6):1342-50 PMID: 17699367
Rutherford C, Wians FH. A large skull mass in a 67 year-old woman. Lab Med 2006;37(7):417-21
Sanchorawala V. Light-chain (AL) amyloidosis: diagnosis and treatment. Clin J Am Soc Nephrol 2006;1(6):1331-41 PMID: 17699366
Scherberich J, Hammer F, Rolinski B. Impact of chronic renal failure and hemodialysis on serum free polyclonal immunoglobulin kappa/lambda light-chains. Nephrol Dial Transplant 2006;21(s4):SP021a
Shaw GR. Nonsecretory plasma cell myeloma-becoming even more rare with serum free light-chain assay: a brief review. Arch Pathol Lab Med 2006;130(8):1212-5 PMID: 16879026
Shimizu K, Itoh J, Sugiura I, Tsushita K, Kosugi H, Nagura E. [Evaluation of the clinical relevance of serum measurements of free-light chains in patients with multiple myeloma]. Rinsho Ketsueki 2006;47(4):303-9 PMID: 16715965
Showell PJ, Scurvin M, Chnivimba A, Carr-Smith HC, Bradwell AR. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light-chains on The Binding Site automated analyser. Clin Chem 2006;52(s6):E41a
Singhal S, Mehta, J. Multiple myeloma. Clin J Am Soc Nephrol 2006;1(6):1322-30 PMID: 17699365
Singhal S, Stein R, Vickrey E, Resseguie W, Mehta J. The serum free light chain assay cannot replace 24-hour urine protein estimation in plasma cell dyscrasias. Blood 2006;108:3516a
Smellie WS, Spickett GP. Paraprotein management. BMJ 2006;333(7560):185-7 PMID: 16858048
Smellie WSA, Spickett GP. Practice: Paraprotein management. Reply to Bradwell AR and Harding SJ. BMJ 2006;333(7560):185-6
Smellie WSA. Practice: Paraprotein management. Reply to Mehta AB. BMJ 2006;333(7560):185-7
Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006;132(4):410-51 PMID: 16412016
Stein R, Mehta J, Vickrey E, Resseguie W, Singhal S. Serum free light chain measurement in myeloma patient samples with oligoclonal protein bands. Blood 2006;108(s11):5044a
Stein R, Mehta J, Vickrey E, Resseguie W, Singhal S. Correlation of serum free light chain levels with other parameters in myeloma. Blood 2006;108(s11):5019a
Sumnà E, Novácková L, Martínek A, Scudla V. Význam hodnocení sérových hladin volných lehkých retezcu imunoglobulinu u monoklonálních gamapatií. Interní Med 2006;11:502-4
Tate JR, Mollee P, Carter A, Gill D. Clinical utility and technical pitfalls of the serum free light chain (FLC) assay for monitoring of monoclonal light-chain diseases. Clin Chem 2006;52:E44a
Tucker KF. Computer program for monitoring disease status in multiple myeloma with serum free kappa, and free lambda chains. Clin Chem 2006;52(6):D137a
van der Heijden M, Kraneveld A, Redegeld F. Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases. Eur J Pharmacol 2006;533(1-3):319-26 PMID: 16455071
van Gysel M, Marien G, Verhoef G, Delforge M, Bossuyt X. Free light chain testing in follow-up of multiple myeloma. Clin Chem Lab Med 2006;44(8):1044-6 PMID: 16879076
Wechalekar AD, Gillmore JD, Lachmann HJ, Offer M, Hawkins PN. Efficacy and safety of bortezomib in systemic AL amyloidosis - a preliminary report. Blood 2006;108(11):129a
Weichman K, Dember LM, Prokaeva T, Wright DG, Quillen K, Rosenzweig M et al. Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 2006;38(5):339-43 PMID: 16862166

2007

Abdalla SH. Use of Freelite assay to monitor myeloma with renal failure. Haematologica 2007;92(s2):PO1016a
Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Comenzo RL et al. Multiple myeloma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007;5(2):118-47 PMID: 17335683
Ayliffe MJ, Davies FE, de Castro D, Morgan GJ. Demonstration of changes in plasma cell subsets in multiple myeloma. Haematologica 2007;92(8):1135-8 PMID: 17335683
Barlogie B, Anaissie E, van RF, Pineda-Roman M, Zangari M, Shaughnessy J et al. The Arkansas approach to therapy of patients with multiple myeloma. Best Pract Res Clin Haematol 2007;20(4):761-81 PMID: 18070718
Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007;138(2):176-85 PMID: 17593024
Basu S, Cook M, Hutchison C, Galvin GP, Harding S, Mead G et al. High rate of renal recovery in patients with cast nephropathy treated by removal of free light chains using extended hemodialysis. Haematologica 2007;92(s2):PO1109a
Batuman V. Proximal tubular injury in myeloma. Contrib Nephrol 2007;153:87-104 PMID: 17075225
Beetham R, Wassell J, Wallage MJ, Whiteway AJ, James JA. Can serum free light chains replace urine electrophoresis in the detection of monoclonal gammopathies? Ann Clin Biochem 2007;44(Pt 6):516-22 PMID: 17961305
Behrens J. Fighting fit. Med Lab World 2007;August:7
Bergner R, Hoffmann M, Landmann T, Uppenkamp M. Free light chains in urine - an additional diagnostic advantage? Haematologica 2007;92(s2):PO1012a
Bradwell AR, Cockwell P, Hutchison CA. Removal of nephrotoxic free light chains by haemodialysis in patients with myeloma kidney. NHS Nat Library for Health 2007;
Clark RJ, Lockington KS, Tostrud LJ, Katzmann JA. Incidence of antigen excess in serum free light chain assays. Clin Chem 2007;53(6):C145a
Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol 2007;139(2):224-33 PMID: 17897298
Collier G. Controversies of the free light chain assay explored in Dublin. ACB News 2007;March(527):24-5
Comenzo RL. Managing systemic light-chain amyloidosis. J Natl Compr Canc Netw 2007;5(2):179-87 PMID: 17335687
Comenzo RL, Maurer M, Cohen A, Hassoun H, Zhou P, Lu P et al. Predictors of survival in de novo cardiac Amyloidosis. Blood 2007;110(11):2870a
Comenzo RL. Current and emerging views and treatments of systemic immunoglobulin light-chain (AL) amyloidosis. Contrib Nephrol 2007;153:195-210 PMID: 17075231
Cook M, Hutchison C, Basu S, Harding S, Basnayake K, Mead G et al. Renal recovery in 75% of myeloma patients with cast nephropathy following FLC removal by hemodialysis. Haematologica 2007;92(s2):PO1106a
Corso A, Barbarano L, Mangiacavalli S, Montalbetti L, Brasca P, Zappasodi P et al. Bortezomib with HIG-dose dexamethasone as first line therapy in patients with multiple myeloma candidates to high-dose therapy. Blood 2007;110(11):3595a
Cserti C, Haspel R, Stowell C, Dzik W. Light-chain removal by plasmapheresis in myeloma-associated renal failure. Transfusion 2007;47(3):511-4 PMID: 17319833
Daval S, Tridon A, Mazeron N, Ristori JM, Evrard B. Risk of antigen excess in serum free light chain measurements. Clin Chem 2007;53(11):1985-6 PMID: 17954504
Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica 2007;92(1):143-4 PMID: 17229655
De Souza CA, Oliveira-Duarte G, Dias DF, Bottini PV, Vigorito AC, Aranha FJP et al. Serum free light-chain measurements for monitoring minimal residual disease after stem cell transplantation in multiple myeloma patients. Haematologica 2007;92(S2):PO1181a
Dingli D, Pacheco JM, Nowakowski GS, Kumar SK, Dispenzieri A, Hayman SR et al. Relationship between depth of response and outcome in multiple myeloma. J Clin Oncol 2007;25(31):4933-7 PMID: 17971591
Dingli D, Pacheco JM, Dispenzieri A, Hayman SR, Kumar SK, Lacy MQ et al. Serum M-spike and transplant outcome in patients with multiple myeloma. Cancer Sci 2007;98(7):1035-40 PMID: 17488336
Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007;109(2):465-70 PMID: 17008538
Dispenzieri A, Kyle RA, Katzmann JA, Larson D, Benson J, Clark RJ et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering multiple myeloma. Blood 2007;110:1487a
Dispenzieri A, Zhang L, Snyder M, Blood E, Katzmann JA, DeGoey R et al. FLC as a marker of response in a mature dataset: EC0G E9486. Haematologica 2007;92(s2):PO1013a
Émond JP, Harding S, Lemieux B. Aggregation of serum free light chains (FLC) causes overestimation of FLC nephelometric results as compared to serum protein electrophoresis (SPE) while preserving clinical usefulness. Blood 2007;110(11):4767a
Émond JP, Lemieux B, Biron G. Two algorithms for screening or follow up of monoclonal gammopathies: advantages and pitfalls of serum free light chains. Clin Chem Lab Med 2007;45(s1):M057a
Émond JP, Harding S, Giroux M. Interpretation of serum free light chains (FLC) for monoclonal gammopathies investigation: Effects of some clinical conditions and of the FLC physiochemical polymeric state. Presented at Canadian Laboratory Medicine Congress 2007
Fonseca R, Hayman S. Waldenstrom Macroglobulinaemia. Br J Haematol 2007;138(6):700-20 PMID: 17672883
Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar S. Transplantation for amyloidosis. Curr Opin Oncol 2007;19(2):136-41 PMID: 17272986
Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Leung N, Gastineau DA. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica 2007;92(10):1415-8 PMID: 17768110
Gironella M. Free-light chain contribution to the evaluation of response after stem-cell transplantation in multiple myeloma. Haematologica 2007;92(s2):1312a
Gonzalez D, van der Burg M, Garcia-Sanz R, Fenton JA, Langerak AW, Gonzalez M et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 2007;110(9):3112-21 PMID: 17634408
Gottenberg JE, Aucouturier F, Goetz J, Sordet C, Jahn I, Busson M et al. Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. Ann Rheum Dis 2007;66(1):23-7 PMID: 16569685
Grosbois B. [New insights into monoclonal gammopathy and multiple myeloma]. Rev Med Interne 2007;28(10):667-9 PMID: 17553600
Gu M, Wilton R, Stevens FJ. Diversity and diversification of light chains in myeloma: the specter of amyloidogenesis by proxy. Contrib Nephrol 2007;153:156-81 PMID: 17075229
Guenet L, Decaux O, Lechartier H, Ropert M, Grosbois B. [Usefulness of a free light chain immunoassay in serum for the diagnosis and the follow-up of monoclonal gammopathy]. Rev Med Interne 2007;28(10):689-97 PMID: 17566612
Hajek R, Hajek R, Cermakova Z, Pour L, Novotna H, Maisnar V et al. Free light chain assays for early detection of resistance to bortezomib-based regimens. Haematologica 2007;92(s2):257a
Harding S, Drayson M, Ayliffe M, Mead G. Flow cytometry detection of free light chains. Haematologica 2007;92(s2):PO205a
Harding S, Mead G, McSkeane T, Beardsmore C, Hatterskey SJ, Moss P et al. Use of free light chain measurements as prediction of response to induction chemotherapy. Br J Haematol 2007;137(s1):134a
Harousseau JL. New insights into the biology and advances in the management of multiple myeloma. Best Pract Res Clin Haematol 2007;20(4):569-70 PMID: 18070706
Harousseau JL. Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(s2):ii44-ii46 PMID: 17491042
Hassoun H, Rafferty BT, Flombaum C, D'Agati VD, Klimek VM, Cohen A et al. High dose chemotherapy and autologous stem cell transplantation with melphalan in patients with monoclonal immunoglobulin deposition disease associated with Multiple Myeloma. Blood 2007;110(11):5113a
Herrera GA, Sanders PW. Paraproteinemic renal diseases that involve the tubulo-interstitium. Contrib Nephrol 2007;153:105-15 PMID: 17075226
Herrera GA. The kidney in plasma cell dyscrasias: a current view and a look at the future. Contrib Nephrol 2007;153:1-4 PMID: 17075220
Herzum I, Klingebiel R. Monitoring of plasmacytoma by measurement of free light chains in serum versus urine. Clin Chem Lab Med 2007;45(8):P98a
Heyne N, Weisel KC, Hutchison CA, Friedrich B, Goehl H, Kanz L, Risler L. Characterisation of extracorporal serum free light chain elimination kinetics via a high cut-off protein permeable membrane in light chain multiple myeloma. Nephrol Dial Transplant 2007;22(s6):FP315a
Higgins C. Science Review: Multiple myeloma and serum free light chain measurement. The Biomedical Scientist 2007;51(6):428-31
Higgins T, Cho C, Dayton J. Evaluation of a method to measure free light chains using Bayer Advia 1650 chemistry analyzer. Clin Chem Lab Med 2007;45:M316a
Hildebrandt B, Muller C, Pezzutto A, Daniel P, Dorken B, Scholz C. Assessment of free light chains in the cerebrospinal fluid of patients with lymphomatous meningitis - a pilot study. BMC Cancer 2007;7:185 PMID: 17915026
Holding S, Spradbery D, Hoole R, Wilmot R, Shields ML, Patmore R, Dore PC. Prevalence of abnormal serum free light chain ratio in monoclonal gammopathies at presentation and sensitivity for Bence Jones proteinuria. Blood 2007;110(11):1495a
Holding S, Spradbery D, Robson EJD, Dore PC, Wilmot R, Shields ML. Combination of serum free light chain analysis with capillary zone electrophoresis improves screening for monoclonal gammopathies. Blood 2007;110(11):1497a
Hutchison C, Harding S, Bradwell AR, Cockwell P. Serum free light chain removal by high cut-off hemodialysis: Optimising removal and supportive care. J Am Soc Nephrol 2007;18:SAPO511a
Hutchison C, Harding S, Basnayake K, Mead G, Townsend J, Landray M et al. Chronic kidney disease patients and renal transplant recipients have a high prevalent rate of MGUS. Nephrol Dial Transplant 2007;22(s6):SaP072a
Hutchison C, Cockwell P, Basnayake K, Cook M, Harding S, Basu S et al. Removal of free light chains by extended hemodialysis in patients with cast nephropathy: A phase 1/2 clinical trial. Nephrol Dial Transplant 2007;22(s6):FP122a
Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007;18(3):886-95 PMID: 17229909
Hutchison CA, Cook M, Basu S, Harding S, Basnayake K, Mead G et al. Renal recovery in myeloma patients with cast nephropathy following light chain removal by hemodialysis. Proceedings of 29th Congress of Nordic Society of Nephrology, Gothenburg 2007;K28a
Hutchison CA, Cockwell P, Harding S, Barnett A, Bradwell AR. Quantitative assessment of serum and urinary polyclonal free light chains in diabetics patients: An early marker of diabetic kidney disease? J Am Soc Nephrol 2007;18:FPO1010a
Hutchison CA, Cook M, Basu S, Cockwell P, Basnayake K, R. BA. Combined chemotherapy and high cut-off hemodialysis improve outcomes in multiple myeloma patients with severe renal failure. Blood 2007;110(11):3610a
Hutchison CA, Cook M, Basnayake K, Harding S, Bradwell AR, Cockwell P. Free light chain removal hemodialysis increases rates of renal recovery from myeloma kidney. J Am Soc Nephrol 2007;18:PUB582a
Hutchison CA, Cook M, Basu S, Harding S, Mead G, Cockwell P, Bradwell AR. High rate of renal recovery in patients with cast nephropathy treated by removal of free light chains using extended hemodialysis: a phase 1/2 clinical trial. Br J Haematol 2007;137(s1):137a
Hutchison CA, Cook M, Harding S, Mead G, Hattersley J, Evans N et al. Mathematical modelling of free light chain removal by plasma exchange and extended hemodialysis in patients with cast nephropathy. Am J Kidney Dis 2007;49(4):88a
Hutchison CA, Cook M, Harding S, Mead G, Cockwell P, Bradwell AR. Renal function recovery following Velcade and extended hemodialysis in patients with refractory multiple myeloma and cast nephropathy: case studies. Am J Kidney Dis 2007;49(4):90a
Hutchison CA, Harding S, Basnayake K, Townsend J, Landray M, Mead GP et al. Increased MGUS prevalance in chronic kidney disease patients. Haematologica 2007;92(s2):PO905a
Hutchison CA, Cook M, Harding S, Mead G, Cockwell P, Bradwell AR. Removal of free light chains by extended hemodialysis in patients with cast nephropathy: a phase 1/2 clinical trial. Am J Kidney Dis 2007;49(4):89a
Hutchison CA, Harding S, Mead G, Townsend J, Landray M, Cockwell P, Bradwell AR. Chronic kidney disease patients and renal transplant recipients have an increased incidence of monoclonal gammopathies. Am J Kidney Dis 2007;49(4):87a
Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007;357(11):1083-93 PMID: 17855669
Jagannath S. Value of serum free light chain testing for the diagnosis and monitoring of monoclonal gammopathies in hematology. Clin Lymphoma Myeloma 2007;7(8):518-23 PMID: 18021469
Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Migkou M et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007;92(10):1351-8 PMID: 18024372
Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Tassidou A et al. Treatment of light chain (AL) amyloidosis and light chain deposition disease (LCDD) with the combination of bortezomib and dexamethasone. Blood 2007;110(11):191a
Katzel JA, Hari P, Vesole DH. Multiple myeloma: charging toward a bright future. CA Cancer J Clin 2007;57(5):301-18 PMID: 17855486
Khoriaty RN, Hussein MA, Lally J, Kelly M, Kalaycio M, Baz R. Prediction of response and progression in multiple myeloma (MM) with serum-free light chains (sFLC): Corroboration of the International Myeloma Working Group (IMWG) criteria. J Clin Oncol 2007;25(s18):8047a
Kilvington F. Eliminating urine testing during initial investigations for monoclonal gammopathies. Clin Lab Int 2007;3(May):16-7
Kruger WH, Kiefer T, Schuler F, Lotze C, Busemann C, Dolken G. Complete remission and early relapse of refractory plasma cell leukemia after bortezomib induction and consolidation by HLA-mismatched unrelated allogeneic stem cell transplantation. Onkologie 2007;30(4):193-5 PMID: 17396042 </font>
Kumar S, Pérez WS, Zhang MJ, Bredeson CN, Lacy MQ, Milone G et al. Comparable outcomes in secretory (SM) versus non-secretory (NSM) multiple myeloma (MM) with autologous hematopoietic stem cell transplantation (AuHCT). Blood 2007;110(11):944a
Kuypers DR, Lerut E, Claes K, Evenepoel P, Vanrenterghem Y. Recurrence of light chain deposit disease after renal allograft transplantation: potential role of rituximab? Transpl Int 2007;20(4):381-5 PMID: 17326779
Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. Br J Haematol 2007;139(5):730-43 PMID: 18021088
Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol 2007;20(4):637-64 PMID: 18070711
Kyle RA. Serum free light chain assays - their role in multiple myeloma. Touch Briefings 2007;US Hematology:24-7
Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007;356(25):2582-90 PMID: 17582068
Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, Anagnostopoulos A, Delimpasi S, Terpos E et al. Prognostic implication of the combination SFLCR + ISS in MM. Haematologica 2007;92(s2):PO1023a
Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, Sachanas S, Tzenou T, Papadogiannis A et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol 2007;137(3):240-3 PMID: 17408464
Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, Maltezas D, Anagnostopoulos A, Terpos E et al. The addition of sFLCR improves ISS prognostication in multiple myeloma (MM). Blood 2007;110(11):1490a
Lakshminarayanan R, Li Y, Janatpour K, Beckett L, Jialal I. Detection by immunofixation of M proteins in hypogammaglobulinemic patients with normal serum protein electrophoresis results. Am J Clin Pathol 2007;127(5):746-51 PMID: 17439833
Lebovic D, Kendall T, Brozo C, McAllister A, Hari M, Alvi S et al. Serum free light chain analysis improves monitoring of multiple myeloma patients receiving first-line therapy with the combination of Velcade, Doxil, and Dexamethasone (VDD). Blood 2007;110(11):2736a
Leleu X, Moreau AS, Manning R, Coiteux V, Darre S, Nelson M et al. Serum free light chain is a marker of tumor burden and of prognostic impact in Waldenstrom's Macroglobulinemia. Haematologica 2007;92(s2):PO1230a
Leleu X, Hatjiharissi E, Roccaro AM, Moreau AS, Leduc R, Nelson M et al. Serum immunoglobulin free light chain (sFLC) is a sensitive marker of response in Waldenstrom Macroglobulinemia (WM). Blood 2007;110(11):1486a
Leung N, Zeldenrust SR, Dispenzieri A, Fervenza FC, Gertz MA, Kumar S et al. Serum free light chain and renal biopsy accurately predict renal response to plasma exchange in patients with light chain cast nephropathy. J Am Soc Nephrol 2007;18:SUP074a
Leung N, Dispenzieri A, Lacy MQ, Kumar SK, Hayman SR, Fervenza FC et al. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation. Clin J Am Soc Nephrol 2007;2:440-4 PMID: 17699449
Lewis E, Young C, Watson D. Comparison of western blotting and free light chains in the laboratory diagnosis of multiple sclerosis. Annals Clin Biochem 2007;44(s1):T51a
Ludwig H, Drach J, Graf H, Lang A, Meran JG. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 2007;92(10):1411-4 PMID: 17768111
Lynch EA, Showell PJ, Johnson-Brett B, Mead GP, Bradwell AR. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light chains on the Roche Cobas® Integra 400. Clin Chem Lab Med 2007;45(s):W089a
Ma ES, Shek TW, Ma SY. Non-secretory plasma cell myeloma of the true non-producer type. Br J Haematol 2007;138(5):561 PMID: 17610537
Ma ES, Lee ET. A case of IgM paraproteinemia in which serum free light chain values were within reference intervals. Clin Chem 2007;53(2):362-3 PMID: 17259251
Martin W, Abraham R, Shanafelt T, Clark RJ, Bone N, Geyer SM et al. Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Transl Res 2007;149(4):231-5 PMID: 17383597
Mayo Medical Laboratories. Laboratory analysis for monoclonal gammopathies. Mayo Communique 2007;32:1-4
Mayo MM, Johns GS. Serum free light chains in the diagnosis and monitoring of patients with plasma cell dyscrasias. Contrib Nephrol 2007;153:44-65 PMID: 17075223
Mazurkiewicz J, Teal T, Reddy R, Grace R, Gover P. Evaluation of The Binding Site serum free light chain assay in a DGH: clinical aspects. Annals Clin Biochem 2007;44(s1):T47a
Mazurkiewicz J, Teal T, Reddy R. Evaluation of The Binding Site serum free light chain assay in a DGH: analytical aspects. Annals Clin Biochem 2007;44(s1):T46a
Mehta J, Stein R, Vickrey E, Fellingham S, Singhal S. The relationship between serum free light chain assay and serum immunofixation electrophoresis. Haematologica 2007;92(s2):PO1010a
Mitchell F, Showell PJ, Harding SJ, Lynch EA, Mead GP, Hutchison CA, Bradwell AR. Correlation of Freelite™ and Cystatin C in chronic kidney disease on The Binding Site SPAplus bench-top analyser. Clin Chem Lab Med 2007;45(s):T225a
Morgan GJ, Davies FE, Owen RG, Rawstron AC, Bell S, Cocks K et al. Thalidomide combinations improve response rates; results from the MRC IX study. Blood 2007;110(11):3593a
Morris KL, Tate JR, Gill D, Kennedy G, Wellwood J, Marlton P et al. Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis. Intern Med J 2007;37(7):456-63 PMID: 17547724
Mösbauer U, Ayuk F, Schieder H, Lioznov M, Zander AR, Kroger N. Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation. Haematologica 2007;92(2):275-6 PMID: 17296589
Nakano T, Komoda T, Nagata A. To the Editor: Author reply; Nakano et al. Clin Chem Lab Med 2006;44(5):522-532. Clin Chem Lab Med 2007;45(2):266-7 PMID: 17311522
Nakorn TN, Watanaboonyongcharoen P, Suwannabutra S, Theerasaksilp S, Paritpokee N. Early reduction of serum free light chain can predict therapeutic responses in multiple myeloma. Blood 2007;110(s11):4742a
Nguyen T, Bocquet J, Troncy J, Chapuis Cellier C. Ability of capillary zone electrophoresis in detecting monoclonal light chains. Haematologica 2007;92(s2):PO246a
Offidani M, Polloni C, Corvatta L, Busco F, Catarini M, Alesiani F et al. Usefulness of serum FLC assay in predicting outcome in MM. Haematologica 2007;92(s3):PO236a
Orlowski R, Sutherland H, Blade J, Miguel JS, Hajek R, Nagler A et al. Early normalization of serum free light chains is associated with prolonged time to progression following bortezomib {+/-} pegylated liposomal doxorubicin treatment of relapsed/ refractory multiple myeloma. Blood 2007;110(11):2735a
Owen RG, Child JA, Rawstron AC, Bell S, Cocks K, Davies FE et al. Defining complete response in multiple myeloma: Role of the serum free light chain assay and multiparameter flow cytometry. Blood 2007;110(s11):1479a
Palladini G, Nuvolone M, Russo P, Lavatelli F, Perfetti V, Obici L, Merlini G. Treatment of AL amyloidosis guided by biomarkers. Haematologica 2007;92(s2):PO910a
Pasquali S, De Sanctis LB, Mambelli E, Di Felice A, Wratten M, Santoro A. Coupled plasmafiltration adsorption: A new technology for free light chain removal. J Am Soc Nephrol 2007;18:FPO691a
Pattenden RJ, Rogers SY, Wenham PR. Serum free light chains; the need to establish local reference intervals. Ann Clin Biochem 2007;44(Pt 6):512-5 PMID: 17961304
Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007;110(7):2586-92 PMID: 17576818
Pika T, Minarik J, Zemanova M, Budikova M, Backovsky J, Scudla V. Relationship of serum free light chain levels and selected biological parameters in patients with multiple myeloma. Haematologica 2007;92(s2):1113a
Pineda-Roman M, Tricot G. High-dose therapy in patients with plasma cell dyscrasias and renal dysfunction. Contrib Nephrol 2007;153:182-94 PMID: 17075230
Polloni C, Offidani M, Corvatta L, Busco F, Catarini M, Alesiani F et al. Serum FLC as a measure of treatment outcome in MM. Haematologica 2007;92(s2):PO1014a
Puig N, Chen C, Mikhael J, Reece D, Trudel S, Kukreti V. Spontaneous tumoural regression in a patient with t(4;14) translocation multiple myeloma. A case report. Blood 2007;110(11):4777a
Rajkumar SV, Buadi F. Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation. Best Pract Res Clin Haematol 2007;20(4):665-80 PMID: 18070712
Rajkumar SV, Lacy MQ, Kyle RA. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood Rev 2007;21(5):255-65 PMID: 17367905
Ramasamy I. Serum free light chain analysis in B-cell dyscrasias. Ann Clin Lab Sci 2007;37(3):291-4 PMID: 17709698
Rawstron AC, Jones RA, Ferguson C, Hughes G, Selby P, Reid C et al. Outreach monitoring service for patients with indolent B-cell and plasma cell disorders: a UK experience. Br J Haematol 2007;139(5):845-8 PMID: 17970800
Rawstron AC, Davis B, Denman S, de Tute RM, Kerr MA, Owen RG, Ashcroft AJ. Plasma cell phenotype and sFLC provide independent prognostic information in MGUS. Haematologica 2007;92(s2):PO907a
Rezazadeh A, Laber DA, Sharma VR, Kloecker GH. Amyloidosis presenting with platelet dysfunction and recurrent retroperitoneal hemorrhage (RH). Blood 2007;110(11):3944a
Richards T, Horowitz S, Temple S, Nguyen T, Thomas S, Wang M et al. Evaluation of MM response by free light chain assay. Haematologica 2007;92:PO1015a
Richter AG, Harding S, Rimmer S, Pratt G, Huissoon A, Drayson M. Biclonal multiple myeloma with monoclonal free IgG3 heavy chain and kappa free light chains. Blood 2007;110(11):4768a
Ricotta D, Radeghieri A, Amoroso B, Caimi L. Serum free light chains in MM: comparison of 2 assays. Haematologica 2007;92(s2):PO1018a
Robson E, Mead G, Carr-Smith H, Bradwell A. In reply to Tate et al Clin Chim Acta 2007; 376: 30 - 6. Clin Chim Acta 2007;380(1-2):247 PMID: 17368602
Robson E, Mead G, Bradwell A. To the editor: in reply to Nakano et al. Clin Chem Lab Med 2006;44(5):522-532. Clin Chem Lab Med 2007;45(2):264-5 PMID: 17311521
Robson E, Mead G, Das M, Cavet J, Liakpoulou E. Free light chain analysis in patients receiving Bortezomib. Haematologica 2007;92(s2):PO1019a
Ruchlemer R, Reinus C, Paz E, Cohen A, Melnikov N, Ronson A, Rudensky B. Free light chains, monoclonal proteins, and chronic lymphocytic leukemia. Blood 2007;110(s11):4697a
Ruckser R, Tatzreiter G, Kitzweger E, Strecker K, Hraby S, Buxhofer V et al. Combination therapy with lenalidomide, bortezomib, liposomal doxorubicin and dexamethasone (LBlipDD) may overcome resistance to prior treatment with doxorubicin, lenalidomide, and bortezomib in high-risk multiple myeloma (MM). Blood 2007;110(11):4838a
Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: Results of a phase 2 trial. Blood 2007;109(2):492-6 PMID: 16960148
Sheldon J. Free light chains. Ann Clin Biochem 2007;44(Pt 6):503-5 PMID: 17961302
Showell PJ, Lynch EA, Johnson-Brett B, Mead G, Bradwell AR. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light-chains on the Roche COBAS Integra 400 automated analyser. Clin Chem 2007;53(6):C18a
Showell PJ, Hutchison CA, Cockwell P, Harding S, Mead GP, Mitchell F, Bradwell AR. Correlation of FREELITE and Cystatin C in Chronic Kidney Disease on The Binding Site SPAPLUS bench-top analyser. Clin Chem 2007;53(s6):C82a
Sinclair D, Wainwright L. How lab staff and the estimation of free light chains can combine to aid the diagnosis of light chain disease. Clin Lab 2007;53(5-6):267-71 PMID: 17605400
Singhal S, Stein R, Vickrey E, Fellingham S, Mehta J. Serum free light chain levels in myeloma patients with oligoclonal bands. Haematologica 2007;92(s2):PO1011a
Singhal S, Stein R, Vickrey E, Mehta J. The serum-free light chain assay cannot replace 24-hour urine protein estimation in patients with plasma cell dyscrasias. Blood 2007;109(8):3611-2 PMID: 17409349
Snozek CLH, Katzmann JA, Kyle RA, Dispenzieri A, Larson DR, Clark RJ et al. Prognostic value of the serum free light chain ratio in patients with newly diagnosed myeloma: proposed incorporation into the international staging system. Blood 2007;110(s11):659a
Spradberry D, Holding S. Analytical variability of the Binding Site Freelite assay in serum. Presented at IBMS Congress 2007
Storr M, Goehl H, Cockwell P, Hutchison C, Bradwell A. Efficient removal of immunoglobulin free light chains by hemodialysis using a novel high cut-off membrane. Blood purif 2007;25(4):O17a
Sui WW, Yao HJ, Wang YF, Wang L, Zhang K, Xu Y, Qiu LG. Assessment of serum free light chain of patients with multiple myeloma and clinical significance thereof. Zhonghua Yi Xue Za Zhi 2007;87(44):3158-60 PMID: 18269880
Sweeting R, Notkin A, Leung N, Ballard H, Pillon L. Approach to acute renal failure in biopsy proven myeloma cast nephropathy. Is there a role for plasmapheresis? J Am Soc Nephrol 2007;18:PUB570a
Tan TS, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR et al. Melphalan and dexamethasone is an effective therapy for primary systemic amyloidosis. Blood 2007;110(s11):3608a
Tate JR, Mollee P, Dimeski G, Carter AC, Gill D. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clin Chim Acta 2007;376(1-2):30-6 PMID: 16945362
Terrier B, Hummel A, Servais A, Delarue R, Fournier P, Fakhouri F. An unusual cause of lymph nodes enlargement. Am J Med 2007;120(1):e1-e3 PMID: 17208059
Thomas SK, Richards TA, Weber DM. Lenalidomide in multiple myeloma. Best Pract Res Clin Haematol 2007;20(4):717-35 PMID: 18070715
Trieu Y, Xu W, Chen C, Kukreti V, Mikhael J, Trudel S, Reece D. Evaluation of serum free light chains and outcome in multiple myeloma patients with an intact monoclonal immunoglobulin treatment with autologous stem cell transplantation. Haematologica 2007;92(s2):PO1021a
Trigo F, Guimaraes C, Bodas A, Teixeira-Pinto A, Guimaraes JE. Serum free light chain assessment in 311 patients with gammopathy. Blood 2007;110(11):4750a
van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007;110(3):827-32 PMID: 17416735
Veillon DM, Cotelingam JD. Pathologic studies useful for the diagnosis and monitoring of plasma cell dyscrasias. Contrib Nephrol 2007;153:25-43 PMID: 17075222
Wechalekar AD, Goodman HJB, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007;109(2):457-64 PMID: 16990593
Wolff F, Thiry C, Willems D. Assessment of the analytical performance and the sensitivity of serum free light chains immunoassay in patients with monoclonal gammopathy. Clin Biochem 2007;40(5-6):351-4 PMID: 17239359
Yee J. Chronic kidney disease: Clinical practice recommendations for primary care physicians and healthcare providers. 2007
Zarabpouri F, Popov J, Montana L, Ferruzza AS, Naides SJ. Role of nephelometry-based detection of serum free light chain kappa/lambda in diagnosis of multiple myeloma. Clin Chem 2007;53(6):C148a
Zibrat S, Gloria CT, Joseph L, McLawhon R. Analytical and clinical performance limtiations of immunoturbidimetric vs. immunonephelometric methods for free light chain analysis in serum. Clin Chem 2007;53(6):B79a
Zinke-Cerwenka W, Stojakovic T, Scharnagl H, Wassertheurer S, Linkesch W. Therapy response by decrease of free light chain concentration in multiple myeloma patients treated with bortezomib/doxorubicin/dexamethasone as first-line therapy. Blood 2007;110(s11):4818a

2008

Allen S, Vickrey E, Mehta J, Singhal S. The relationship between serum free light chain levels and serum immunofixation electrophoresis: Implications for the definition of "Stringent CR" in myeloma. Blood 2008;112(11):2724a
Alvi A, Harding S, Pietrantuono A, Berard A. Serum free light chain immunoassay (Freelite) as an adjunct to SPE and IFE in the detection of multiple myeloma and other B cell malignancies. Hematology meeting reports 2008;2(2):C25a
Bachmann U, Schindler R, Storr M, Kahl A, Joerres A, Sturm I. Combination of bortezomib-based chemotherapy and extracorporeal free light chain removal for treating cast nephropathy in multiple myeloma. NDT Plus 2008;2:106-8
Barlogie B, van Rhee F, Shaughnessy JD, Epstein J, Yaccoby S, Pineda-Roman M et al. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood 2008;112(8):3122-5 PMID: 18669874
Basnayake K, Ghonemy T, Hutchison C, Bradwell AR, Cockwell P. Immunoglobulin free light chains in situ in patients with chronic kidney disease. Hematology meeting reports 2008;2(2):E34a
Basnayake K, Cheung CK, Hutchison C, Kamel D, Sheaff M, Fuggle W et al. The differential evolution of renal scarring in myeloma kidney despite early reductions in free light chains. Hematology meeting reports 2008;2(2):E35a
Basnayake K, Hutchison C, Kamel D, Sheaff M, Ashman N, Cook M et al. Resolution of cast nephropathy following free light chain removal by haemodialysis in a patient with multiple myeloma: a case report. J Med Case Reports 2008;2:380 PMID: 19068112
Basnayake K, Hutchison C, Kamel D, Sheaff M, Fuggle W, Cook M et al. Rapid reduction of serum free light chains by high cut-off haemodialysis in cast nephropathy: supporting histological evidence from two cases. Presented at Renal Association Annual Meeting 2008;60a
Basnayake K, Hutchison C, Kamel D, Sheaff M, Ashman N, Oakervee H et al. Resolution of cast nephropathy following free light chain removal by hemodialysis in a patient with multiple myeloma. Am J Kidney Dis 2008;51(4):24a
Bergner R, Hoffmann M, Uppenkamp M. Reply. Kastritis E. et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone containing regimes and the impact of novel agents. Haematologica 2007; 92:546-9. Haematologica 2008;93(1):e18-e19 PMID: 18166771
Bergner R, Vilardi S, Hoffmann M, Uppenkamp M. Free light chains in urine - an additional diagnostic advantage? Hematology meeting reports 2008;2(2):B7a
Bergon E, Miravalles E. Estimation of serum M-protein concentration from polyclonal immunoglobulins: an alternative to serum protein electrophoresis and standard immunochemical procedures. Clin Chem Lab Med 2008;46(8):1156-62 PMID: 18605957
Bernon H, Karame A, Dimet I, Villar E, Regad-Pellagru AL, Bienvenu J. About a case of lambda free light chain multiple myeloma treated by bortezomib chemotherapy and long haemodialysis on polymethylmethacrylate membrane. Hematology meeting reports 2008;2(2):E40a
Bidet A, Marit G, Berard AM. [Clinical value of the blood measurement of the free light chains of immunoglobulins]. Ann Biol Clin (Paris) 2008;66(4):427-31 PMID: 18725344
Blade J, Rosinol L, Cibeira MT, de Larrea CF. Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia 2008;22(9):1651-7 PMID: 18668131
Blade J, Rosinol L. SMM: Towards better predictors of progression. Blood 2008;111(2):479-80
Bochtler T, Hegenbart U, Heiss C, Benner A, Cremer F, Volkmann M et al. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. Haematologica 2008;93(3):459-62 PMID: 18287137
Bradwell AR. Serum free light chain analysis (plus Hevylite), 5th ed. 2008:312pp
Brandhorst D, Bockling M, Sammet C, Daniels R, Schuett P, Buttkereit U et al. Monoclonal free light chains and renal dysfunction in multiple myeloma. Hematology meeting reports 2008;2(2):E42a
Bruck P, Atta J, Hildegund SE, Bohme A, Oremek GM. Lambda and kappa free light chains in haematologic patients. Clin Exp Med Lett 2008;49(1):19-22
Burg M, Niederstadt C, Dotzeva E, Kliem V. Serum free light chains in patients with renal failure stage II-V of native kidneys or renal transplants. J Am Soc Nephrol 2008;19:PUB249a
Callis M, Garcia L, Gironella M, Rodrigo MJ, Garcia E, Castella D. Serum fee light chain reference intervals. A study of 133 blood donors. Hematology meeting reports 2008;2(2):B6a
Callis M, Garcia L, Gironella M, Rodrigo MJ, Garcia E, Castella D. Serum free light chain reference intervals. A study of 133 blood donors. Haematologica 2008;93(s1):1332a
Chan PC, Ragosnig B, Oczak M, Rozmanc M. Follow-up investigations for 'nephrotic syndrome' pattern in serum protein electrophoresis. Clin Biochem 2008;41:108a
Chattopadhyay A, Nath UK, De R, Singh A, Sanyal S, Chatterjee SK, Chaudhuri U. Primary plasma cell leukemia with initial cutaneous involvement and IgA biclonal gammopathy. Ann Hematol 2008;87(3):249-51 PMID: 17909800
Chen HF, Hou J, Yuan ZG, Wang DX, Fu WJ, Chen YB. [Detection of serum free light chain and its clinical significance in nonsecretory multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi 2008;29(2):113-6 PMID: 18681313
Civini S, Radeghieri A, Amoroso B, Caimi L, Ricotta D. Free light chain behaviour in sera from patients producing cryoglobulins. Hematology meeting reports 2008;2(2):C16a
Clark WF, Garg AX. Plasma exchange for myeloma kidney: cast(s) away? Kidney Int 2008;73(11):1211-3 PMID: 18480853
Coriu D, Talmaci R, Badelita S, Dobrea D, Dogaru M, Ostroveanu D et al. Clinical study of 35 cases of primary systemic amyloidosis. Haematologica 2008;93:1301a
Davern S, Tang LX, Williams TK, Macy SD, Wall JS, Weiss DT, Solomon A. Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies. Am J Clin Pathol 2008;130(5):702-11 PMID: 18854262
De Filippi R, Laccarino G, Frigeri F, Di Francia R, Amoroso B, Marchei A, Pinto A. The presence of serum free-immunoglobulin light chains and abnormal  ratios is a frequent finding in patients with Hodgkin's and B-cell non-Hodgkin's lymphoma. Hematology meeting reports 2008;2(2):C18a
de Fost M, Out TA, de Wilde FA, Tjin EP, Pals ST, van Oers MH et al. Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Ann Hematol 2008;87(6):439-49 PMID: 18274746
Decaux O, Briand PY, Guenet L, Ropert M, Sebillot M, Grosbois B. An abnormal serum free light chain ratio is associated with higher monoclonal concentration and bone marrow plasmacytosis in a French cohort of patients with monoclonal gammopathy of undetermined significance. Hematology meeting reports 2008;2(2):C22a
Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008;22(8):1485-93 PMID: 18528426
Dispenzieri A, Zhang L, Katzmann JA, Snyder M, Blood E, DeGoey R et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood 2008;111(10):4908-15 PMID: 18364469
Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008;111(2):785-9 PMID: 17942755
Dispenzieri A. How and when I use serum free light chain tests. Hematology meeting reports 2008;2(2):p4
Dispenzieri A. To the editor: Is early, deep free light chain response really an adverse prognostic factor? Blood 2008;111(4):2490-1
Dispenzieri A. Impact of serum free light chain evaluation in monoclonal gammopathies. Hematology Education: the education program for the annual congress of the European Hematology Association 2008;2(1):279-86
Dotzeva E, Niederstadt C, Burg M, Kliem V. Serum free light chains in patients with renal failure stage II-V of native kidneys or renal transplants. Hematology meeting reports 2008;2(2):E43a
Doyle A, Soutar R, Geddes CC. Multiple myeloma in chronic kidney disease. Utility of discretionary screening using serum electrophoresis. Nephron Clin Pract 2008;111(1):c7-c11 PMID: 19033691
Drengler T, Kumar S, Gertz M, Lacy M, Katzmann J, Hayman S et al. Serum immunoglobulin free light chain measurements provide insight into disease biology in patients with POEMS syndrome. Presented at Portuguese myeloma meeting 2008
Encinas Madrazo A, González García ME, Cepeda Piorno J, González Huerta AJ, Fernández Rodríguez E. Serum free light chains: Clinical utility. An Med Interna 2008;25(5):249-50
Espinilla HA. Determinaciande valories esperados de referencia κ libre en suero, Lambda libre in suero y Kappa/Lambda suero en nuestro departamento de salud. Rev Lab Clinic 2008;s1(66)
Exner I, Eigner M, Kraus R, Leithner C. Acute renal failure because of light chain deposition disease and its successful combined treatment with chemotherapy and dialysis with high flux membrane. Hematology meeting reports 2008;2(2):E36a
Forsyth J, Mayne S, Lawson N. A rare case of polyclonal Mu Heavy Chain Disease. Ann Clin Biochem 2008;45(s1):4a
Forsyth J, Hill P. Serum free light chains. Reply to Beetham et al. Can serum free light chains replace urine electrophoresis? Ann Clin Biochem 2008;45:444-5 PMID: 18583637
Gertz MA. Current therapy of myeloma induced renal failure. Leuk Lymphoma 2008;49(5):833-4 PMID: 18452070
Giroux M, Sheridan B. The serum free light chain assay: an alternative to Bence Jones protein analysis in screening for monoclonal gammopathies. Hematology meeting reports 2008;2(2):C21a
Giroux M, Sheridan B. The serum free light chain assay: An alternative to Bence Jones protein analysis in screening for monoclonal gammopathy. Clin Biochem 2008;41:113a
Gottenberg JE, Dillon SR, Combe B, Harder B, Hahne M, Morel J et al. Serum April levels correlate with disease activity and severity of radiologic lesions in early rheumatoid arthritis patients: Results from the French multicenter prospective cohort study (espoir). Presented at ACR Annual Scientific Meeting 2008;328a
Granátová J, Bolková M, Fantová L, Hornová L, Masková Z, Horák J, Lánská V. Free light chains of immunoglobulins in patient with renal insufficiency. Klin Biochem Metab 2008;16(37):106-10
Graubaum K, Heymann GA, Hunger T, Ostapowicz B. Case report: Shift in secretion from intact immunoglobulin to free light chains in multiple myeloma at relapse: early detection by free light chain assay. Hematology meeting reports 2008;2(2):D26a
Gregorini GA, Mazzola G, Valerio F, Econimo L, Gasparotti I, Ricotta D, Cancarini G. Extensive use of serum free light chain test in patients with nephropathy increases the diagnosis number of AL amyloidosis and light chain deposition disease. Hematology meeting reports 2008;2(2):E41a
Harding S, Pratt G, Pepper C, Fegan C, Oscier D, Mead G. Abnormal serum free light chain ratios are associated with poor survival in patients with chronic lymphocytic leukemia. Presented at Lymphoma & Myeloma Congress 2008
Harding S, Pratt G, Holder R, Pepper C, Fegan C, Oscier D, Mead G. Abnormal serum free light chain ratios are associated with poor survival in patients with chronic lymphocytic leukemia. Hematology meeting reports 2008;2(2):C20a
Harding S, Drayson M, Lachmann H, Hawkins P, Hobbs J, Mead G, Bradwell AR. Novel nephelometric immunoassays for the sensitive detection of IgA monoclonal gammopathies in multiple myeloma and AL amyloidosis. Haematologica 2008;93(s1):668a
Harding SJ, Pratt G, Holder R, Fegan C, Pepper C, Oscier D, Mead GP. Abnormal serum free light chain ratios in chronic lymphocytic leukaemia are significantly associated with earlier disease specific death. Haematologica 2008;93(s1):89a
Harousseau JL, Dreyling M. Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(s2):ii55-ii57 PMID: 18456769
Hassoun H, Flombaum C, D'Agati VD, Rafferty BT, Cohen A, Klimek VM et al. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplant 2008;42(6):405-12 PMID: 18574442
Hatjiharissi E, Ciccarelli BT, Ioakimidis L, Borok R, Soumerai JD, Manning RJ et al. Serum Immunoglobulin free light chains as markers of disease burden and response to treatment in patients with Waldenstrom's macroglobulinemia. J Clin Oncol 2008;26(15S):8617a
Hobbs JA, Kilvington F, Sharp K, Harding S, Drayson M, Bradwell AR, Mead GP. Incidence of light chain escape in UK MRC Myeloma VII Trial. Clin Chem 2008;54(s6):C109a
Hobbs JA, Kilvington F, Sharp K, Harding S, Drayson M. Incidence of light chain escape in UK MRC Myeloma VII trial. Hematology meeting reports 2008;2(2):D31a
Hobbs JAR, Sharp K, Harding SJ, Drayson M, Bradwell AR, Mead GP. Incidence of light chain escape in UK MRC myeloma VII trial. Haematologica 2008;93(s1):672a
Hodkinson F, Galligan L, Drain S, Catherwood MA, Morris TCM, Drake MB et al. Investigation of plasma cell dyscrasias with low level plasma cell aspirate involvement. Haematologica 2008;93(s1):1205a
Hoffman-Snyder C, Smith BE. Neuromuscular disorders associated with paraproteinemia. Phys Med Rehabil Clin N Am 2008;19(1):61-79 PMID: 18194750
Hutchison C, Basnayake K, Bradwell A, Cockwell P. Serum free light chain removal by high cut-off hemodialysis: Optimising removal and supportive care. Presented at Renal Association Annual Meeting 2008;129a
Hutchison C, Drayson M, Basnayake K, Mead G, Bradwell A, Plant T, Cockwell P. Serum free light chain measurement aids the diagnosis of myeloma in patients with acute renal failure. J Am Soc Nephrol 2008;19:SA-PO2498a
Hutchison C, Basnayake K, Cook M, Bradwell A, Cockwell P. High rates of renal recovery and patient survival in myeloma kidney using free light chain removal hemodialysis. Presented at Renal Association Annual Meeting 2008;245a
Hutchison C, Basnayake K, Plant T, Drayson M, Cockwell P. Serum free light chain measurement aids the diagnosis of myeloma in patients with acute renal failure. Hematology meeting reports 2008;2(2):E39a
Hutchison C, Plant T, Drayson M, Cockwell P, Basnayake K, Harding S et al. Serum immunoassay is highly sensitive and specific for the diagnosis of monoclonal free light chains in patients with severe renal failure. Nephrol Dial Transplant 2008;23:SP113a
Hutchison C, Basnayake K, Cook M, Cockwell P, Bradwell AR. High renal recovery rate from cast nephropathy following free light chain removal hemodialysis. Am J Kidney Dis 2008;49(4):B47a
Hutchison C, Hewins P, Landray MJ, Townsend J, Cockwell P. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Hematology meeting reports 2008;2(2):E37a
Hutchison C, Basnayake K, Cockwell P. Chronic kidney disease patients and renal transplant recipients have a high prevalence of MGUS. Hematology meeting reports 2008;2(2):E38a
Hutchison C, Cook M, Basnayake K, Cockwell P, Bradwell A. Free light chain removal hemodialysis increases renal recovery rate and improves patient survival in patients with cast nephropathy. Presented at Lymphoma & Myeloma Congress 2008
Hutchison C, Basnayake K, Cook M, Bradwell A, Cockwell P. Free light chain removal hemodialysis increases renal recovery rate and improves patient survival in patients with cast nephropathy. Nephrol Dial Transplant 2008;23:S0019a
Hutchison C, Meryon I, Drayson M, Bradwell A, Cockwell P. High cut-off hemodialysis lowers inflammatory status in chronic dialysis patients. J Am Soc Nephrol 2008;19:TH-PO707a
Hutchison C, Plant T, Drayson M, Basnayake K, Cockwell P. Serum free light chains - a new highly sensitive and specific immunoassay for detecting monoclonal gammopathies in patients with acute renal failure. Presented at Renal Association Annual Meeting 2008;67a
Hutchison CA, Cook M, Heyne N, Weisel K, Billingham L, Bradwell AR, Cockwell P. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. Trials 2008;9(1):55 PMID: 18822172
Hutchison CA, Cockwell P, Harding S, Mead GP, Bradwell AR, Barnett AH. Quantitative assessment of serum and urinary polyclonal free light chains in patients with type II diabetes: an early marker of diabetic kidney disease? Expert Opin Ther Targets 2008;12(6):667-76 PMID: 18479214
Hutchison CA, Harding S, Mead G, Goehl H, Storr M, Bradwell A, Cockwell P. Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care. Artif Organs 2008;32(12):910-7 PMID: 19133018
Hutchison CA, Plant T, Drayson M, Cockwell P, Kountouri M, Basnayake K et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol 2008;9(1):11 PMID: 18808676
Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, Cockwell P. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008;3(6):1684-90 PMID: 18945993
Itzykson R, Le Garff-Tavernier M, Katsahian S, Diemert MC, Musset L, Leblond V. Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom's macroglobulinemia. Haematologica 2008;93(5):793-4 PMID: 18450739
Jagannath S. Serum free light chain testing for diagnosis and monitoring. Myeloma Today 2008;7(5):9
Jiminez J. Utilidad de la determinacion de cedenas ligera libres ensuero para el diagnostico y monitorizacion de gammopatias monoclonales. Rev Lab Clinic 2008;s1(83)
Jung S, Kim M, Lim J, Kim Y, Han K, Min CK, Min WS. Serum free light chains for diagnosis and follow-up of multiple myeloma. Korean J Lab Med 2008;28(3):169-73 PMID: 18594166
Kaplan B, Ramirez-Alvarado M, Dispenzieri A, Zeldenrust SR, Leung N, Livneh A, Gallo G. Isolation and biochemical characterization of plasma monoclonal free light chains in amyloidosis and multiple myeloma: a pilot study of intact and truncated forms of light chains and their charge properties. Clin Chem Lab Med 2008;46(3):335-41 PMID: 18254719
Kapoor P, Snozek C, Colby CL, Larson DR, Katzmann JA, Witzig TE et al. Incorporation of the plasma cell labeling index into the international staging system of multiple myeloma: Impact on prognostic value. J Clin Oncol 2008;26(15S):8591a
Kar R, Dutta S, Bhargava R, Kumar R, Pati HP. Immunoglobulin free light chains: do they have a role in plasma cell leukemia? Hematology 2008;13(6):344-7 PMID: 19055862
Katzmann JA. Laboratory strategies for detecting Multiple Myeloma. Advance for Administrators of the Laboratory 2008;17(4):46
Katzmann JA, Dispenzieri A. Editorial: Screening algorithms for monoclonal gammopathies. Clin Chem 2008;54(11):1753-5
Kim JM, Lee J. The significance of soluble Syndecan-1 in diagnosis and monitoring of multiple myeloma. Haematologica 2008;93(s1):1426a
Kimby E. Treatment of Waldenstrom's macroglobulinaemia. Hematology Education: the education program for the annual congress of the European Hematology Association 2008;2(1):294-301
Krizalkovicova V, Maisnar V, Pour L, Radocha J, Hajek R. [Monoclonal gammopathies of undetermined significance]. Klin Onkol 2008;21(4):160-4 PMID: 19102222
Kumar K, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR et al. A novel staging system for light chain amyloidosis incorporating free light chain levels. Haematologica 2008;93(s1):917a
Kumar K, Dispenzieri A, Lacy M, Hayman S, Buadi F, Zeldenrust S et al. A novel staging system for light chain amyloidosis incorporating free light chain levels. Hematology meeting reports 2008;2(2):C19a
Kumar S, Dispenzieri A, Larson D, Colby CL, Kyle R, Gertz M, Rajkumar SV. Normalization of the serum free light chain (FLC) ratio is associated with superior overall survival among myeloma patients achieving immunofixation negative sate: Results support incorporation of serum FLC ratio in stringent CR definition. Blood 2008;112(11):1692a
Kumar S, Perez WS, Zhang MJ, Ballen K, Bashey A, To LB et al. Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation. Biol Blood Marrow Transplant 2008;14(10):1134-40 PMID: 18804043
Kumar S, Zhang L, Dispenzieri A, Van Wier S, Katzmann J, Snyder M et al. Association of high levels of free light chain and the presence of IgH translocations in multiple myeloma and prognostic implications. Blood 2008;112(11):1677a
Kumar S, Dispenzieri A, Clark R, Larson D, Colby CL, Zeldenrust S et al. Serum immunoglobulin free light chain in primary amyloidosis: Prognostic value and correlations with clinical features. Blood 2008;112(11):2733a
Kyle RA. The role of serum free light chains in monoclonal gammopathy of undetermined significance, solitary plasmacytoma of bone and smoldering multiple myeloma. Hematology meeting reports 2008;2(2):p11
Kyrtsonis M-C, Vassilakopoulos TP, Tzenou T, Kafasi N, Sachanas S, Koulieris E et al. Serum free light chains in Waldenstrom's Macroglobulinaemia (WM) patients at diagnosis. Haematologica 2008;93(s1):1057a
Kyrtsonis MC, Maltezas D, Repousis P, Vassilakopoulos KT, Tzenou T, Papanikolaou X et al. Possible role of myeloma biologically important cytokines in the inappropriate light chain secretion of malignant plasma cells. Hematology meeting reports 2008;2(2):B13a
Kyrtsonis MC, Tzenou T, Vassilakopoulos N, Kafasi N, Sachanas S, Maltezas D et al. Free light chain ratio in the serum of patients with Waldenstroms macroglobulinemia at diagnosis. Hematology meeting reports 2008;2(2):C24a
Kyrtsonis MC, Vassilakopoulos D, Maltezas D, Kafasi N, Terpos E, Elefterakis-Papaiakovou E et al. Suggested risk-stratification models including serum free light chain ratio for improved prognostication in multiple myeloma. Hematology meeting reports 2008;2(2):C23a
Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Kyle RA, Rajkumar SV et al. Autologous stem cell transplant after heart transplant for light chain (AL) amyloid cardiomyopathy. J Heart Lung Transplant 2008;27(8):823-9 PMID: 18656793
Lebovic D, Hoffman J, Levine BM, Hassoun H, Landau H, Goldsmith Y et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 2008;143(3):369-73 PMID: 18691169
Leleu X, Moreau AS, Hennache B, Dupire S, Faucompret JL, Facon T et al. Serum free light chain immunoassays measurements for monitoring solitary bone plasmacytoma. Haematologica 2008;91(s1):PO410a
Leleu X, Moreau AS, Weller E, Roccaro AM, Coiteux V, Manning R et al. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma 2008;49(6):1104-7 PMID: 18452095
Leleu X, Roccaro AM, Leduc R, Poulain S, Moreau AS, Gay J et al. Early response using serum immunoglobulin free light chain (sFLC) measurement predicts response to therapy in Waldenstrom Macroglobulinemia (WM). Blood 2008;112(11):3755a
Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 2008;73(11):1282-8 PMID: 18385667
Lonial S, Gertz MA. To the editor: Eliminating the complete response penalty from myeloma response assessment. Blood 2008;111(6):3297-8 PMID: 18332233
Lopez de la Guila A, Pollmar IR, Salvatierra MG, Rodrigo E, Martin-Salces M, De Paz R et al. IgD multiple myeloma: Case report. Hematology meeting reports 2008;2(2):D28a
Ludwig J, Aulmann M, Zorn M, Nawroth P. Evaluation of the SPAPLUS for serum free light chain measurement. Hematology meeting reports 2008;2(2):A1a
Lynch EA, Showell PJ, Johnson-Brett B, Mead GP, Bradwell AR. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light-chains on the Roche cobas Integra 800. Clin Chem 2008;54(s6):C94a
Lynch EA, Showell PJ, Johnson-Brett B, Mead GP, Bradwell AR. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light chains on the Roche cobas c501. Clin Chem 2008;54(s6):C93a
Lynch EA, Showell PJ, Kaur A, Mead GP, Bradwell AR. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light-chains on the Beckman Synchron LX20 Pro and Beckman UniCel DxC Synchron. Clin Chem 2008;54(s6):C97a
Lynch HT, Ferrara K, Barlogie B, Coleman EA, Lynch JF, Weisenburger D et al. Familial myeloma. N Engl J Med 2008;359(2):152-7 PMID: 18614782
Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ. Cardiovascular Magnetic Resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 2008;10(1):54 PMID: 19032744
Maisnar V, Hajek R. Revision of criteria for the diagnosis and evaluation of response to therapy in multiple myeloma. Klin Biochem Metab 2008;16(37):84-8
Mao XB, Chen XQ, Zhai YP, Liang R, Gao GX, Ma GG et al. [Measurement of serum free light chains and its clinical significance in 20 newly diagnosed patients of multiple myeloma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008;16(4):829-32
Marionneaux S, Zetlmeisl M, van Hoeven KH, Fagan D, Elkins B, Shulman S. Analytical evaluation of kappa and lambda serum free light chains on The Binding Site SPAPLUS. Clin Chem 2008;54(s6):C79a
Mark T, Jayabalan D, Coleman M, Pearse RN, Wang YL, Lent R et al. Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. Br J Haematol 2008;143(5):654-60 PMID: 18950461
Martinez-Sanchez P, Montejano L, Sarasquete ME, Garcia-Sanz R, Fernandez-Redondo E, Ayala R et al. Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response. Br J Haematol 2008;142(5):766-74 PMID: 18637804
Matsuda M, Gono T, Katoh N, Yoshida T, Tazawa K, Shimojima Y et al. Nephrotic syndrome due to primary systemic AL amyloidosis, successfully treated with VAD (vincristine, doxorubicin and dexamethasone) alone. Intern Med 2008;47(6):543-9 PMID: 18344643
Matters DJ, Solanki M, Jones R, Rose S, Carr-Smith H, Bradwell AR. Statistical analysis of free light chain results between seven nephelometric and turbidimetric platforms. Clin Chem 2008;54(s6):C107a
Matters DJ, Solanki M, Jones R, Rose S. Statistical analysis of free light chain results between eight nephelometric and turbidimetric platforms. Hematology meeting reports 2008;2(2):A5a
Matters DJ, Smith L. Comparison of New Scientific Company and Binding Site kits for free light chain measurements in serum. Hematology meeting reports 2008;2(2):B14a
McCudden CR, Hammett-Stabler CA. A case of hook effect in the serum free light chain assay using the Olympus AU400e. Clin Biochem 2008;41:148a
Mead G, Harding S, Pratt G, Basu S, Jacob A, Beardsmore C, Bradwell AR. Serum immunoglobulin and free light chain abnormalities in non Hodgkin lymphoma. Ann Oncol 2008;19(s4):315a
Mead GP, Carr-Smith HD, Bradwell AR. Free light chains. Reply to Beetham et al., Can serum free light chains replace urine electrophoresis? Ann Clin Biochem 2008;45:444 PMID: 18583638
Mead GP, Hobbs JAR, Sharp K, Harding S, Drayson M. Incidence of light chain escape in myeloma patients at relapse. Br J Haematol 2008;141(s1):98a
Mead GP, Stubbs PD, Goodman HJB, Hawkins PN. Comparison of serum versus urine for the identification of monoclonal free light chain production in 219 patients with AL amyloidosis. Hematology meeting reports 2008;2(2):B12a
Merlini G, Palladini G. Advances in AL amyloidosis. Hematology Education: the education program for the annual congress of the European Hematology Association 2008;2(1):287-93
Mignot A, Bridoux F, Thierry A, Varnous S, Pujo M, Delcourt A et al. Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis. Haematologica 2008;93(3):e32-e35 PMID: 18310532
Mignot A, Varnous S, Redonnet M, Jaccard A, Epailly E, Vermes E et al. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients. Arch Cardiovasc Dis 2008;101(9):523-32 PMID: 19041836
Morandeira F, Soriano A, Quandt E, Castro P, Ruiz E, Oriol A et al. Comparacion de 2 ensayos para la determination de cadenas ligeras libres en suero en pacientes con gammapatia monoclonal. Immunologia 2008;27(s1):118a
Morgera S, Kleeberg L, Jakob C, Schneider M, Muller C, Kaiser M et al. Elimination of serum free light chains by novel replacement strategies in combination with chemotherapy in patients with multiple myeloma and kappa light chain nephropathy. Hematology meeting reports 2008;2(2):E34a
Munshi NC. Investigative tools for diagnosis and management. Hematology Am Soc Hematol Educ Program 2008;298-305 PMID: 19074100
Nam M, McRoberts J, Moody M, Al Swanamy T, Poynton C. Light chain escape from paraproteinemia - myth or reality? Hematology meeting reports 2008;2(2):D32a
Navarro J, Ravell JC, Velastegui A, Fernandez A, Fernandez-Cruz E. Quantification of kappa and lambda free light chains. Accreditation according the international standard ISO 15189. Presented at Biennial Meeting 2008
Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008;111(3):1101-9 PMID: 17989313
Offidani M, Polloni C, Piersantelli M-N, Corvatta L, Gentili S, Catarini M et al. Impact of free light chains ratio normalization on response duration in multiple myeloma (MM) patients treated with new drugs. Haematologica 2008;93(s1):1476a
Park M, Song W, Kim J, Hang H, Lee K. Diagnostic performance of serum free light chain assay in monoclonal gammopathies. Clin Chem 2008;54(s6):C108a
Pasquali S, Mancini E, Santoro A. Removal of free circulating light chains (LC) by a high cut-off membrane: Different dialysis strategies. J Am Soc Nephrol 2008;19:F-PO1560a
Piehler AP, Gulbrandsen N, Kierulf P, Urdal P. Quantitation of serum free light chains in combination with protein electrophoresis and clinical information for diagnosing multiple myeloma in a general hospital population. Clin Chem 2008;54(11):1823-30 PMID: 18801937
Pika T, Minarík J, Zemanovà M, Schneiderka P, Bacovský J, Slézar J, Scudla V. Serum free light chain immunoglobulin levels in multiple myeloma and monoclonal gammopathy of undetermined significance. Klin Biochem Metab 2008;16(37):102-5
Pika T, Minarik J, Schneiderka P, Budikova M, Langova K, Lochman P et al. The correlation of serum immunoglobulin free light chain levels and selected biological markers in multiple myeloma. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008;152(1):61-4 PMID: 18795076
Pillon L, Sweeting RS, Arora A, Notkin A, Ballard HS, Wieczorek RL, Leung N. Approach to acute renal failure in biopsy proven myeloma cast nephropathy: is there still a role for plasmapheresis? Kidney Int 2008;74(7):956-61 18418353
Pinto A, De Filippi R, Iaccarino G, Di Francia R, Distinto M, Frigeri F et al. Abnormalities in serum free-immunoglobulin light chains show a high and differential frequency among WHO subtypes of B-cell non-Hodgkin's lymphoma (NHL) and may turn of value for therapeutic monitoring: A study of 354 newly diagnosed patients. Blood 2008;112(11):2813a
Pisani F, Cordone I, Dessanti ML, Cigliana G, Frollano B, Masi S et al. Bortezomib, liposomal doxorubicin and dexamethasone regimen for relapsed or refractory multiple myeloma and introduction of serum free light chains (sFLC) in response monitoring: Preliminary data. Haematologica 2008;93(s1):1106a
Popat R, Oakervee H, Williams C, Cook M, Craddock C, Basu S et al. Bortezomib, low dose intravenous melphalan and dexamethasone for patients with relapsed multiple myeloma. Haematologica 2008;93(s1):918a
Pratt G. The evolving use of serum free light chain assays in haematology. Br J Haematol 2008;141(4):413-22 PMID: 18318757
Pratt G, Harding S, Holder R, Fegan C, Pepper C, Oscier D, Mead G. Abnormal serum free light chain ratios are associated with poor survival in patients with chronic lymphocytic leukaemia. Br J Haematol 2008;141(s1):80a
Pratt G, Mead G, Basu S, Jacobs A, Holder R, Fegan C et al. Abnormal serum free light chain ratios are associated with earlier time to first treatment and poor survival in patients with chronic lymphocytic leukaemia. Blood 2008;112(11):3141a
Pratt G, Holding S. More studies are needed to assess the performance of serum free light chain measurement for the diagnosis of B-cell disorders in routine clinical practice - response to Vermeersch et al. Br J Haematol 2008;143(1):145-6 PMID: 18671705
Presslauer S, Milosavljevic D, Brucke T, Bayer P, Hubl W. Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis. J Neurol 2008;255(10):1508-14 PMID: 18685917
Recasens V, Rubio-Escuin R, Rubio-Martinez A, Pascual T, Lopez N, Sanjuan M, Giraldo P. Serum free light chains profile as early biomarker with predictive value after autologous transplant in multiple myeloma. Blood 2008;112(11):5142a
Recasens V, Rubio-Escuin R, Rubio-Martinez A, Rodriguez T, Lopez N, Giraldo P. Early predictive value of serum free light chains profile in relapsed of multiple myeloma after autologous transplant. Hematology meeting reports 2008;2(2):D33a
Robin H, Gaertner R, Parton A, Zetlmeisl M, Garcia A, Kuus-Reichel K. Utility of serum free light chain analysis in the diagnosis of monoclonal gammopathies in a community hospital. Hematology meeting reports 2008;2(2):C17a
Rodriguez GP, Jimenez JJ, Rodriguez MJR, de Carvalho NB, Manzanal RM, de Larramendi CH, Godoy PS. Patient with multiple myeloma, in extramedullary relapse associated to light chain excretion and disappearing of intact immunoglobulin 'light chain escape'. Hematology meeting reports 2008;2(2):D29a
Roussou M, Kastritis E, Migkou M, Psimenou E, Grapsa I, Matsouka C et al. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma 2008;49(5):890-5 PMID: 18464107
Sackmann F, Pavlovsky MA, Corrado C, Pizzolato M, Alejandre M, Pavlovsky S. Prognostic factors in monoclonal gammopathy of undetermined significance. Haematologica 2008;93(1):153-4 PMID: 18166806
Schonland SO, Hansmann J, Mechtersheimer G, Goldschmidt H, Ho AD, Hegenbart U. Bone involvement in patients with systemic AL amyloidosis mimics lytic myeloma bone disease. Haematologica 2008;93(6):955-6 PMID: 18515883
Seldin DC, Ward JE. Serum free light chain analysis, 4th Edition. Amyloid 2008;15(2):142-3 PMID: 18484342
Shaheen SP, Talwalkar SS, Medeiros LJ. Multiple myeloma and immunosecretory disorders: an update. Adv Anat Pathol 2008;15(4):196-210 PMID: 18580096
Sharp K, Emond JP, Giroux M, Steiner A, Russ G, Harding S. Serum free light chain measurements by electrophoretic and nephelometric methods may differ due to the presence of aggregated light chains. Hematology meeting reports 2008;2(2):B11a
Sheldon J. Free light chains: author's response. Ann Clin Biochem 2008;45(Pt 4):445-6 PMID: 18583639
Showell PJ, Lynch EA, Mitchell F, Mead GP, Bradwell AR. Comparison of serum free immunoglobulin light-chain assays on eight Nephelometric/Turbidimetric analysers. Clin Chem 2008;54(s6):C92a
Showell PJ, Lynch EA, Mitchell F. Comparison of serum free immunoglobulin light chain assays on eight nephelometric/ turbidimetric analysers. Hematology meeting reports 2008;2(2):A4a
Showell PJ, Lynch EA, Johnson-Brett B. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light chains on the Roche COBAS C501. Hematology meeting reports 2008;2(2):A2a
Showell PJ, Lynch EA, Johnson-Brett B. Evaluation of latex-enhanced turbidimetric reagents for measuring free immunoglobulin light-chains on the Roche COBAS INTEGRA 800. Hematology meeting reports 2008;2(2):A3a
Siegel DS, McBride L, Lendvai N, Gonsky J, Berges T, Schillen D et al. Pitfalls in the calculation of 24-urine test results in patients with monoclonal gammopathies: serum free light chain assays provide a more accurate assessment in this setting. Hematology meeting reports 2008;2(2):B8a
Snozek CL, Katzmann JA, Kyle RA, Dispenzieri A, Larson DR, Therneau TM et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia 2008;22(10):1933-7 PMID: 18596742
Snyder MR, Clark R, Bryant SC, Katzmann JA. Quantification of urinary light chains. Clin Chem 2008;54(10):1744-6 PMID: 18824580
Sobas M, Perez L, de Carvalho N, Encinas MP. Serum immunoglobulin free light chains for monitoring patients with oligosecretory myeloma. Hematology meeting reports 2008;2(2):D30a
Šcudla V, Schneiderka P, Pika T, Minarík J, Bacovsky J, Farbiaková V. Clinical importance of evaluating serum levels of free light chains of immunoglobulins in monoclonal gammopathies. Klin Biochem Metab 2008;16(37):76-83
Špicka I, Mecl J, Benáková H, Nohejlová A, Straub J, Novotová E, Zima T. Comparing the detection of monoclonal protein by means of presently available biochemical methods. Klin Biochem Metab 2008;16(37):89-92
Tang G, Snyder M, Rao LV. Assessment of serum free light chain (FLC) assays with immunofixation electrophoresis (IFE) and bone marrow (BM) immunophenotyping in the diagnosis of plasma cell disorders. Clin Chem 2008;54(s6):A96a
Tate J, Bazeley S, Sykes S, Mollee P. Serum free light chain assay for diagnosis and monitoring of monoclonal light-chain diseases: analytical and clinical correlations. Ann Clin Biochem 2008;45(s1):Th40a
Tate JR, Bazeley S, Sykes S, Mollee P. Serum free light chain assay for diagnosis and monitoring of monoclonal light-chain diseases - analytical and clinical correlations. Clin Chem 2008;54(s6):C75a
Thio M, Blokhuis BR, Nijkamp FP, Redegeld FA. Free immunoglobulin light chains: a novel target in the therapy of inflammatory diseases. Trends Pharmacol Sci 2008;29(4):170-4 PMID: 18353446
Tichý M, Vávrová J, Friedecký B, Maisnar V. Methods for detection of free immunoglobulin light chains. Klin Biochem Metab 2008;16(37):93-6
Trieu Y, Xu W, Anglin P, Chen C, Kukreti V, Trudel S, Reece DE. Evaluation of serum free light chains and outcome in multiple myeloma patients with an intact monoclonal immunoglobulin treated with autologous stem cell transplantation. Blood 2008;112(11):3323a
van Gameren II, Bijzet J, Limburg PC, Vellenga E, van Rijswijk MH, Hazenberg BP. Diagnostic performance of measuring free light chains in fat tissue of patients with AL amyloidosis. Presented at ACR Annual Scientific Meeting 2008;831a
van Hoeven KH, Wells J, Abadie A. Serum protein electrophoresis (SPEP) and serum free light chain assays: A more sensitive approach than SPEP and urine protein electrophoresis (UPEP) for the diagnosis of monoclonal gammopathy. J Am Soc Nephrol 2008;19:SA-PO2501a
van Hoeven KH, McBride L, Lendvai N, Gonsky J, Berges T, Siegel DS. Serum free light chain testing is a more sensitive baseline marker than urine protein electrophoresis among patients undergoing primary autologous stem cell transplantation in multiple myeloma. Hematology meeting reports 2008;2(2):B9a
van Rhee F, Crowley J, Barlogie B. Response: Top tertile SFLC reduction indeed is an independent feature of myeloma aggressiveness. Blood 2008;111(4):2491a
Vavrova J, Friedecky B, Tichy M, Holeckova M, Maisnar V, Hajek R. The evaluation of light chains using ELISA method. Blood 2008;112(11):5147a
Vávrová J, Friedecký B, Tichý M, Holecková M, Maisnar V, Hájek R. The determination of free light chains by immunoturbidimetry and ELISA. Klin Biochem Metab 2008;16(37):97-101
Vermeersch P, Marien G, Bossuyt X. More studies are needed to assess the performance of serum free light chain measurement for the diagnosis of B-cell disorders in routine clinical practice. Br J Haematol 2008;143(1):143-5 PMID: 18671704
Vermeersch P, Van Hoovels L, Delforge M, Marien G, Bossuyt X. Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder. Br J Haematol 2008;143(4):496-502 PMID: 18729849
Vescio R. Advances in the diagnosis of multiple myeloma. Clin Adv Hematol Oncol 2008;6(4):299-300 PMID: 18496497
Vickrey E. Multiple myeloma: vague symptoms can challenge diagnostic skills. JAAPA 2008;21(11):19-22 PMID: 19105542
Vickrey E, Allen S, Krishnamurthy J, Singh V, Mehta J, Singhal S. The utility of serum free light chain measurement in myeloma patients with oligoclonal bands on serum or urine Immunofixation. Blood 2008;112(11):5121a
Wechalekar AD, Lachmann HJ, Goodman HJ, Bradwell A, Hawkins PN, Gillmore JD. AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood 2008;112(10):4009-16 PMID: 18708629
Wechalekar AD, Hawkins PN, Gillmore JD. Perspectives in treatment of AL amyloidosis. Br J Haematol 2008;140(4):365-77 PMID: 18162121
Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008;93(2):295-8 PMID: 18245653
Wells JM, van Hoeven KH, Abadie JM. Serum free light chains assays in clinical practice: Impact of impaired renal function on interpretation. Clin Chem 2008;54(s6):C91a
Went R, Chan-Lam D, Thornhill M. Isolated tongue amyloid in a patient with multiple myeloma. Br J Haematol 2008;143(5):606 PMID: 18710391
White DA, Rose S, Galsinh S, Perry A, Parker A, Smith A. Comparison of normal and multiple myeloma samples measured by an ELISA free light chain assay (Biovendor) and the Binding Site Ltd nephelometric Freelite assay. Hematology meeting reports 2008;2(2):B15a
Willenbacher E, Gastl G, Nachbaur D, Willenbacher W. Free light chain analysis: Is it useful to monitor patients undergoing haematological stem cell therapy for multiple myeloma? An analysis of "real life" data. Bone Marrow Transplant 2008;41(s1):674a
Willenbacher E, Gastl G, Nachbaur D, Clausen J, Willenbacher W. Free light chain analysis: Is it useful to monitor patients undergoing hematological stem cell therapy for multiple myeloma? An analysis of 'real life' data. Hematology meeting reports 2008;2(2):D27a
Wood P, McElroy Y, Stone MJ. Comparison of serum immunofixation electrophoresis and free light chain assays in detection of monoclonal gammopathies. Hematology meeting reports 2008;2(2):B10a
Wurster U. Cerebrospinal fluid analysis in multiple sclerosis and neuroborreliosis: free light chains compared with oligoclonal bands and IgG, IgA, IgM synthesis. Ann Clin Biochem 2008;45(s1):T9a

2009

Abadie JM, van Hoeven KH, Wells JM. Are renal reference intervals required when screening for plasma cell disorders with serum free light chains and serum protein electrophoresis? Am J Clin Pathol 2009;131(2):166-71 PMID:19141376
Aggarwal R, Sequeira W, Mikolaitis R, Kokebie R, Block JA, Jolly M. Measurement of serum free light chains performs better than known immunological biomarkers for systemic lupus erythematosus disease activity. Presented at ACR/AHRP Annual Scientific Meeting 2009;916a
Airoldi A, Quaglia M, Fenoglio R, Lazzarich E, Crespi I, Bellomo G et al. Pitfalls in nephrology: Renal threshold for serum free light chains required to produce Bence-Jones proteinuria. Presented at World Congress of Nephrology 2009;M182a
Almeshhedani M, Salamat A, Al-Ismail S. Evaluating the potential use of risk categorisation in the management of MGUS. Haematologica 2009;94(s2):969a
Arneth B. Author's Response to Professor Reiber's second letter concerning our article: High sensitivity of free lambda and free kappa light chains for the detection of intrathecal immunoglobulin synthesis in cerebrospinal fluid. Acta Neurol Scand 2009;120(6):447-9
Arneth B, Birklein F. High sensitivity of free lambda and free kappa light chains for detection of intrathecal immunoglobulin synthesis in cerebrospinal fluid. Acta Neurol Scand 2009;119(1):39-44 PMID:18573131
Arrobas Velilla T, Bermudo Guitarte C, Duro Millan R, Santos Rey K, Sanchez Margalet V, Arjona Rueda I, Goberna Ortiz R. Use of serum free light chain concentrations as an early response marker in multiple myeloma (MM). Clin Chem 2009;55(s6):C69a
Asenova S, Bacher U, Gerritzen A, Zander AR, Kröger N. Role of free light chain assay ratio to distinguish between CR according EBMT criteria or stringent complete remission (sCR) according IMWG in multiple myeloma patients. Blood 2009;114(22):1787a
Audard V, Matignon M, Weiss L, Remy P, Pardon A, Haioun C et al. Successful long-term outcome of the first combined heart and kidney transplant in a patient with systemic AL amyloidosis. Am J Transplant 2009;9(1):236-40 PMID:19067666
Avet-Loiseau H, Harousseau JL, Moreau P, Mathiot C, Facon T, Attal M et al. Heavy/light chain specific immunoglobulin ratios at presentation are prognostic for progression free survival in the IFM 2005-01 myeloma trial. Blood 2009;114(22):1818a
Bakker AJ, Bierma-Ram A, Elderman-van der Werf C, Strijdhaftig ML, van Zanden JJ. Screening for M-proteinemia: serum protein electrophoresis and free light chains compared. Clin Chem Lab Med 2009;47(12):1507-11 PMID:19842994
Bakker AJ, Bierma-Ram A, Elderman-van der Werf C, Strijdhaftig ML, van Zanden JJ. Quantitation of serum free light chains. Clin Chem 2009;55(8):1585-7 PMID:19498053
Basnayake K, Ghonemy T, Hutchison C, Bradwell AR, Cockwell P. Immunoglobulin free light chains in situ in patients with chronic kidney disease. Presented at NKF Spring Clinical Meeting 2009
Basnayake K, Cheung CK, Hutchison C, Cook M, Rylance P, Stoves J et al. Differential evolution of renal scarring in cast nephropathy despite early reductions in serum free light chains. Presented at NKF Spring Clinical Meeting 2009
Bird J, Behrens J, Westin J, Turesson I, Drayson M, Beetham R et al. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2009;147(1):22-42 PMID:19673884
Bladé J, Rosinol L, Cibeira MT. Are all myelomas preceded by MGUS? Blood 2009;113(22):5370 PMID:19478048
Böer K, Deufel T. Quantitation of serum free light chains does not compensate for serum immunofixation only when screening for monoclonal gammopathies. Clin Chem Lab Med 2009;47(9):1109-15 PMID:19728853
Bradwell AR, Harding SJ, Fourrier NJ, Wallis GL, Drayson MT, Carr-Smith HD, Mead GP. Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. Clin Chem 2009;55(9):1646-55 PMID:19617289
Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica 2009;94(3):380-6 PMID:19211640
Chanan-Khan AA, Jagannath S, Heffner LT, Avigan D, Lee KP, Lutz RJ et al. Phase I study of BT062 given as repeated single dose once every 3 weeks in patients with relapsed or relapsed/refractory multiple myeloma. Blood 2009;114(22):1862a
Chee CE, Kumar S, Larson DR, Kyle RA, Dispenzieri A, Gertz MA et al. The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. Blood 2009;114(13):2617-8 PMID:19641191
Cohen G, Horl WH. Free immunoglobulin light chains as a risk factor in renal and extrarenal complications. Semin Dial 2009;22(4):369-72 PMID:9708983
Comenzo RL. How I treat amyloidosis. Blood 2009;114(15):3147-57 PMID:19617578
Cook M, Hutchison C, Basu S, Cockwell P, Bradwell AR. FLC removal HD improves outcome in myeloma kidney. Clin Lymphoma Myeloma 2009;9(s1):A069a
de Cruz M, Pawarova B, Lachmann H, Gillmore J, Gibbs S, Sattianayagam P et al. Early detection of cardiac systolic functional impairment and correlation with NT-ProBNP change in AL amyloidosis by cardiac lateral wall tissue Doppler S wave. Blood 2009;114(22):2814a
De Filippi R, Iaccarino G, Frigeri F, Di FR, Crisci S, Capobianco G et al. Elevation of clonal serum free light chains in patients with HIV-negative primary effusion lymphoma (PEL) and PEL-like lymphoma. Br J Haematol 2009;147(3):405-8 PMID:19681885
De Filippi R, Laccarino G, Frigeri F, Russo F, Di Francia R, Distinyo M et al. Serum free-immunoglobulin light chains testing is frequently abnormal in patients with B-cell Non-Hodgkin and Hodgkin Lymphoma and may change in value for prognosis and therapeutic monitoring. Clin Lymphoma Myeloma 2009;9(s1):A412a
De Filippi R, Russo F, Iaccarino G, Crisci S, Frigeri F, Riemma C et al. Abnormally elevated levels of serum free-immunoglobulin light chains are frequently found in classic Hodgkin Lymphoma (cHL) and predict outcome of patients with early stage disease. Blood 2009;114(22):267a
de Larrea CF, Cibeira MT, Elena M, Arostegui JJ, Rosinol L, Rovira M et al. Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition. Blood 2009;114(24):4954-6 PMID:19797521
Decaux O, Briand PY, Guenet L, Sebillot M, Jego P, Grosbois B. Frequency of abnormal serum free light chain ratio in a French cohort of patients with MGUS. Clin Lymphoma Myeloma 2009;9(s1):B373a
Decaux O, Karras A. Update in multiple myeloma: international response criteria and renal complications. Rev Med Interne 2009;30(12):1080-3 PMID:19833418
Decaux O. 5th International Symposium on clinical applications of serum free light chain analysis. Rev Med Interne 2009;30(1):96-100 PMID:19054596
Delbes S, Bridoux F, Tennent G, Valleix S, Touchard G, Goujon JM. Predominant renal hereditary amyloidosis caused by a novel apolipoprotein (Apo) A1 variant. Presented at World Congress of Nephrology 2009;Su046a
Diamantidis MD, Loannidou-Papagiannaki E, Ntaios G. Novel extended reference range for serum kappa/lambda free light chain ratio in diagnosing monoclonal gammopathies in renal insufficient patients. Clin Biochem 2009;42(10-11):1202-3 PMID:19375413
Dimopoulos MA, Roussou M, Gavriatopoulou M, Zagouri F, Migkou M, Matsouka C et al. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin Lymphoma Myeloma 2009;9(4):302-6 PMID:19717380
Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23(2):215-24 PMID:19020545
Doyle A, Soutar R, Geddes CC. Multiple myeloma in chronic kidney disease. Utility of discretionary screening using serum electrophoresis. Nephron Clin Pract 2009;111(1):c7-11 PMID:19033691
Drayson M, Cobbold M, Goodall M, Wang Y, Birtwhistle J, Jefferis R. Monoclonal antibodies that provide a reliable new assay for serum immunoglobulin FLC in myeloma. Clin Lymphoma Myeloma 2009;9(s1):A355a
Drayson MT, Behrens J, Cohen DR, Iggo N, Gregory WM, Bell SE et al. Serum FLC levels can be reduced rapidly; lower levels are associated with renal recovery. Clin Lymphoma Myeloma 2009;9(s1):A351a
Drayson MT, Morgan GJ, Jackson GH, Davies FE, Owen RG, Ross FM et al. Prospective study of serum FLC and other M-protein assays: when and how to measure response? Clin Lymphoma Myeloma 2009;9(s1):A346a
Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS et al. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma. Jpn J Clin Oncol 2009;39(7):449-55 PMID:19487425
Esperanza E, Sanchez-Navarro MR, Caffarena C, Mora-Vallellano J, Zafra-Ceres M, Samaniego-Sanchez C. Algorithm for monoclonal gammopathies diagnosis. To prospective study of incidence from our population. Haematologica 2009;94(s2):1611a
Fernández de Larrea C, Cibeira MT, Elena M, Rosiñol L, Rovira M, Arostegui JJ et al. Abnormal serum free-light chain ratio in patients with multiple myeloma in long-lasting complete remission: strong association with oligoclonal bands. Haematologica 2009;94(s2):375a
Fulton RB, Fernando SL. Serum free light chain assay reduces the need for serum and urine immunofixation electrophoresis in the evaluation of monoclonal gammopathy. Ann Clin Biochem 2009;46(Pt 5):407-12 PMID:19641008
Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, Kumar S et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 2009;115(7):1343-50 PMID:20008302
Giarin MM, Giaccone L, Sorasio R, Sfiligoi C, Amoroso B, Cavallo F et al. Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. Clin Chem 2009;55(8):1510-6 PMID:19520760
Gibbs SDJ, Gillmore JD, Sattianayagam PT, Offer M, Lachmann HJ, Hawkins PN, Wechalekar AD. In AL amyloidosis, both oral melphalan and dexamethasone (Mel-Dex) and risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) have similar efficacy as upfront treatment. Blood 2009;114(22):745a
Gibbs SDJ, de Cruz M, Sattianayagam PT, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD. Transient post chemotherapy rise in NT Pro-BNP in AL amyloidosis: implications for organ response assessment. Blood 2009;114(22):1791a
Gibbs SDJ, Sattianayagam PT, Gillmore JD, Offer M, Lachmann HJ, Hawkins PN, Wechalekar AD. Is there a role for thalidomide maintenance in the treatment of AL amyloidosis? Blood 2009;114(22):1863a
Gillmore J, Cocks K, Gibbs SDJ, Sattianayagam PT, Lane T, Lachmann H et al. Cyclophosphamide, thalidomide and dexamethasone (CTD) versus melphalan plus dexamethasone (MD) for newly-diagnosed systemic AL amyloidosis - results from the UK amyloidosis treatment trial. Blood 2009;114(22):2869a
Giraldo P, Recasens V, Rubio-Escuin R, Rubio-Martinez A, Pascual T, Giraldo P. Predictive value of serum free light chains ratio in relapsed of multiple myeloma after autologous transplant. Haematologica 2009;94(s2):1615a
Girnius S, Tsai F, Seldin DC, Quillen K, Yanarella L, Finn KT et al. Early serum free light chain responses following high-dose melphalan and stem cell transplantation for AL amyloidosis. Blood 2009;114(22):4352a
Go RS, Doyle LM. A monoclonal gammopathy in search of clinical significance: 57 years later. Blood 2009;114(11):2355-6 PMID:19745077
Gottenberg JE, Miceli-Richard C, Ducot B, Goupille P, Combe B, Mariette X. Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. Arthritis Res Ther 2009;11(4):R114 PMID:19627580
Groot Kormelink T, Thio M, Blokhuis BR, Nijkamp FP, Redegeld FA. Atopic and non-atopic allergic disorders: current insights into the possible involvement of free immunoglobulin light chains. Clin Exp Allergy 2009;39(1):33-42 PMID:19040467
Harding S, Koulieris E, Kyrtsonis MC, Bradley C, Drayson M, Morgan G et al. Serum free light chain and serum heavy/ light chain ratios are independently prognostic in multiple myeloma patients. Blood 2009;114(22):4880a
Harding S, Sharp K, Fourrier N, Margetts C, Mead G, Bradwell AR. Nephelometric immunoassays for IgGκ and IgGλ for the assessment of multiple myeloma patients. Clin Chem 2009;55(S6):C23a
Harding SJ, Margetts C, Fourrier NJ, Drayson MT, Mead GP, Bradwell AR. Comparison of serum protein immunofixation electrophoresis, serum free light chains and heavy/light chain ratios for monitoring IgA multiple myeloma patients. Haematologica 2009;94(s2):1578a
Harding SJ, Sharp K, Steiner A, Russ G, Blackmore S, Mead G et al. Quantification of polymerising serum free light chains. Clin Lymphoma Myeloma 2009;9(s1):B101a.
Harding SJ, Mead GP, Hobbs JAR, Drayson MT, Bradwell AR. Free light and heavy/light chain monitoring in IgGλ sera. Clin Lymphoma Myeloma 2009;9(s2):B225a
Harding SJ, Mead GP, Bradwell AR, Berard AM. Serum free light chain immunoassay as an adjunct to serum protein electrophoresis and immunofixation electrophoresis in the detection of multiple myeloma and other B-cell malignancies. Clin Chem Lab Med 2009;47(3):302-4 PMID:19676141
Harding SJ, Drayson MT, Mead GP, Bradwell AR. Prognostic value of free and heavy/light chain analysis. Clin Lymphoma Myeloma 2009;9(s2):B555a
Harding SJ, Alvi A, Margetts C, Plant T, Drayson M, Mead G, Bradwell AR. Immunoglobulin ratios: an alternative to immunofixation. Clin Lymphoma Myeloma 2009;9(s2):B596a
Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009;114(15):3139-46 PMID:19638622
Harousseau JL, Dreyling M. Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(s4):97-9 PMID:19454476
Harris JC, Harding SJ, Fourrier N, Drayson MT, Mead GP, Bradwell AR. Nephelometric immunoassays for IgA kappa and IgA lambda quantification for the assessment of patients with multiple myeloma. Clin Chem 2009;C49a
Hata H, Nishi K, Oshihara W, Arai J, Shimizu K, Kawakita T et al. Adsorption of Bence-Jones protein to polymethylmethacrylate membrane in primary amyloidosis. Amyloid 2009;16(2):108-10 PMID:20536405
Haynes R, Hutchison CA, Dasgupta T, Emberson J, Wheeler DC, Townend J et al. Associations of serum free light chains (FLCs) with the risks of end-stage renal disease (ESRD) and of death in chronic kidney disease. Presented at ASN Renal Week 2009;TH-PO552a
Heher EC, Spitzer TR, Goes NB. Light chains: heavy burden in kidney transplantation. Transplantation 2009;87(7):947-52 PMID:19352111
Herrera GA. Renal lesions associated with plasma cell dyscrasias: practical approach to diagnosis, new concepts, and challenges. Arch Pathol Lab Med 2009;133(2):249-67 PMID:19195968
Higgins C. Myeloma and monoclonal gammopathy of undetermined significance. Biomed Sci 2009;September
Hobbs J, Legg A, Giroux M. Clinical applications of serum free light chain analysis. Biomed Sci 2009;April:285-6
Hobbs JA, Drayson MT, Sharp K, Harding S, Bradwell AR, Mead GP. Frequency of altered monoclonal protein production at relapse of multiple myeloma. Br J Haematol 2009;148(4):659-61 PMID:19863537
Hobbs JA, Sharp K, Harding S, Drayson M, Bradwell AR, Mead GP. Changes in M-protein at multiple myeloma relapse. Clin Lymphoma Myeloma 2009;9(s1):A162a
Holding S. Serum free light chain used with electrophoresis increases sensitivity for monoclonal gammopathies. Clin Lymphoma Myeloma 2009;9(s1):A189a
Hughes M, Soutar R, Lucraft H, Owen R, Bird J. Guidelines on the diagnosis and management of solitary plasmacytoma of bone, extramedullary plasmacytoma and multiple solitary plasmacytomas: 2009 update. Online publication 2009.http://www.bcshguidelines.com/documents/solitary_plamacytoma_bcsh_FINAL_190109.pdf
Hutchison C, Airia P, Cook M, Grima D. Improving outcomes in patients with renal failure secondary to multiple myeloma: results from ChAR2M2. Blood 2009;114(22):1875a
Hutchison C, Meryon I, Hewins P, Drayson M, Cockwell P. High cut-off haemodialysis improves pro-inflammatory status when used in a chronic haemodialysis schedule: An open label crossover study. Presented at World Congress of Nephrology 2009;Su384a
Hutchison C, Meryon I, Hewins P, Drayson M, Cockwell P. High cut-off haemodialysis lowers inflammatory status in chronic dialysis patients. Presented at Renal Association Annual Meeting 2009;104a
Hutchison CA, Bradwell AR, Cook M, Basnayake K, Basu S, Harding S et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009;4(4):745-54 PMID:19339414
Hutchison CA, Basnayake K, Cockwell P. Serum free light chain assessment in monoclonal gammopathy and kidney disease. Nat Rev Nephrol 2009;5(11):621-8 PMID:19786994
Hutchison CA, Airia P, Cockwell P, Grima D. Free light chain removal by high cut-off hemodialysis is associated with high rates of renal recovery in patients with renal failure secondary to multiple myeloma. Presented at ASN Renal Week 2009;SA-PO2448a
Iancu DM. Correlation of serum free light chains (Freelite) with urine immunofixation (IFE) free light chains (FLC) in the diagnostic and follow-up of patients with intact immunoglobulin multiple myeloma (IIMM) in a comprehensive cancer center. Clin Chem 2009;55(S6):C37a
Kaplan B, Ramirez-Alvarado M, Sikkink L, Golderman S, Dispenzieri A, Livneh A, Gallo G. Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease. Br J Haematol 2009;144(5):705-15 PMID:19076171
Kastritis E, Migkou M, Gavriatopoulou M, Zirogiannis P, Hadjikonstantinou V, Dimopoulos MA. Treatment of light chain deposition disease with bortezomib and dexamethasone. Haematologica 2009;94(2):300-2 PMID:19066331
Katzmann JA. Screening panels for monoclonal gammopathies: time to change. Clin Biochem Rev 2009;30(3):105-11 PMID:19841692
Katzmann JA, Kyle RA, Benson J, Larson DR, Snyder MR, Lust JA et al. Screening panels for detection of monoclonal gammopathies. Clin Chem 2009;55(8):1517-22 PMID:19520758
Keren DF. Heavy/light-chain analysis of monoclonal gammopathies. Clin Chem 2009;55(9):1606-8 PMID:19589841
Kleeberg L, Morgera S, Jakob C, Hocher B, Schneider M, Peters H et al. Novel renal replacement strategies for the elimination of serum free light chains in patients with kappa light chain nephropathy. Eur J Med Res 2009;14(2):47-54 PMID:19258212
Kuhnemund A, Liebisch P, Bauchmuller K, Zur Hausen A, Veelken H, Wasch R, Engelhardt M. 'Light-chain escape-multiple myeloma'-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol 2009;135(3):477-84 PMID:18802723
Kumar R, Gupta D, Raina V, Sharma A, Kumar L, Irshad M et al. sFLC in healthy Indian subjects and myeloma patients. Clin Lymphoma Myeloma 2009;9(s1):A576a
Kumar S, Hayman SR, Buadi F, Allred J, Laumann K, Roy V et al. A phase II trial of lenalidomide, cyclophosphamide and dexamethasone (RCD) in patients with light chain amyloidosis. Blood 2009;114(22):3853a
Kumar S, Gertz MA, Lacy MQ, Hayman SR, Buadi F, Zeldenrust SR et al. Changes in serum free light chain rather than intact monoclonal immunoglobulin levels predict outcome with therapy in patients with light chain amyloidosis. Blood 2009;114(22):747a
Kumar S, Dispenzieri A, Lacy MQ, Hayman S, Buadi F, Zeldenrust SR et al. A novel prognostic staging system for light chain amyloidosis (AL) incorporating markers of plasma cell burden and organ involvement. Blood 2009;114(22):2797a
Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23(1):3-9 PMID:18971951
Kyrtsonis MC, Maltezas D, Tzenou T, Koulieris E, Bradwell AR. Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma. Semin Hematol 2009;46(2):110-7 PMID:19389494
Landgren O, Kyle RA, Rajkumar V. Response: Multiple myeloma is universally preceded by a prolonged premalignant stage: novel clinical insights and future directions. Blood 2009;114(11):2356-7
Landgren O, Goedert J, Rabkin C, Wilson W, Dunleavy K, Kyle R et al. Risk of AIDS non-Hodgkin's lymphoma is strongly predicted by elevated levels of circulating immunoglobulin-free light chains. Presented at Retroviruses and Opportunistic Infections Conference 2009;29a
Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009;113(22):5412-7 PMID:19179464
Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia 2009;23(10):1691-7 PMID:19587704
Lee CK, Berg M, Ryder J, Myint H, Kolhouse JF, Robinson W. Presence of dysregulated immune recovery (IMD) following autotransplant may change the type of predominant serum light chain and elevate the level in patients with multiple myeloma (MM). Blood 2009;114(22):4870a
Legg A, Hobbs JA, Mead GP, Bradwell AR, Davern S, Solomon A. Monoclonal vs polyclonal free light chain assays. Am J Clin Pathol 2009;131(6):901-2 PMID:19461100
Leleu X, Leduc R, Rourke M, Chuma S, Sam A, Harris B et al. Serum immunoglobulin free light chain (sFLC) measurement as a new marker of response to therapy and survival in Waldenstrom macroglobulinemia (WM). Blood 2009;114(22):3952a
LeSourd S, Sweat K, Johnston M, Marshall J, Bornhorst J. Method comparison of quantitative serum free light chain immunoassays performed on nephelometric versus turbidimetric platforms. Clin Chem 2009;55(S6):D160a
Madan S, Greipp PR. The incidental monoclonal protein: current approach to management of monoclonal gammopathy of undetermined significance (MGUS). Blood Rev 2009;23(6):257-65 PMID:19699016
Magarotto V, Londhe A, Lantz KC, Lowery C, Sonneveld P, Bladé J et al. Impact of baseline free light chain ratio (rFLC) on clinical outcomes and change in rFLC during treatment in patients with relapsed/refractory multiple myeloma treated with pegylated liposomal doxorubicin plus bortezomib or bortezomib alone. Blood 2009;114(22):4778a
Maisnar V, Vavrova J, Friedecky B, Tichy M, Radocha J, Hajek R. The evaluation of free light chains using the ELISA method. Clin Lymphoma Myeloma 2009;9(s1):B391a
Mancini E, Severi S, Pasquali S, Mambelli E, Guarnieri F, Santoro A. Mathematical model for the simulation and parametric estimate of intercompartmental kinetics of the free light chains (FLC) in patients with multiple myeloma (MM) on high cut-off dialysis. Presented at ASN Renal Week 2009;F-PO1490a
Mark T, Coleman M, Jayabalan DS, Pearse R, Zafar F, Ely S et al. T-Bird (thalidomide, clarithromycin/[Biaxin], lenalidomide/[Revlimid], dexamethasone) therapy for upfront use in symptomatic multiple myeloma. Blood 2009;114(22):1861a
Marshall G, Tate J, Mollee P. Borderline high serum free light chain κ/λ ratios are seen not only in dialysis patients but also in non-dialysis-dependent renal impairment and inflammatory states. Am J Clin Pathol 2009;132(2):309 PMID:19605825
Matschke J, Eisele L, Sellmann L, Duehrsen U, Duerig J, Nückel H. Abnormal free light chain ratios in chronic lymphocytic leukemia: a new prognostic factor? Blood 2009;114(22):1237a
Maurer MJ, Micallef IN, Katzmann JA, Nikcevich D, Witzig TE. Elevated pre-treatment serum immunoglobulin free light chains (FLC) are associated with poor event-free and overall survival in diffuse large B-cell lymphoma (DLBCL). Blood 2009;114(22):136a
McCudden CR, Voorhees PM, Hammett-Stabler CA. A case of hook effect in the serum free light chain assay using the Olympus AU400e. Clin Biochem 2009;42(1-2):121-4 PMID:18996106
Mead GP, Stubbs PD, Goodman HJB, Hawkins PN. Serum and urine light chains in AL amyloidosis. Clin Lymphoma Myeloma 2009;9(s1):B153a
Mead GP, Drayson MT. Sensitivity of serum free light chain measurement of residual disease in multiple myeloma patients. Blood 2009;114(8):1717 PMID:19696211
Mehta J, Vickrey E, Ramadurai D, Voigt E, Fitzpatrick C, Singhal S. The relationship between serum free light chain levels and urine protein in patients with IgG or IgA myeloma. Blood 2009;114(22):1810a
Merlini G. Serum-free light chain analysis: works in progress. Clin Chem Lab Med 2009;47(9):1021-2 PMID:19728842
Mollee P. Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies. Clin Biochem Rev 2009;30(3):93-103 PMID:19841691
Nair B, Waheed S, Szymonifka J, Shaughnessy JD, Jr., Crowley J, Barlogie B. Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols. Br J Haematol 2009;145(1):134-7 PMID:19120351
Paiva B, Vidriales MB, Mateo G, Perez JJ, Montalban MA, Sureda A et al. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. Blood 2009;114(20):4369-72 PMID:19755674
Palladini G, Merlini G. Current treatment of AL amyloidosis. Haematologica 2009;94(8):1044-8 PMID:19644136
Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 2009;55(3):499-504 PMID:19131635
Palladini G, Russo P, Foli A, Bragotti LZ, Lavatelli F, Perfetti V et al. Treatment with oral melphalan and dexamethasone of an extended patient population with AL amyloidosis. Blood 2009;114(22):3889a
Palladini G, Russo P, Bosoni T, Sarais G, Lavatelli F, Foli A et al. AL Amyloidosis associated with IgM monoclonal protein: a distinct clinical entity. Clin Lymphoma Myeloma 2009;9(1):80-3 PMID:19362981
Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009;23(10):1716-30 PMID:19494840
Palumbo A, Gay F. How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. Hematology Am Soc Hematol Educ Program 2009;566-77 PMID:20008241
Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia 2009;23(3):449-56 PMID:19005483
Pasquali S, Mancini E, Mambelli E, Santoro A. Kinetic study on light chain removal: comparison between traditional plasmapheresis, cascade plasmapheresis with absorbent resins, haemodialysis by means of high cut-off membrane. Presented at ASN Renal Week 2009;F-PO1517a
Pasquali S, Mancini E, Morabito S, Perego A, Besso L, Frascà G et al. A kinetic study on free light chains (FLC) removal by means of a high cut-off (HCO) membrane: Comparison between hemodialysis (HD) and hemodiafiltration (HDF). Presented at World Congress of Nephrology 2009;M449a
Patriarca F, Petrucci MT, Bringhen S, Baldini L, Caravita T, Corradini P et al. Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. Eur J Haematol 2009;82(2):93-105 PMID:19018865
Pattenden RJ, Davidson KL, Wenham PR. The value of serum free light chains in a case of Waldenstrom's macroglobulinaemia that produces a type I cryoglobulinaemia. Ann Clin Biochem 2009;46(Pt 6):531-2 PMID:19822697
Petchey M, Fletcher M, Hobbs J. Screening for monoclonal gammopathies in patients with unexplained renal failure. Presented at Renal Association Annual Meeting 2009;126a
Piehler AP, Urdal P. In Reply. Clin Chem 2009;55:1587-8 PMID:19520757
Poshusta TL, Sikkink LA, Leung N, Clark RJ, Dispenzieri A, Ramirez-Alvarado M. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis. PLoS ONE 2009;4(4):e5169 PMID:19365555
Powe DG, Kormelink TG, Sisson M, Blokhuis BJ, Kramer MF, Jones NS, Redegeld FA. Evidence for the involvement of free light chain immunoglobulins in allergic and nonallergic rhinitis. J Allergy Clin Immunol 2009;125(1):139-45 PMID:19818484
Pratt G, Richter A, Huisson A, Drayson M, Harding S. Multiple myeloma with monoclonal free IgG3 heavy chains and free kappa light chains. Clin Lymphoma Myeloma 2009;9(s1):A177a
Pratt G, Harding S, Holder R, Fegan C, Pepper C, Oscier D et al. Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia. Br J Haematol 2009;144(2):217-22 PMID:19016722
Pratt G, Harding S, Fegan C, Pepper CJ, Oscier D, Gardiner A et al. Serum FLC levels at presentation have independent prognostic significance in CLL and levels above 50mg/L identify patients with progressive disease. Blood 2009;114(22):2355a
Radovic V. Recommendations for use of FLC tests in monoclonal gammopathies. Haematologica 2009;94(s2):1628a
Radovic VR. Advantage of serum measurements free light chain in plasma cells disorders. Haematologica 2009;94(s2):1635a
Rajkumar SV. Multiple myeloma. Curr Probl Cancer 2009;33(1):7-64 PMID:19254626
Rajkumar SV. Prevention of progression in monoclonal gammopathy of undetermined significance. Clin Cancer Res 2009;15(18):5606-8 PMID:19737944
Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 2009;114(8):1489-97 PMID:19498019
Reiber H. Free light chains in CSF - pushing a method with biased interpretations. Acta Neurol Scand 2009;120(6):445-6 PMID:19878109
Robson EJD, Taylor J, Beardsmore C, Basu S, Mead G, Lovatt T. Utility of serum free light chain analysis when screening for lymphoproliferative disorders. Lab Med 2009;40(6):325-9
Rogoski RR. Serum free light chain assays: detecting plasma cell disorders. Med Lab Obs 2009;41(7):12-6 PMID:19685691
Sanchez-Jimenez F, Bermudo-Guitarte C, Cisneros-Barrera G, Goberna R. Demonstration of serum monoclonal immunoglobulin light chain in a case of non-secretory multiple myeloma. Presented at 2nd European Congress of Immunology 2009
Schonland S, Hegenbart U, Benner A, Perz J, Bochtler T, Beimler J et al. Prospective phase II study using dexamethasone induction therapy and high-dose melphalan chemotherapy followed by autologous stem cell transplantation in 30 patients with systemic AL amyloidosis. Blood 2009;114(22):3401a
Scudla V, Pika T, Bacovsky J, Lochman P, Faber E, Minarik J. The high-dose chemotherapy with autologous stem-cell transplantation sweeps away the prognostic importance of serum levels of free light chains and kappa/lambda ratio in multiple myeloma. Presented at Lymphoma & Myeloma Congress 2009;P00011a
Sethi S, Zand L, Fernando FC. Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Presented at ASN Renal Week 2009;TH-PO847a.
Shaheen SP, Levinson SS. Serum free light chain analysis may miss monoclonal light chains that urine immunofixation electrophoreses would detect. Clin Chim Acta 2009;406(1-2):162-6 PMID:19410572
Shustik C, Harding S, Ding K, Zhu L, Rassenti LZ, Kipps TJ et al. Analysis of the serum free light chain ratio and its prognostic value in a cohort of patients with chronic lymphocytic leukemia. Blood 2009;114(22):2631a
Siegel DS, McBride L, Bilotti E, Lendvai N, Gonsky J, Berges T et al. Inaccuracies in 24-hour urine testing for monoclonal gammopathies. Lab Med 2009;40(6):341-4
Siegel DS, Bilotti E, Van Hoeven K. Serum free light chain analysis for diagnosis, monitoring, and prognosis of monoclonal gammopathies. Lab Med 2009;40(6):363-6
Singhal S, Vickrey E, Krishnamurthy J, Singh V, Allen S, Mehta J. The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios. Blood 2009;114(1):38-9 PMID:19411633
Snyder M, Dispenzieri A, Rajkumar SV, Kyle R, Benson J, Katzmann JA. The biologic and analytic variability of serum protein electrophoresis M-spike, nephelometric Ig quantitation, serum FLC quantitation, and urine M-spike in monoclonal gammopathies. Blood 2009;114(22):1803a
Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients. Blood 2009;114(27):5436-43
Sthaneshwar P, Nadarajan V, Maniam JA, Nordin N, Gin Gin G. Serum free light chains: diagnostic and prognostic value in multiple myeloma. Clin Chem Lab Med 2009;47(9):1101-7 PMID:19728852
Stringer S, Harding S, Koulieris E, Kyrtsonis MC, Drayson M, Morgan G et al. Serum free light chain and serum heavy/light chain ratios are independently prognostic in multiple myeloma patients. Presented at Lymphoma & Myeloma Congress 2009;P00028a
Tate J, Bazeley S, Sykes S, Mollee P. Quantitative serum free light chain assay - analytical issues. Clin Biochem Rev 2009;30(3):131-40 PMID:19841696
Tate J, Mollee P, Johnson R. Monoclonal gammopathies - clinical and laboratory issues. Clin Biochem Rev 2009;30(3):89-91 PMID:19841689
Tate JR, Bazeley S, Sykes S, Mollee P. Dilution anomalies in serum free light chain measurement. Clin Chem 2009;55(s6):C11a
Tekstra J, Groot Kormelink T, Thurlings RM, Boumans MJH, Vos K, Tak PP et al. Inhibition of immunoglobulin light chains by Rituximab correlates with inhibition of clinical activity in patients with RA. Presented at ACR/AHRP Annual Scientific Meeting 2009;682a
Telio D, Bailey D, Chen C, Crump M, Reece DE, Kukreti V. Two distinct syndromes of lymphoma-associated amyloidosis: findings from a case series. Blood 2009;114(22):2938a
Terrier B, Sene D, Saadoun D, Ghillani-Dalbin P, Thibault V, Delluc A et al. Serum-free light chain assessment in hepatitis C virus-related lymphoproliferative disorders. Ann Rheum Dis 2009;68(1):89-93 PMID:18375535
Tong W, Wienholt L, Adelstein S. Cerebrospinal fluid free kappa light chain quantification by nephelometry compared to oligoclonal bands by isoelectric focusing in the diagnosis of multiple sclerosis. Intern Med J 2009;39(s5):53a
Tsai HT, Caporaso NE, Kyle RA, Katzmann JA, Dispenzieri A, Hayes RB et al. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood 2009;114(24):4928-32
Tsai WL, Lin PH, Chang WW, Shiesh SC. Assessment of serum free light chains in patients with monoclonal gammopathies. Clin Chem Lab Med 2009;47(s1):M-C030a
Tuck HH, James GW. Spontaneous tumor lysis syndrome caused by high grade plasma cell dyscrasia. Presented at ASN Renal Week 2009;PUB652a
Tzenou T, Vassilakopoulos TP, Kafasi N, Sachanas S, Koulieris E, Maltezas D et al. sFLC R in LPL/WM patients at diagnosis. Clin Lymphoma Myeloma 2009;9(s1):A424a
Uljon SN, Richardson PG, Grudzien C, Schur PH, Tanasijevic MJ, Lindeman NI. Changes in serum free light chain values do not precede changes in M-spike in a series of patients with relapsed/refractory intact immunoglobulin multiple myeloma. Clin Chem 2009;55(s6):D176a
Vachon CM, Kyle RA, Therneau TM, Foreman BJ, Larson DR, Colby CL et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood 2009;114(4):785-90 PMID:19179466
van Gameren II, van Rijswijk MH, Bijzet J, Vellenga E, Hazenberg BP. Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain. Haematologica 2009;94(8):1094-100 PMID:19644141
Van Hoeven K, Wells J, Abadie J. Serum protein electrophoresis (SPEP) plus serum free light chain (sFLC) testing: a sensitive panel for diagnosis of monoclonal gammopathy (MG). Presented at NKF Spring Clinical Meeting 2009
van Hoeven KH, Bilotti E, McBride L, Berges T, McNeill A, Schillen D, Siegel D. Serum free light chain assays are more sensitive than urinary tests for light chain monoclonal proteins. Clin Chem 2009;55(s6):C30a
Vavrova J, Friedecky B, Tichy M, Holeckova M, Maisnar V, Spacilova J. Measurement of free light chains using ELISA method. Clin Chem Lab Med 2009;47(s1):W-B019a
Vermeersch P, Vercammen M, Holvoet A, Broeck IV, Delforge M, Bossuyt X. Use of interval-specific likelihood ratios improves clinical interpretation of serum FLC results for the diagnosis of malignant plasma cell disorders. Clin Chim Acta 2009;410(1-2):54-8 PMID:19778527
Watanaboonyongcharoen P, Suwannabutra S, Theerasaksilp S, Paripokee N, Na Nakorn T. The roles of serum free light chain assay on the prognosis of multiple myeloma. Clin Lymphoma Myeloma 2009;9(s1):A420a
Wechalekar A, Hawkins PN, Wassef NJ, Gillmore ND, Lachmann HJ, Morris J et al. Monoclonal protein detection in AL amyloidosis revisited: analysis of 642 patients. Clin Lymphoma Myeloma 2009;9(s1):A300a
Wechalekar AD, Nassef N, Lachmann H, Sattianayagam P, Gibbs SDJ, Gillmore J, Hawkins PN. High early mortality and poor outcomes for patients with AL amyloidosis presenting with high serum free light chains - a new risk stratification model. Haematologica 2009;94(s2):544a
Wechalekar AD, Wassef NL, Gibbs SDJ, Gillmore J, Dike F, Lachmann H et al. A new staging system for AL amyloidosis incorporating serum free light chains, cardiac troponin-T and NT-ProBNP. Blood 2009;114(22):2796a
Weisel KC, Hänel M, Niederwieser D, Naumann R, Kröger N, Engelhardt M et al. Speed of response with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma: first results of the MM-019 German compassionate use protocol. Haematologica 2009;94(s2):397a
Weiss B, Minter A, Laquer M, Howard R, Abadie J, Ascencao J et al. Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in African-American compared to Caucasian MGUS patients. Blood 2009;114(22):2838a
Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009;113(22):5418-22 PMID:19234139
Wians FH. Use of Excel spreadsheets to create interpretive reports for laboratory tests requiring complex calculations. Lab Med 2009;40(1):5-12
Willenbacher E, Nachbaur D, Gastl G, Gasser S. Free light chain (by rFLC) monitoring reveals early relapse after HSCT. Clin Lymphoma Myeloma 2009;9(s1):A326a
Willenbacher E, Gasser S, Gastl G, Willenbacher W. Serum & urine free light chain analysis compared to conventional paraprotein measurements: usefulness for clinical decision making in real life haematology. Blood 2009;114(22):2889a
Yegin ZA, Yagci M, Özkurt ZN, Kursunoglu N, Aki SZ. Abnormal serum free light chain ratio as a predictor of adverse outcome in chronic lymphocytic leukemia: has the time come for a simple prognostic marker? Haematologica 2009;94(s2):929a
Zabek-Adamska A, Dyrka A, Drozdz R. Investigation of factors affecting immunoglobulin free light chain level. Clin Chem Lab Med 2009;47(s1):M-C075a

2010

Abdalla S. Serum free light chain (sFLC) assays in patients with unquantifiable low-level parprotein (LLPP) and transient paraproteinaemia (TP). Hematology Reports 2010;2(s2):C35a
Adballa S. Serum free light chain assays (sFLC) in patients with MGUS attending the Haematology Department at St. Mary's Hospital in London. Hematology Reports 2010;2(s2):B16a
Ahmed H, Simpson S, Roy A. Normal serum free light chain ratio at presentation is more common in IgA-κ multiple myeloma: a single centre observational study. Hematology Reports 2010;2(s2):B17a
Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD et al. NCCN clinical practice guidelines in oncology (NCCN guidelines): multiple myeloma. Online publication [1]
Andriani A, Villiva N, Felici S, Gualandi C, Palladini G. Efficacy of bortezomib (B) plus dexamethasone (D) in a patient with AL amyloidosis resistant to melphalan (M) and dexamethasone. Amyloid 2010;17(s1):P-181a
Arellano-Rodrigo E. Case 23-2010: Unusual paraprotein effects in MGUS - treat or not? N Engl J Med 2010;363(19):1874 PMID:21047250
Assi LK, Hughes RG, Gunson B, Webb G, Adams DH. Polyclonally raised serum free light chains in liver disease compared to markers of liver damage. Hematology Reports 2010;2(s2):E49a
Assi LK, Hughes RG, Gunson B, Webb GM, Drayson MT, Bradwell AR, Adams DH. Abnormally elevated serum free light chains in patients with liver disease. Presented at EASL Conference 2010
Ayliffe N, Sumar N, Behrens J. Bone marrow cell populations and serum free light chain levels in monoclonal gammopathy patients. Hematology Reports 2010;2(s2):A11a
Azais I, Brault R, Debiais F. New treatments for myeloma. Joint Bone Spine 2010;77(1):20-6 PMID:20031467
Bae SY, Lee JJ. Multiple myeloma with huge extramedullary plasmacytomas. Korean J Hematol 2010;45(2):88 PMID:1120184
Barbosa-de-Carvalho NM, Morais-Sarmento-Campos ML. Identificacion de cadenas ligeras libres en suero y su aplicacíon en las gammapatias monoclonales. Hematología 2010;11(4):199-207
Basnayake K, Ying WZ, Wang PX, Cockwell P, Bradwell A, Hutchison C, Sanders PW. Myeloma light chains activate tubular epithelial cells by a c-Src mediated redox signaling mechanism. Presented at BRS/RA Conference 2010;P238a
Basnayake K, Ying WZ, Wang PX, Sanders PW. Immunoglobulin light chains activate tubular epithelial cells through redox signaling. J Am Soc Nephrol 2010;21(7):1165-73 PMID:20558542
Basnayake K, Cheung CK, Sheaff M, Fuggle W, Kamel D, Nakoinz S et al. Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney. J Clin Pathol 2010;63(10):884-7 PMID:20876319
Basnayake K, Ghonimi T, Sanders P, Hutchison C, Stringer S, Bradwell A, Cockwell P. An assessment of the pathogenicity of polyclonal free light chains in chronic kidney disease. Presented at BRS/RA Conference 2010;P240a
Basnayake K, Cheung CK, Hutchison C, Stringer S, Cook M, Rylance P et al. Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney. Presented at BRS/RA Conference 2010;P239a
Bazari H, Attar EC, Dahl DM, Uppot RN, Colvin RB. Case records of the Massachusetts General Hospital. Case 23-2010. A 49-year-old man with erythrocytosis, perinephric fluid collections, and renal failure. N Engl J Med 2010;363(5):463-75 PMID:20818867
Bârsan L, Stancu S, Lipan M, Decu V, Talangescu C, Sântimbrean C et al. Beta 2-microglobulin, kappa and lambda light chains reduction by haemodialysis. Hematology Reports 2010;2(s2):D39a
Bennett ST. Commentary. Clin Chem 2010;56(9):1393 PMID:20802100
Bensinger WI, Jagannath S, Vescio R, Camacho E, Wolf J, Irwin D et al. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma. Br J Haematol 2010;148(4):562-8 PMID:19919652
Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA et al. Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 2010;150(1):28-38 PMID:20507313
Bermudo C, Garcia JL, Martin Ruiz JA, Duro Millán R, Merchan Iglesias M, Romero FF. Monitoring of serum free light chains in the treatment of light chain deposition disease with high cut-off haemodialysis. Hematology Reports 2010;2(s2):D36a
Bermudo C, Garcia JL, Martin Ruiz JA, Duro Millán R, Iglesias MM, Romero FF. Serum free light chains in monitoring a lambda light chain multiple myeloma patient's treatment. Hematology Reports 2010;2(S2):C34a
Bianchi G, Kyle RA, Colby CL, Larson DR, Kumar S, Katzmann JA et al. Impact of optimal follow-up of monoclonal gammopathy of undetermined significance (MGUS) on early diagnosis and prevention of myeloma-related complications. Blood 2010;116(12):2019-25 PMID:20495076
Bibas M, Trotta MP, Lorenzini P, Cozzi-Lepri A, Borderi M, Tozzi V et al. The predictive role of circulating serum free light chains (sFLC) in HIV-associated non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) and its correlation with effective combined antiretroviral treatment (cART). Blood 2010;116(21):3089a
Bijzet J, van Gameren II, Limburg PC, Bos R, Vallenga E, Hazenberg BPC. Diagnostic performance of measuring free light chains in fat tissue of patients with AL amyloidosis. Amyloid 2010;17(s1):OP-042a
Binnani P, Bahadur MM, Kedia N, Sharbidre P. Disease recurrence in a transplant kidney in a patient with extramedullary plasmacytoma. Indian J Med Paediatr Oncol 2010;31(3):91-3 PMID:21206716
Binotto G, Pavan A, Trentin L, Bocccagni P, Zaninotto M, Semenzatol G, Adams D. Double autologous bone marrow transplantation (ASCT) and orthotopic liver transplantation (OLTX) in a patient with primary AL amyloidosis. Amyloid 2010;17(s1):P-123a
Bladé J, Dimopoulos M, Rosinõl L, Rajkumar SV, Kyle RA. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol 2010;28(4):690-7 PMID:20026810
Bladé J, Cibeira MT, Fernandez de Larrea C, Rosinõl L. Multiple myeloma. Ann Oncol 2010;21 Suppl 7:vii313-vii319 PMID:20943635
Bochtler T, Hegenbart U, Schonland S, Hermann G, Deckert T, Rohde S et al. A case of localised cerebral light-chain amyloidosis with disseminated periventricular pattern. Amyloid 2010;17(s1):P-215a
Bosmann M, Kossler J, Stolz H, Walter U, Knop S, Steigerwald U. Detection of serum free light chains: the problem with antigen excess. Clin Chem Lab Med 2010;48(10):1419-22 PMID:20626301
Boyle A. A study of the use of free light chains to improve the interpretation of capillary electrophoresis. Hematology Reports 2010;2(s2):A5a
Bradwell AR. Serum free light chain analysis (plus Hevylite), Sixth ed. 2010
Briand PY, Decaux O, Caillon H, Grosbois B, Le Treut A, Guenet L. Analytical performance of the serum free light chain assay. Clin Chem Lab Med 2010;48(1):73-9 PMID:19929752
Bridoux F, Tennent A, Delbes S, Desport E, Lacombe C, Kalopissis A et al. The p.Ala154fsX47 ApoAI frameshift variant is a novel disulfide-linked ApoAI. Amyloid 2010;17(s1):P-058a
Brunvand MW, Bitter M. Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant. Haematologica 2010;95(3):519-21 PMID:19903681
Buadi F, Dispenzieri S, Hayman S, Allred J, Laumann K, Roy V et al. A phase II trial of lenalidomide, cyclophosphamide and dexamethasone (RCD) in patients with primary amyloidosis. Amyloid 2010;17(s1):P-156a
Budd R, Taylor D, Bunce A, Harding S, Bradwell AR, Mead G. Monoclonal gammopathy diagnosis using an antibody coated bead array immunoassay, for free kappa and lambda light chain and IgG, IgA and IgM kappa and lambda. Hematology Reports 2010;2(s2):A8a
Cabanas López de Vergara B, Rodríguez López MA, Ocampo Martínez R, Plaza Villa JP. Smoldering multiple myeloma with IgEλ plus λ free light chains. A diagnostic clinical case. Hematology Reports 2010;2(s2):B22a
Cania A, Bergesio F, Curciarello G, Perfetto F, Ciciani AM, Nigrelli S et al. The Florence Register of amyloidosis: 20 years' experience in the diagnosis and treatment of the disease in the Florence District Area. Amyloid 2010;17(s1):P-177a
Carr-Smith HD. Serum FLC assay: technical considerations. Hematology Reports 2010;2(s2):p2
Cermakova Z, Dastych M, Gottwaldova J. Serum free light chain measurements in screening for lymphoproliferative diseases - comparison recommended and renal reference interval for free light chain ratios in patients with renal failure. Hematology Reports 2010;2(s2):B13a
Chenine-Khoualef L, Rodriguez A, Leray-Moragues H, Gontiers A, Morena M, Cognot-Pons C et al. Conventional high efficiency haemodiafiltration as an adjunctive treatment of kappa light chain nephropathy: a clinical case report. Hematology Reports 2010;2(s2):D42a
Cockwell P, Hutchison CA. Management options for cast nephropathy in multiple myeloma. Curr Opin Nephrol Hypertens 2010;19(6):550-5 PMID:20827195
Cohen AD, Comenzo RL. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Educ Program 2010;2010:287-94 PMID:21239808
Cook M. EuLITE trial: results to date. Hematology Reports 2010;2(s2):p5
Corazzelli G, De Filippi R, Capobianco G, Frigeri F, De Rosa V, Iaccarino G et al. Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma. Am J Hematol 2010;85(1):87-90 PMID:20029955
Coriu D, Badelita S, Talmaci R, Dobrea C, Dogaru M, Ostroveanu D, Crisan M. Bortezomib in systemic AL amyloidosis: a single centre experience. Amyloid 2010;17(s1):P-195a
Craig WY, Ledue TB. Free light-chains and renal disorders: when small is worse. Lancet 2010;376(9748):1221 PMID:20934591
Davids MS, Murali MR, Kuter DJ. Serum free light chain analysis. Am J Hematol 2010;85(10):787-90 PMID:20721885
de Kat Angelino CM, Raymakers R, Teunesen MA, Jacobs JF, Klasen IS. Overestimation of serum kappa free light chain concentration by immunonephelometry. Clin Chem 2010;56(7):1188-90 PMID:20413429
de Larrea CF, Cibeira MT, Elena M, Arostegui JI, Rosinõl L, Rovira M et al. Free light chain assay and stringent complete remission in multiple myeloma: more questions than answers. Blood 2010;115(16):2414-5
Decaux O. Sixth International Symposium on clinical applications of serum free light chain analysis, Bath, England, 23-24 September 2010. Rev Med Interne 2010 PMID:21126805
Dhodapkar M, Shaughnessy J, Hoering A, Nair B, Bolejack V, van Rhee F et al. Predicting disease progression to multiple myeloma (MM) from MGUS/SMM in SWOG-0120 Observational Trial. Blood 2010;116(21):1932a
Dietrich S, Schonland SO, Benner A, Bochtler T, Kristen AV, Beimler J et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood 2010;116(4):522-8 PMID:20375312
Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010;28(33):4976-84 PMID:20956629
Dimopoulos MA, Terpos E. Multiple myeloma. Ann Oncol 2010;21 Suppl 7:vii143-vii150 PMID:20943607
Dispenzieri A, Kyle R, Katzmann JA, Larson D, Kumar S, Mead GP et al. Non-clonal serum immunoglobulin free light chains (FLC) as markers of overall survival. Blood 2010;116(21):3893a
Dispenzieri A, Dingli D, Kumar SK, Rajkumar SV, Lacy MQ, Hayman S et al. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol 2010;85(10):757-9 PMID:20872958
Dispenzieri A, Kyle RA, Rajkumar SV. Free light-chains and renal disorders: when small is worse - Authors' reply. Lancet 2010;376(9748):1221-2
Dispenzieri A, Gertz MA, Saenger AK, Kumari SK, Lacy MQ, Kyle RA et al. High sensitivity troponin assay (hsTnT): utility in patients with AL. Amyloid 2010;17(s1):P-128a
Dispenzieri A, Katzmann JA, Kyle RA, Larson D, Rajkumar SV. Non-clonal serum immunoglobulin free light chains (FLC) as markers of overall survival. Hematology Reports 2010;2(s2):p12
Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ, III, Colby CL et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 2010;375(9727):1721-8 PMID:20472173
Dispenzieri A, Kumari SK, Lacy MQ, Kyle RA, Leung N, Zeldenrust SR et al. Do the immune modulatory drugs (IMiDs^®) affect levels of troponin T (TnT) and N-terminal brain naturietic peptide (NTproBNP) in patients with immunoglobulin light chain amyloidosis (AL)? Amyloid 2010;17(s1):P-169a
Dobson R, Miller RF, Palmer HE, Feldmann M, Thompson EJ, Thompson AJ et al. Increased urinary free immunoglobulin light chain excretion in patients with multiple sclerosis. J Neuroimmunol 2010;220(1-2):99-103 PMID:20171744
Dogaru M, Coriu D, Badelita S, Crisan M. Monitoring patients with monoclonal plasma cell disorders (PCDS) after autologous stem cell transplantation by using serum free light chains and serum protein electrophoresis. Hematology Reports 2010;2(s2):C27a
Durie BGM. Serum free light chain (sFLC) guidelines for monoclonal gammopathies. Hematology Reports 2010;2(s2):p2
Durrieu F, Dubois J, Eghbali H, Correia P, Demarthe F, Etienne G. Abnormal serum free light chain (sFLC) ratio is a predictor of aggressive form of CLL and is related to response to treatment. Hematology Reports 2010;2(s2):E51a
Dürig J, Eisele L, Hüttmann A, Dührsen U, Führer A, Kieruzel S et al. Polyclonal free light chain elevation and mortality in the German Heinz Nixdorf Recall study. Hematology Reports 2010;2(s2):p13
Eisele L, Durig J, Huttman A, Duhrsen U, Fuhrer A, Kieruzel S et al. Prevalence of monoclonal gammopathy of undetermined significance (MGUS) and light-chain MGUS (LCMGUS) in a metropolitan area in Germany. Blood 2010;116(21):4037a
Eisele L, Durig J, Huttman A, Duhrsen U, Fuhrer A, Kieruzel S et al. Polyclonal free light chain elevation and mortality in the German Heinz Nixdorf Recall Study. Blood 2010;116(21):3903a
Elliott BM, Peti S, Lee D, Osman K, Isola LM, Scigliano E, Kostakoglu L. Use of combined FDG-PET and laboratory data for predicting relapse in multiple myeloma. J Clin Oncol 2010;28(7s):8148a
Emile C. Freelite: chronologie et dernieres mises a jour. Option Bio 2010;430:15-9
Eve HE, Rule SA. Lenalidomide-induced tumour flare reaction in mantle cell lymphoma. Br J Haematol 2010;151(4):410-2 PMID:20880113
Faiman B, Licata AA. New tools for detecting occult monoclonal gammopathy, a cause of secondary osteoporosis. Cleve Clin J Med 2010;77(4):273-8 PMID:20360121
Fernández Redondo ME, Paiva B, Martínez-López J, Lahuerta JJ, Mateos MV, San Miguel JF et al. The clinical value of serum free light chain assay in newly diagnosed uniformly treated elderly patients. Hematology Reports 2010;2(s2):B19a
García de Veas Silva J, Bermudo Guitarte C, Arrobas Velilla T, Sánchez Margalet V, Martín Ruiz J, Merchan Iglesias M, Goberna Ortiz R. Utility of free light chains ratio in the monitoring of the treatment of a patient with light chain lambda multiple myeloma. Clin Chem 2010;56(6):C113a
Geri G, Terrier B, Semoun O, Saadoun D, Sene D, Charlotte F et al. Surrogate markers of B cell non-Hodgkin's lymphoma in patients with hepatitis C virus-related cryoglobulinaemia vasculitis. Ann Rheum Dis 2010;69(12):2177-80 PMID:20876592
Gertz MA, Lacy M, Dispenzieri A, Kumar S, Buadi F, Dingli D et al. Transplantation for immunoglobulin light chain amyloidosis. A statistical analysis of factors predicting outcome in over 400 patients. Blood 2010;116(21):3557a
Gertz MA, Merlini G. Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion. Amyloid 2010;17(s1):CP-Ba
Gertz MA. I don't know how to treat amyloidosis. Blood 2010;116(4):507-8 PMID:20671130
Gibbs SDJ, Sattianayagum PT, Whelan CJ, de Cruz M, Abreu M, Pinney JH et al. Rise in serum NT pro-BNP associated with chemotherapy in patients with AL amyloidosis: implications for organ response assessment. Amyloid 2010;17(s1):P-170a
Gibbs SDJ, Gillmore JD, Sattianayagum PT, Lachmann HJ, Lane T, Goodman HJB et al. CTD versus Mel-Dex as upfront treatment in AL amyloidosis: a matched case-control study. Amyloid 2010;17(s1):OP-078a
Gillmore JD, Cocks K, Gibbs SDJ, Sattianayagum PT, Lane T, Lachmann HJ et al. UK AL Amyloidosis Treatment Trial (UKATT) - a randomised study: lessons for future trial design. Amyloid 2010;17(s1):OP-088a
Girmius S, Tsai F, Seldin DC, Quillen K, Finn KT, Andrea NT et al. Early serum free light chain responses following high-dose melphalan and stem cell transplantation (HDM/SCT) for AL amyloidosis. Amyloid 2010;17(s1):P-185a
Go RS. Monoclonal gammopathy of undetermined significance: to screen or not to screen for multiple myeloma? Br J Haematol 2010;149(4):620-1 PMID:20148888
Gottenberg J. Free light chains of immunoglobulins as disease markers in autoimmune diseases. Hematology Reports 2010;2(s2):p14
Goyal M, Mohammad N, Palanki SD, Vaniawala SN. Primary plasma cell leukemia with light chain secretion and multiple chromosomal abnormalities: How successfully treated? - A case report with review of literature. Indian J Med Paediatr Oncol 2010;31(3):96-100 PMID:21206718
Granátová J, Valentová K, Bolková M, Haber J, Hanzal V, Hachová L. Can light chain escape phenomenon be observed without prior haematological therapy? Hematology Reports 2010;2(S2):C30a
Gregorini G, Jeannin G, Econimo L, Morassi L, Faggiano P, Nardi M, Cancarini G. Recurrent haemorrhagic bullae of oral cavity and cranial nerve palsy: two rare manifestations at the onset of AL amyloidosis in the same patient. Amyloid 2010;17(s1):P-217a
Guastafierro S, Falcone U, Ferrara MG, Parascandola RR, Fiorillo P, Cuomo C et al. Biclonal gammopathies: review of 19 cases. Clin Chem 2010;56(6):D59a
Guillemette T, Bardin N, Cournac JM, Mancini J, Jean R, Schleinitz N et al. Serum free light chain levels as a marker of disease activity following treatment with B-cell depletion in systemic lupus erythematosus (SLE). Hematology Reports 2010;2(s2):E43a
Gupta D, Bachegowda L, Phadke G, Boren S, Johnson D, Misra M. Role of plasmapheresis in the management of myeloma kidney: a systematic review. Hemodial Int 2010;14(4):355-63 PMID:20955270
Hanf W, Guillaume C, Jolivot A, Chapuis-Cellier C, Guebre-Egziabher F, Fontana A et al. Prolonged hemodialysis for acute kidney injury in myeloma patients. Clin Nephrol 2010;74(4):319-22 PMID:20875387
Hanoun M, Schmitz KJ, Duhrsen U, Roth A. Amyloid tumour. Br J Haematol 2010;150(4):387 PMID:19344394
Hansen CT, Nielsen L, Munster AM, Abildgaard N. Determination of light chains in serum. Ugeskr Laeger 2010;172(34):2302-5 PMID:20727297
Harding S, Stringer S, Cockwell P, Hutchison C. Failure to remove immunoglobulin free light chains by high cut-off haemodialysis. Presented at BRS/RA Conference 2010;P312a
Harle L, Chan C, Bhagavan NV, Rios CN, Sugiyama CE, Loscalzo M et al. A healthy young man presenting with multiple rib fractures. Clin Chem 2010;56(9):1390-2 PMID:20802098
Hasegawa M, Kondo F, Yamamoto K, Murakami K, Tomita M, Nabeshima K et al. Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy. Ther Apher Dial 2010;14(5):451-6 PMID:20802098
Hawkins P. FLCs in the amyloidosis clinic. Hematology Reports 2010;2(s2):p7
Heher EC, Goes NB, Spitzer TR, Raje NS, Humphreys BD, Anderson KC, Richardson PG. Kidney disease associated with plasma cell dyscrasias. Blood 2010;116(9):1397-404 PMID:20462963
Hernandez JM, Jimenez-Cobaleda MJ, Muñoz H, Caro R, Qiueizan JA, Latorre M et al. Normal ranges and reference intervals of serum free light chains concentrations in a Spanish urban population. Hematology Reports 2010;2(s2):A9a
Hillengass J, Neben K, Goldschmidt H. Current status and developments in diagnosis and therapy of multiple myeloma. J Cancer Res Clin Oncol 2010;136(1):151-5 PMID:19763621
Hoffmann-Luecke E, Hojskov C, Solling H, Nielsen JL, Moller HJ. Local experience from measurements of serum free light chains - a necessity to establish local reference ranges. Presented at XXXII Nordic Congress in Medical Biochemistry 2010;O-040a
Honma R, Fukase S, Suzuki M, Omoto E. Serum free light-chain assay for nonsecretory multiple myeloma with light chain cast nephropathy and light chain deposition disease. Rinsho Ketsueki 2010;51(4):270-4 PMID:20467224
Hutchison C. Use of high cut-off haemodialysis for treatment of myeloma kidney: worldwide experience to date. Hematology Reports 2010;2(s2):p4
Hutchison C, Leung N, Stringer S, Cockwell P. Early reductions in serum immunoglobulin free light chains (FLC) predict renal recovery in myeloma kidney and dialysis-dependent AKI. Presented at BRS/RA Conference 2010;P105a
Hutchison C, Mead G, Harding S, Basnayake K, Stringer S, Ferro C et al. Polyclonal immunoglobulin free light chains predict patient survival and renal decline in chronic kidney disease. Presented at BRS/RA Conference 2010;P148a
Hutchison CA, Cockwell P, Reid SD, Chandler KL, Millard JL, Mead GP et al. Removal of serum free light chains by hemodialysis in patients with multiple myeloma. Clin Chem 2010;52(s6):A81a
Hutchison CA, Pratt G. Free light-chains and renal disorders: when small is worse. Lancet 2010;376(9748):1220 PMID:20934588
Hutchison CA. Reduction of serum free light chains predict renal recovery. Ann Hematol 2010;89(6):627-8 PMID:19784650
Jaccard A, Abraham J, Debarri H, Penot A, Desport E, Aguilar C et al. Effectiveness of second line treatment in AL amyloidosis patients refractory to M-Dex. Amyloid 2010;17(s1):P-189a
Jacob S, Karim A, Drayson M, Mitchell J. Kappa and lambda free light chains in CSF in the differential diagnosis of multiple sclerosis and its correlation with clinical subtypes. J Neurol Neurosurg Psychiatry 2010;81(11):PATH58a
Jacobs JF, Joosten I, Klasen IS. Detecting only light chains, now what? Clin Chem 2010;56(8):1368 PMID:20668174
Jiménez Jiménez J, Barbosa de Carvalho NM, Crespo Echeverría M, Jañez Carrera R, Hernando de Larramend C. Systemic lupus erythematosus and free light chains. Hematology Reports 2010;2(s2):E45a
Jolly M, Aggarwal R, Francis S, Mikolaitis AR, Niewold T, Chubinskaya S et al. Serum free light chains and disease activity in sytemic lupus erythematosus. Hematology Reports 2010;2(s2):E46a
Jolly M, Mikolaitis AR, Block JA, Sequeira W. Free light chains: a predictor of emergent medical care utilization in lupus. Hematology Reports 2010;2(s2):E44a
Kaplan B, Aizenbud BM, Golderman S, Yaskariev R, Sela BA. Free light chain monomers in the diagnosis of multiple sclerosis. J Neuroimmunol 2010;229(1-2):263-71 PMID:20870296
Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010;28(6):1031-7 PMID:20085941
Katzmann JA, Kyle RA, Benson J, Larson DR, Snyder MR, Lust J et al. In Reply. Clin Chem 2010;56(4):679-80 PMID:20075181
Katzmann JA, Stankowski-Drengler TJ, Kyle RA, Lockington KS, Snyder MR, Lust JA, Dispenzieri A. Specificity of serum and urine protein electrophoresis for the diagnosis of monoclonal gammopathies. Clin Chem 2010;56(12):1899-900 PMID:20844060
Katzmann JA, Synder MR, Larson DR, Rajkumar SV, Kyle RA, Dispenzieri A. The variability of serum protein electrophoresis (SPEP) M-spike, serum free light chain (FLC) quantitation and urinary protein electrophoresis (UPEP) M-spike in monoclonal gammopathies. Amyloid 2010;17(s1):P-174a
Katzmann JA. Role of sFLC assays in the laboratory. Hematology Reports 2010;2(s2):p3
Kawano Y, Nakama T, Hata H, Kimura E, Maruyoshi N, Uchino M, Mitsuya H. Successful treatment with rituximab and thalidomide of POEMS syndrome associated with Waldenstrom macroglobulinemia. J Neurol Sci 2010;297(1-2):101-4 PMID:20673674
Kayserova J, Capkova S, Skalicka A, Vernerova E, Polouckova A, Malinova V et al. Serum immunoglobulin free light chains in severe forms of atopic dermatitis. Scand J Immunol 2010;71(4):312-6 PMID:20384876
Keren DF. Laboratory evaluation for monoclonal gammopathies: MGUS to myeloma. Warde Report 2010;21(2)
Khaliq W, Uzoaru I, Konchanin RP, Sapiente RA, Egner JR. Solitary extramedullary plasmacytoma of the bladder: a case report and literature. Oncology (Williston Park) 2010;24(9):832-5 PMID:20923037
Khoriaty R, Hussein MA, Faiman B, Kelly M, Kalaycio M, Baz R. Prediction of response and progression in multiple myeloma with serum free light chains assay: corroboration of the serum free light chain response definitions. Clin Lymphoma Myeloma Leuk 2010;10(1):E10-E13 PMID:20223721
Kormelink TG, Tekstra J, Thurlings RM, Boumans MH, Vos K, Tak PP et al. Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity. Ann Rheum Dis 2010;69(12):2137-44 PMID:20679475
Kroger N, Asenova S, Gerritzen A, Bacher U, Zander A. Questionable role of free light chain assay ratio to determine stringent complete remission in multiple myeloma patients. Blood 2010;115(16):3413-4 PMID:20413663
Kumar L, Verma R, Radhakrishnan VR. Recent advances in the management of multiple myeloma. Natl Med J India 2010;23(4):210-8 PMID:21192514
Kumar S, Gertz M, Lacy M, Hayman S, Buadi F, Zeldenrust S et al. Changes in serum free light chain rather than intact monoclonal immunoglobulin levels predict outcome with therapy in patients with light chain amyloidosis. Amyloid 2010;17(s1):P-173a
Kumar S. Treatment of newly diagnosed multiple myeloma: advances in current therapy. Med Oncol 2010;27 Suppl 1:S14-S24 PMID:20035387
Kumar S. AL amyloidosis - role of FLC assay in risk estimation. Hematology Reports 2010;2(s2):p7
Kumar S, Dispenzieri A, Clark R, Larson D, Colby C, Zeldenrust S et al. Serum immunoglobulin free light chain in AL amyloidosis: prognostic value and correlations with clinical features. Amyloid 2010;17(s1):P-171a
Kumar S, Dispenzieri A, Katzmann JA, Larson DR, Colby CL, Lacy MQ et al. Serum immunoglobulin free light chain measurement in AL amyloidosis: prognostic value and correlations with clinical features. Blood 2010;116(24):5126-9 PMID:20798235
Kumar S, Zhang L, Dispenzieri A, Van WS, Katzmann JA, Snyder M et al. Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma. Leukemia 2010;24(8):1498-505 PMID:20520636
Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Curr Hematol Malig Rep 2010;5(2):62-9 PMID:20425398
Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24(6):1121-7 PMID:20410922
Kyle RA. The monoclonal proteins: a brief history. Hematology Reports 2010;2(s2):p1
Lachmann HJ, Harding S, Wechalekar A, Gillmore JD, Amft EN, Hawkins PN. Remarkable efficacy of IL-1 receptor antagonist in Schnitzler's syndrome: a series of 6 cases. Blood 2010;116(21):3958a
Lamm W, Willenbacher W, Lang A, Zojer N, Muldu E, Ludwig H et al. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Amyloid 2010;17(s1):P-194a
Landau H, Hassoun H, Bello C, Hooveri E, Jia X, Riedel ER et al. Adjuvant bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis. Amyloid 2010;17(S1):OP-074a
Landgren O, Waxman AJ. Multiple myeloma precursor disease. JAMA 2010;304(21):2397-404 PMID:21119086
Landgren O. Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology. Hematology Am Soc Hematol Educ Program 2010;2010:295-302 PMID:21239809
Landgren O. Progressing serum immune abnormalities in myalomagenesis. Hematology Reports 2010;2(s2):p10
Landgren O. Circulating serum free light chains as predictors of AIDS lymphoma and beyond. Hematology Reports 2010;2(s2):p13
Landgren O, Goedert JJ, Rabkin CS, Wilson WH, Dunleavy K, Kyle RA et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol 2010;28(5):773-9 PMID:20048176
Lee KC, Berg M, Ryder J, Myint H, Gutman J, Robinson W. Normalisation and maintenance of normal levels and ratios of serum free light chain (sFLC) over 1 year post-transplant are associated with longer survival of patients with multiple myeloma (MM). Hematology Reports 2010;2(s2):C28a
Leleu X, Xie W, Rourke M, Banwait R, Leduc R, Roper N et al. The role of serum immunoglobulin free light chain in response and progression in Waldenstrom Macroglobulinemia. Blood 2010;116(21):3095a
Levinson SS. Polyclonal free light chain of Ig may interfere with interpretation of monoclonal free light chain κ/λ ratio. Ann Clin Lab Sci 2010;40(4):348-53 PMID:20947809
Levinson SS. Hook effect with lambda free light chain in serum free light chain assay. Clin Chim Acta 2010;411(21-22):1834-6 PMID:20667445
Levoguer AM. Utility of serum free light chain measurement in monoclonal gammopathies: diagnosis, monitoring and prognosis. Presented at Japanese Myeloma Meeting 2010
Levoguer AM, Legg A, Hughes RG. Serum free light chains in chronic lymphocytic leukemia: light at the end of the tunnel? Clin Lab Int 2010;(June):16-9
Liang Y, Chen W, Wang Q, Zhai Y. Establishment of serum free light chains reference intervals, selection and evaluation of cut-off value for κ/λ ratio. Hematology Reports 2010;2(s2):A10a
Lonial S. The White House crusade against ... MGUS? Blood 2010;116(7):1020-1 PMID:20724546
Lopez-Anglada L, Puig N, Diez-Campelo M, Alonso-Ralero L, Barrena S, Aparicio MA et al. Monoclonal free light chains can be found in heavy chain diseases. Ann Clin Biochem 2010;47(6):570-2 PMID:20930031
Lorenz EC, Sethi S, Poshusta TL, Ramirez-Alvarado M, Kumar S, Lager DJ et al. Renal failure due to combined cast nephropathy, amyloidosis and light-chain deposition disease. Nephrol Dial Transplant 2010;25(4):1340-3 PMID:20061318
López-Corral L, García-Sanz R, n Miguel JF. Aplicaciones del test sérico de cadenas ligeras libres en las gammapatías monoclonales. Med Clin (Barc) 2010;135(8):368-74
Ludwig H, Adam Z, Hajek R, Greil R, Tothova E, Keil F et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 2010;28(30):4635-41 PMID:20823423
Ludwig H, Mirbahai L, Zojer N, Bradwell A, Harding S. The ratio of monoclonal to polyclonal immunoglobulins assessed with the Hevylite test predicts prognosis, is superior for monitoring the course of the disease and allows detection of monoclonal immunoglobulin in patients with normal or subnormal involved immunoglobulin isotype. Blood 2010;116(21):4038a
Lukacik P, Hughes RG, Pratt G, Hutchison CA, Mead GP. Differences between C-reactive protein and free light chain production after trauma. Hematology Reports 2010;2(s2):E50a
Madan S, Dispenzieri A, Lacy MQ, Buadi F, Hayman SR, Zeldenrust SR et al. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clin Proc 2010;85(3):232-8 PMID:20194151
Mahdi A, Andrews D, Evans N, Moody M, Poynton C. Monitoring myeloma patients on lenalidomide - efficacy and incidence of light chain escape. Hematology Reports 2010;2(s2):C31a
Maignan M, Driad A, Jacob C, Jay N, Dousset B, Vignaud JM, De Korwin JD. Sjögren's syndrome and serum free light chain analysis in newly diagnosed patients. Hematology Reports 2010;2(s2):E47a
Mailankody S, Mena E, Yuan CM, Balakumaran A, Kuehl WM, Landgren O. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma. Leuk Lymphoma 2010;51(12):2159-70 PMID:20958231
Mark TM, Koirala A, Pearse RN, Zafar F, Jayabalan D, Leonard JP et al. An evaluation of the role of bone marrow biopsy in patients with multiple myeloma who achieve an unconfirmed stringent complete remission. J Clin Oncol 2010;28(7s):8144a
Martin Reyes G, Barbosa de Carvalho NM, Torres de Rueda A, Toledo Rojas R, Martín Velásquez M, Gironda Gallegos C et al. Free light chain removal with high cut-off haemodialysis in patients with cast nephropathy. Hematology Reports 2010;2(s2):D37a
Mateos M-V, López-Corral L, Hernández M, Giraldo P, de la Rubia J, de Arriba F et al. Smoldering multiple myeloma (SMM) at high-risk of progression to symptomatic disease: a phase III, randomized, multicenter trial based on Lenalidomide-Dexamethasone (Len-Dex) as induction therapy followed by maintenance therapy with Len alone vs no treatment. Blood 2010;116(21):1935a
Matsue K, Fujiwara H, Iwama K, Kimura S, Yamakura M, Takeuchi M. Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8 years. Ann Hematol 2010;89(3):291-7 PMID:19693498
Matsumori A, Shimada M, Jie X, Higuchi H, Groot KT, Redegeld FA. Effects of free immunoglobulin light chains on viral myocarditis. Circ Res 2010;106(9):1533-40 PMID:20360247
Matters D. Stability of free light chains and heavy/light chains in serum samples after an initial shipping period at 22 degrees celcius. Hematology Reports 2010;2(s2):G73a
Maurer MJ, Cerhan J, Katzmann JA, Link B, Allmer C, Zent CS et al. Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. Blood 2010;116(21):2409a
Maurer MJ, Katzmann JA, Link BK, Cerhan JR, Witzig TE. Serum free light chains in non-Hodgkin lymphoma. Hematology Reports 2010;2(s2):p9
Maurer MJ, Cerhan J, Katzmann JA, Link B, Micallef IN, Colgan J et al. Elevation of serum free light chains are common in lymphoma and associated with poor event free and overall survival. Blood 2010;116(21):4136a
McCarthy H, Lasebai M, Hall R. A single centre experience of clonal evolution in relapsed myeloma manifested by light chain escape. Hematology Reports 2010;2(S2):C32a
Mead G. Diseases associated with polyclonal free light chains - concepts. Hematology Reports 2010;2(s2):p11
Mead GP, Carr-Smith HD. Overestimation of serum kappa free light chain concentration by immunonephelometry. Clin Chem 2010;56(9):1503-4 PMID:20581080
Mehta J, Cavo M, Singhal S. How I treat elderly patients with myeloma. Blood 2010;116(13):2215-23 PMID:20644120
Meier-Ewert HK, Sanchorawala V, Berk J, Finn KT, Skinner M, Seldin DC, Rurberg FL. Regression of cardiac wall thickness following chemotherapy and stem-cell transplantation for AL amyloidosis. Amyloid 2010;17(s1):P-120a
Mijuskovic Z, Radovic V, Pejovic J, Tukic L, Marjanovic S. Free light chains ratio as a marker of the course and survival in plasmaproliferative diseases. Hematology Reports 2010;2(s2):B20a
Mikhael J, Jimenez VH, Reeder CB, Stewart AK, Bergsagel PL, Fonseca R. Cyclophosphamide-bortezomibdexamethasone (CYBORD) is highly effective in producing rapid and complete responses in patients with AL amyloidosis not eligible for transplant. Amyloid 2010;17(s1):P-157a
Miles OA, Miller E. Serum free light chain assay monitoring in plasma cell disorders - a single centre audit. Br J Haematol 2010;149(s1):144a
Miralles A, Martinez C, Sempere C, Galar G, Alegre B. Serum free light chains in the screening of monoclonal gammopathies. Hematology Reports 2010;2(s2):B14a
Mollee P, Tate J, Weiss D, Solomon A. Assessment of a monoclonal antibody-based free light chain enzyme-linked immunosorbent assay (ELISA) and the polyclonal antibody based Freelite assay in AL amyloidosis. Amyloid 2010;17(s1):P-206a
Morabito F, De Filippi R, Cavalcanti S, Iaccarino G, Gentile M, Attolico I et al. Abnormal serum immunoglobulin free light chain (sFLC) ratio predicts therapy requirements and allows definition of a novel prognostic score system for patients with chronic lymphocytic leukemia (CLL). Hematology Reports 2010;2(s2):E52a
Morabito F, De Filippi R, Laurenti L, Zirlik K, Recchia AG, Gentile M et al. The total amount of kappa plus lambda serum immunoglobulin free light chains (sFLC κ + λ) is a powerful independent predictor of time to first treatment in chronic lymphocytic leukemia (CLL) and allows definition of a novel prognostic scoring system: a study of 449 therapy-naive patients. Blood 2010;116(21):2437a
Morabito F, Mazzone C, Gigliotti V, Caruso N, Madeo A, Recchia A et al. Flow cytometry evaluation of bone marrow plasma cells in monoclonal gammopathy of undetermined significance (MGUS): correlation with monclonal component, free light chain and magnetic resonance imaging. Haematologica 2010;95(s2):0938a
Morabito F, De Filippi RD, Gentile M, Iaccarino GI, Attolico I, Cutrona G et al. Abnormal immunoglobulin serum free light chains (sFLC) ratio is associated with unfavourable prognostic markers and is a predictor of treatment free survival (TFS) in chronic lymphocytic leukemia (CLL). Haematologica 2010;95(s2):0118a
Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010;376(9757):1989-99 PMID:21131037
Mori S, Crawford B, Roddy J, Phillips G, Elder P, Hofmeister C et al. Serum free light chains add to M-protein by immunofixation in response assessment in newly diagnosed patients with myeloma receiving novel therapies and may hold unique, a priori prognostic power prior to HDC/SCT. Hematology Reports 2010;2(s2):C24a
Morris C, Drake M, Apperley J, Iacobelli S, van BA, Bjorkstrand B et al. Efficacy and outcome of autologous transplantation in rare myelomas. Haematologica 2010;95(12):2126-33 PMID:20971818
Moscetti A, Saltarelli F, Bianchi MP, Monarca B, Bandiera G, De Biase L, La Verde G. Two cases of localised amyloidosis. Amyloid 2010;17(s1):P-200a
Moumas E, Desport E, Lacombe C, Gombert JM, Goujon JM, Bridoux F, Touchard G. Systemic AL amyloidosis with renal involvement in a region of western France. Amyloid 2010;17(s1):P-122a
Munshi NC, Lee S, Roodman GD, Behler C, Kambhampati S, Rose MG et al. Phase II multisite study to evaluate efficacy and safety of single weekly administration of bortezomib (BZ) and dexamethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients (pts). J Clin Oncol 2010;28(7s):TPS307a
Murata K, Clark RJ, Lockington KS, Tostrud LJ, Greipp PR, Katzmann JA. Sharply increased serum free light-chain concentrations after treatment for multiple myeloma. Clin Chem 2010;56(1):16-8 PMID:20040623
Murray DL, Theis JD, Vrana JA, Ramirez-Alvarado M, Abraham R, Dispenzieri A et al. Proteomic analysis of immunoglobulin light chains (LC) in AL amyloidosis shows that the sequence of clonal LC secreted by the neoplastic plasma cells is identical to the LC deposited in the amyloid plaques. Blood 2010;116(21):1909a
Nguyen ML, Patel AS. Images in clinical medicine. Plasmacytoma of the skull. N Engl J Med 2010;363(22):e33 PMID:21105787
Noorgahan N, Goyal M, Murthy S, Palanki D, Nirni S. Serum free light chain analysis correlation with serum protein electrophoresis in multiple myeloma - an Indian study. Hematology Reports 2010;2(s2):A6a
Nydegger U, Matozan K, Sakem B, Risch L. Side-effect prone components in IgG preparations: Anti-A and free light chains kappa and lambda. Presented at ESID Conference 2010
Palladini G, Dispenzieri A, Gertz MA, Wechalekar A, Hawkins P, Schonland SO et al. Validation of the criteria of response to treatment in AL amyloidosis. Blood 2010;116(21):1364a
Paudice N, Farsetti S, Caroti L, Ciuti G, Tempestini A, Perfetto F, Bergesio F. Severe intrahepatic cholestasis in systemic AL amyloidosis: early reversal after bortezomib therapy. Amyloid 2010;17(s1):P-166a
Pavan M, Ashwini KA, Ravi R, Suratkal LH. Complete remission of lambda light chain myeloma presenting with acute renal failure following treatment with bortezomib and steroids. Indian J Nephrol 2010;20(2):94-6 PMID:20835325
Pepperkok B, Zeuch A, Jehlicka-Rose R, Bartel J. Incidence and handling of antigen excess when measuring free light chains. Hematology Reports 2010;2(s2):A2a
Perlini S, Musca F, Salinaro F, Fracchioni I, Palladini G, Obiei L et al. Functional correlates of NT-proBNP response to therapy in cardiac AL amyloidosis. Amyloid 2010;17(s1):OP-083a
Piehler AP. Serum free light chains in multiple myeloma and related disorders. Presented at XXXII Nordic Congress in Medical Biochemistry 2010;039a.
Pinney JH, Lachmann HJ, Bansi L, Wechalekar AD, Gilbertson JA, Rowczenio D et al. Clinical outcome of systemic AL amyloidosis affecting the kidneys. Amyloid 2010;17(s1):OP-048a
Pinto A, Iaccarino G, Russo F, Amoroso B, Morelli E, Riemma C, De Filippi R. Clinical and biological relevance of serum free light chains (sFLC) assessment in patients with Hodgkin's lymphoma. Hematology Reports 2010;2(s2):p15
Pratt G. Serum free light chains in chronic lymphocytic leukaemia. Hematology Reports 2010;2(s2):p8
Pretorius CJ, Ungerer JPJ, Wilgen U, Klingberg S. Screening Panels for Detection of Monoclonal Gammopathies: Confidence Intervals. Clin Chem 2010;56(4):677-9 PMID:20110450
Qian Q, Leung N, Theis JD, Dogan A, Sethi S. Coexistence of myeloma cast nephropathy, light chain deposition disease, and nonamyloid fibrils in a patient with multiple myeloma. Am J Kidney Dis 2010;56(5):971-6 PMID:20870327
Qu X, Zhang L, Fu W, Zhang H, Xiang X, Qiu L, Hou J. An infrequent relapse of multiple myeloma predominantly manifesting as light chain escape: clinical experience from two Chinese centers. Leuk Lymphoma 2010;51(10):1844-9 PMID:20846099
Radocha J, Maisnar V, Sandecka V, Vavrova J, Spacilova J, Tichy M et al. Projekt MGUS 2010 - analyza dat 616 pacientu z registru RMG. Klin Biochem Metab 2010;18(39):80-2
Rajkumar SV, Kyle RA, Buadi FK. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc 2010;85(10):945-8 PMID:20884827
Richter AG, Harding S, Huissoon A, Drayson M, Pratt G. Multiple myeloma with monoclonal free IgG3 heavy chains and free kappa light chains. Acta Haematol 2010;123(3):158-61 PMID:20215741
Ricotta D, Di Noto G, Dossi A, Paolini L, Radeghieri A, Amoroso B, Caimi L. Internalization pathway of amyloidogenic serum free light chains. Hematology Reports 2010;2(s2):D40a
Rizzi R, Miccoolis R, Rinaldi E, Bonerba B, Manno C, Curci P et al. A case of AL amyloidosis associated with IgD multiple myeloma (MM): clinical and laboratory findings, and outcome. Amyloid 2010;17(s1):P-216a
Ruiz Ortiz de Arrizabaleta E, Teniente Serra A, Marín Sánchez A, Salvador Corres I, Sáez Bruguera M, Ester Codins A et al. Prevalence of monoclonal components in plasma donors in Catalonia. Hematology Reports 2010;2(s2):B15a
Saltarelli F, Bianchi MP, Moscetti A, Ferranti G, Capogreco F, Corsetti MT et al. Correlation between serum levels of free light chain and circulating cytokines in a patient with AL cardiac amyloidosis. Amyloid 2010;17(s1):P-196a
Sanchorawala V, Finn KT, Fennessey S, Shelton A, Doros G, Zeldis JB, Seldin DC. Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Blood 2010;116(11):1990-1 PMID:20847211
Sanchorawala V, Seldin DC, Quillen K, Finn KT, Sloan JM, Andrea NT et al. Modified high-dose melphalan and stem cell transplantation for AL amyloidosis: experience of 14 years. Amyloid 2010;17(s1):P-172a
Sanchorawala V, Quillen K, Sloan JM, Andrea NT, Finn KT, Seldin DC. Bortezomib and high-dose melphalan with stem cell transplantation for AL amyloidosis: a pilot study. Amyloid 2010;17(s1):P-183a
Sanchorawala V, Finn KT, Fennessey S, Shelton A, Dember LM, Zeldis JB et al. Durable haematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Amyloid 2010;17(s1):P-84a
Sauter A, Weisel K, Horger M. Imaging findings in relapsing multiple myeloma. Br J Haematol 2010;150(4):388 PMID:19344424
Sánchez-Castañón M, Gago M, Fernandez-Fresnedo G, Gomez-Alamillo C, Ruiz-Criado J, Lopez-Hoyos M, Arias M. Quantitative assessment of serum free light chains in renal transplantation. Transplant Proc 2010;42(8):2861-3 PMID:20970552
Sánchez-Castañón M, Gago M, Fernandez-Fresnedo G, Gómez C, Ruiz-Criado J, Lopez-Hoyos M, Arias M. Measurement of serum free light chains in renal transplantation. Hematology Reports 2010;2(s2):D41a
Schlüter B, Bonsmann G, Becker H, Willeke P. Serum free light chains and IgAκ/IgAλ ratios in patients with systemic inflammatory rheumatic diseases without monoclonal gammopathy. Hematology Reports 2010;2(s2):E48a
Schouten B, van Esch BC, van Thuijl AO, Blokhuis BR, Groot KT, Hofman GA et al. Contribution of IgE and immunoglobulin free light chain in the allergic reaction to cow's milk proteins. J Allergy Clin Immunol 2010;125(6):1308-14 PMID:20434201
Schroers R, Baraniskin A, Heute C, Kuhnhenn J, Alekseyev A, Schmiegel W et al. Detection of free immunoglobulin light chains in cerebrospinal fluids of patients with central nervous system lymphomas. Eur J Haematol 2010;85(3):236-42 PMID:20528903
Shao H, Xi L, Raffeld M, Pittaluga S, Dunleavy K, Wilson WH et al. Nodal and extranodal plasmacytomas expressing immunoglobulin A: an indolent lymphoproliferative disorder with a low risk of clinical progression. Am J Surg Pathol 2010;34(10):1425-35 PMID:20871216
Shimazaki C, Murakami H, Sawamura M, Matsuda M, Kinoshita T, Hata H et al. Clinical usefulness of serum free light chain measurement in monoclonal gammopathy. Rinsho Ketsueki 2010;51(4):245-52 PMID:20467220
Shimazaki C. [Progress in the management of multiple myeloma introduced by serum free light chain measurement]. Rinsho Ketsueki 2010;51(10):1491-8 PMID:20962483
Showell PJ, Buckley CJ, Mead GP. A single, latex-enhanced turbidimetric assay for total kappa and lambda free light chains in serum. Hematology Reports 2010;2(s2):A7a
Shum HP, Chan KC, Chow CC, Kho BC, Yan WW. Cast nephropathy with acute renal failure treated with high cut-off haemodialysis in a patient with multiple myeloma. Hong Kong Med J 2010;16(6):489-92 PMID:21135429
Sinclair D. Commentary. Clin Chem 2010;56(9):1392 PMID:20802099
Singh V, Cornell FF, Paruchuri S, Sala M, Saad A, Bredeson C et al. Patterns of serum free light chain (FLC) recovery after reduced intensity conditioning (RIC) allogeneic transplant for multiple myeloma (MM) predict long term outcomes. Blood 2010;116(21):1301a.
Singh V, Cornell R, Sala M, Paruchuri S, Saad A, Palmer J, Hari P. Free light chain recovery after reduced intensity allogenic transplant (RIC) for multiple myeloma (MM) - effect of chronic graft versus host disease (CGVHD) and progression. Hematology Reports 2010;2(s2):C29a
Sobh M, Morisset S, Guilli T, Ducastelle-Lepretre S, Fiorenza B, Chelghoum Y et al. Serum kappa/lambda ratio, an independent prognostic factor at diagnosis and serum free-light chains level, an early indicator of relapse/progression in multiple myeloma. Blood 2010;116(21):2954a
Sobh M, Morisset S, Guilli T, Ducastelle S, Barraco F, Chelghoum Y et al. Serum free light chains ratio: an independent prognostic factor for overall survival and progression free surivial in multiple myeloma. Hematology Reports 2010;2(s2):B18a
Solanki M, Dominic M, Hardy E. Comparison of throughput of free light chain assays with automated antigen excess detection on the Siemens BNII analyser™ and the Binding Site SPAPLUS. Hematology Reports 2010;2(s2):A1a
Solanki M, Matters D. Evaluation of parameters for measuring free immunoglobulin light-chains with automated antigen excess detection on the Siemens BNII analyser. Hematology Reports 2010;2(s2):A4a
Song L, Mistry N, Cross B. Laboratory detection of a nonsecretory multiple myeloma using free light chain assay and anti-free light chain immunofixation electrophoresis. Clin Chem 2010;56(6):D126a
Spencer A, Walker P, Asvadi P, Wong M, Campbell D, Reed K et al. A phase I study of the anti-kappa monoclonal antibody, MDX-1097, in previously treated multiple myeloma patients. J Clin Oncol 2010;28(7s):8143a
Stangou AJ, Rela M, Monaghan M, Mathia CJ, Mufti G, Heaton N, O'Grady J. Liver failure in association with hepatic amyloidosis and the role of liver transplantation: the King's College Hospital experience. Amyloid 2010;17(s1):P-204a
Stankowski-Drengler T, Gertz MA, Katzmann JA, Lacy MQ, Kumar S, Leung N et al. Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome. Am J Hematol 2010;85(6):431-4 PMID:20513121
Stratta P, Airoldi A, Izzo C, Rossi D, Gaidano GL. Free light-chains and renal disorders: when small is worse. Lancet 2010;376(9748):1221 PMID:20934589
Stringer S. Polyclonal FLC and chronic kidney disease. Hematology Reports 2010;2(s2):p6.
Suggate E, Levoguer A, Evans J, Legg A, Hughes R. The 6th International Symposium on clinical applications of serum free light chain analysis (plus Hevylite): meeting highlights. Clin Lab Int 2010;(December 2010/January 2011):34-6
Suvannasankha A, Farag S, Harding S, Durie BGM, Abonour R. Assessment of the performance of serum heavy chains immunoassay to monitor response to treatment and its correlation with other tumor measurements in serial samples from patients with newly diagnosed MM. Blood 2010;116(21):2986a
Talamo G, Castellani W, Dolloff NG. Prozone effect of serum IgE levels in a case of plasma cell leukemia. J Hematol Oncol 2010;3(1) PMID:20828419
Tate JR, Bazeley S, Sykes S, Hawley C, Mollee P. Serum free light chain anomalies in a case of light-chain cast nephropathy. Clin Chem 2010;56(6):D112a
Terrier B, Cacoub P. Hepatitis C virus and lymphoma development. Hematology Reports 2010;2(s2):p14
Testa A, Dejoie T, Lecarrer D, Wratten M, Sereni L, Renaux JL. Reduction of free immunoglobulin light chains using adsorption properties of hemodiafiltration with endogenous reinfusion. Blood purification 2010;30(1):34-6 PMID:20588010
Tsakiris DJ, Stel VS, Finne P, Fraser E, Heaf J, de MJ et al. Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study. Nephrol Dial Transplant 2010;25(4):1200-6 PMID:20037169
Turesson I. Guidelines on diagnosis and follow-up of Multiple Myeloma and MGUS. XXXII Nordic Congress in Medical Biochemistry 2010;038a.
Utz K, Neumon B, Frye BL, Chao J-H, Toro J, Haile D, Freytes C. Have clinicians adopted the International Uniform Response Criteria (IURC) for multiple myeloma (MM)? Adherence to the IURC for posttransplant evaluations in patients with multiple myeloma. Blood 2010;116(21):84a
van Gameren II, Bijzet J, Bos R, Limburg PC, Vellenga E, Hazenberg BPC. Measurable regression of systemic AL amyloid in fat tissue after response of serum free light chain. Amyloid 2010;17(s1):P-109a
Van Hoeven K, McNeill A, Bilotti E, McBride L, Schmidt L, Schillen D, Siegel D. Value of serum free light chain analysis in IgD and IgE multiple myeloma. Hematology Reports 2010;2(s2):B22a
Van Hoeven K, Bilotti E, McBride L, McNeill A, Schmidt L, Schillen D, Siegel D. Progressive clonal serum free light chain abnormalities prior to relapse of oligosecretory multiple myeloma (MM). Hematology Reports 2010;2(S2):C33a
Van Hoeven K, McBride L, Bilotti E, McNeill A, Schmidt L, Schillen D, Siegel D. Impact of serum free light chains on the anion gap in monoclonal gammopathies. Hematology Reports 2010;2(s2):A12a
van Rhee F. Light-chain MGUS: implications for clinical practice. Lancet 2010;375(9727):1670-1 PMID:20472153
van Vuuren MJ, Zemlin AE, Germishuys JJ. Monoclonal gammopathy and other serum protein electrophoresis patterns in patients with HIV infection in South Africa. Ann Clin Biochem 2010;47(Pt 4):366-74 PMID:20592336
Varettoni M, Corso A, Cocito F, Mangiacavalli S, Pascutto C, Zappasodi P et al. Changing pattern of presentation in monoclonal gammopathy of undetermined significance: a single-center experience with 1400 patients. Medicine (Baltimore) 2010;89(4):211-6 PMID:20616660
Varsi K, Aakre KM, Sandberg S. Targeted requesting followed by a specific laboratory test algorithm; a simple but expensive method for diagnosing monoclonal gammopathies. Presented at XXXII Nordic Congress in Medical Biochemistry 2010;006a
Vavrova J, Tichy M, Friedecky B, Maisnar V, Hajek R, Cermakova Z et al. Mezilaboratorni studie stanoveni volnych monoklonalnich lehkych retezcu imunoglobulinu (Inter-laboratory study for the measurement of free monoclonal light chain of immunoglobulins). Klin Biochem Metab 2010;18(39):73-6
Villar LM, Espino M, Alvarez-Cermeno JC. Role of kappa free index in predicting conversion of clinically isolated syndromes to multiple myeloma. Hematology Reports 2010;2(s2):B23a
Wadhera RK, Rajkumar SV. Prevalence of monoclonal gammopathy of undetermined significance: a systematic review. Mayo Clin Proc 2010;85(10):933-42 PMID:20713974
Waxman AJ, Kuehl M, Balakumaran A, Weiss B, Landgren O. Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future. Clin Lymphoma Myeloma Leuk 2010;10(4):248-57 PMID:20709660
Wechalekar AD, Harding S, Lachmann HJ, Gillmore JD, Wassef NL, Thomas M et al. Serum immunoglobulin heavy/light chain ratios (Hevylite) in patients with systemic AL amyloidosis. Amyloid 2010;17(s1):P-186a
Wechalekar AD, Merlini G, Gillmore JD, Russo P, Lachmann HJ, Perlini S et al. N-terminal fragment of brain natriuretic peptide (NT-ProBNP) – a new response criterion in AL amyloidosis. Amyloid 2010;17(s1):OP-081a
Wechalekar AD, Kastritis E, Merlini G, Hawkins PN, Dimopoulos MA, Gillmore JD et al. A European collaborative study of treatment outcomes in 428 patients with systemic AL amyloidosis. Blood 2010;116(21):988a
Weiss BM, Kuehl WM. Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma. Expert Rev Hematol 2010;3(2):165-74 PMID:20473362
White D, Gardner N, Harding S, Provot F, Beuscart JB, Cook M et al. Failure to remove polymerised immunoglobulin free light chains by high cut-off haemodialysis. Hematology Reports 2010;2(s2):D38a
White DA, Gardner N, Harding S, Stang H, Gisslinger H, Perkmann T, Naides SJ. Monoclonal IgM proteins can cause abberant nephelometric free light chain results making data interpretation difficult. Hematology Reports 2010;2(s2):A3a
Willenbacher W, Gastl G, Prokop W, Willenbacher E. Serum and urine free light chain monitoring compared to conventional SPE: an update on usefulness and pitfalls in "real life haematology". Hematology Reports 2010;2(s2):C26a
Witteles W, Witteles R, Liedtke M, Arai S, Lafayette R, George TI, Schrier SL. AL amyloidosis and concomitant myeloma: time to reconsider assumptions. Blood 2010;116(21):4044a
Wiwanitkit V. Nonsecretory multiple myeloma, how to make a diagnosis? Indian J Orthop 2010;44(1):112 PMID:20165688
Wood PB, McElroy YG, Stone MJ. Comparison of serum immunofixation electrophoresis and free light chain assays in the detection of monoclonal gammopathies. Clin Lymphoma Myeloma Leuk 2010;10(4):278-80 PMID:20709664
Yegin ZA, Ozkurt ZN, Yagci M. Free light chain : A novel predictor of adverse outcome in chronic lymphocytic leukemia. Eur J Haematol 2010;84(5):406-11 PMID:20059535

2011

American Society of Hematology. Asymptomatic myeloma/MGUS. Hematology web focus 2011
Adam Z, Stepankova S, Sirotkova A, Cermakova Z, Pour L, Krejci M et al. [Kidney failure in a patient with chronic B-lymphocytic leukaemia (B-CLL) with underlying cast nephropathy. The value of free immunoglobulin light chain identification for early diagnosis of this complication]. Vnitr Lek 2011;57(2):214-21 PMID:21416862
Adams D, Lozeron P, Theaudin M, Ribrag V, Bourhis JH, Lacroix C. [New elements in the diagnosis and the treatment of primary AL amyloid polyneuropathy and neuropathy due to POEMS syndrome.]. Rev Neurol (Paris) 2011 Jan;167(1):57-63 PMID:21190703
Aggarwal R, Sequeira W, Kokebie R, Mikolaitis RA, Fogg L, Finnegan A et al. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity. Arthritis Care Res 2011 PMID:21312346
Baweja S, Wiggins K, Lee D, Blair S, Fraenkel M, McMahon LP. Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach. J Artif Organs 2011;14(1):9-22 PMID:21153038
Bird JM, Owen RG, D'sa S, Snowden JA, Pratt G, Ashcroft J et al. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 2011 PMID: 21569004
Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J et al. International Myeloma Working Group (IMWG) consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem-cell transplantation. Blood 2011
Chiche L, Cournac JM, Mancini J, Bardin N, Thomas G, Jean R et al. Normalization of serum-free light chains in patients with systemic lupus erythematosus upon rituximab treatment and correlation with biological disease activity. Clin Rheumatol 2011 PMID:21221683
de Larrea CF, Tovar N, Cibeira MT, Arostegui JI, Rosinõl L, Elena M et al. Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents. Haematologica 2011;96(1):171-3 PMID:20884709
Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San MJ, Chanan-Khan A et al. Guidelines for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011 PMID:21292778
Elliott BM, Peti S, Osman K, Scigliano E, Lee D, Isola L, Kostakoglu L. Combining FDG-PET with laboratory data yields superior results for prediction of relapse in multiple myeloma. Eur J Haematol 2011 PMID:21198866
Gertz MA, Buadi FK, Hayman SR. IgM Amyloidosis: clinical features in therapeutic outcomes. Clin Lymphoma Myeloma Leuk 2011;11(1):146-8 PMID:21454218
Harding S, Provot F, Beuscart JB, Cook M, Bradwell AR, Stringer S et al. Aggregated serum free light chains may prevent adequate removal by high cut-off haemodialysis. Nephrol Dial Transplant 2011 PMID:21406545
Haznedar R, Aki SZ, Akdemir OU, Ozkurt ZN, Ceneli O, Yagci M et al. Value of (18)F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging 2011 PMID:21287167
Holding S, Spradbery D, Hoole R, Wilmot R, Shields ML, Levoguer AM, Dore PC. Use of serum free light chain analysis and urine protein electrophoresis for detection of monoclonal gammopathies. Clin Chem Lab Med 2011;49(1):83-8 PMID:20961192
Hutchison, C. A. and Bridoux, F. Renal impairment in multiple myeloma: time is of the essence. J Clin Oncol 29(11), e312-e313 PMID:21343553
Kaplan B, Livneh A, Sela BA. Immunoglobulin free light chain dimers in human diseases. ScientificWorldJournal 2011;11:726-35 PMID:21442150
Kim YI, Kim HR, Shin MG, Lee YJ, Shin JH, Suh SP, Ryang DW. Donor cell origin of multiple myeloma occurring after allogeneic haematopoietic stem cell transplantation in a patient with refractory anaemia with ring sideroblast. J Clin Pathol 2010;64(3):265-268 PMID:21177746
Korde N, Kristinsson SY, Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood 2011 PMID:21441462
Kumar SK, Gertz MA, Lacy MQ, Dingli D, Hayman SR, Buadi FK et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc 2011;86(1):12-8 PMID:21193650
Landgren O, Rajkumar SV. Development of early treatment strategies for high-risk myeloma precursor disease in the future. Semin Hematol 2011;48(1):66-72 PMID:21232660
Landgren O, Kyle RA, Rajkumar SV. From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention. Clin Cancer Res 2011;17(6):1243-52 PMID:21411440
Laubach J, Richardson P, Anderson K. Multiple myeloma. Annu Rev Med 2011;62:249-64 PMID:21090965
Lavatelli F, Brambilla F, Valentini V, Rognoni P, Casarini S, Di SD et al. A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum. Biochim Biophys Acta 2011 PMID:21215335
Legg A, Suggate E, Levoguer A, Evans J, Hughes R. Clinical applications of serum free light chain analysis: from leeches to light chains. The Biomedical Scientist 2011;(January 2011):30-2
Leleu XP, Xie W, Bagshaw M, Banwait R, Leduc R, Roper N et al. The role of serum immunoglobulin free light chain (sFLC) in response and progression in Waldenstrom Macroglobulinemia (WM). Clin Cancer Res 2011 PMID:21415221
Levinson SS. Regarding the overestimation of serum κ free light chains. Clinical Chemistry 2011;57(5):775-777 PMID:21303911
Levoguer A, Hughes R. Myeloma screening for the 21st century. Clin Lab Int 2011;(February/March)
Li C, Geng H, Yang Z, Zhong R. Influence of immunoglobulin light chain dimers on the results of the quantitative nephelometric assay. Clin Lab 2011;57:53-7 PMID:21391465
Li J, Zhang W, Jiao L, Duan MH, Guan HZ, Zhu WG et al. Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome. Blood 2011 PMID:21393478
Lopes da SR, Monteiro A, Veiga J. Non-secretory multiple myeloma relapsing as extramedullary liver plasmacytomas. J Gastrointestin Liver Dis 2011;20(1):81-3 PMID:21451803
Maisnar V, Tichy M, Stulik J, Vavrova J, Friedecky B, Palicka V et al. The problems of proteinuria measurement in urine with presence of Bence Jones protein. Clin Biochem 2011 PMID:21291878
Maurer MJ, Micallef IN, Cerhan JR, Katzmann JA, Link BK, Colgan JP et al. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. J Clin Oncol 2011 PMID:21383282
Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011 PMID:21292777
Ozsan GH, Dispenzieri A. Serum free light chain analysis in multiple myeloma and plasma cell dyscrasias. Expert Rev Clin Immunol 2011;7(1):65-73 PMID:21162651
Paiva B, Martinez-Lopez J, Vidriales MB, Mateos MV, Montalban MA, Fernandez-Redondo E et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol 2011 PMID:21402611
Paiva B, Vidriales MB, Perez JJ, Lopez-Berges MC, Garcia-Sanz R, Ocio EM et al. The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in AL amyloidosis. Blood 2011
Palladini G, Merlini G. Transplantation vs. conventional-dose therapy for amyloidosis. Curr Opin Oncol 2011;23(2):214-20 PMID:21178616
Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364(11):1046-60 PMID:21410373
Paulus A, Swaika A, Miller KC, Spangenthal EJ, Guo R, Vonfricken K et al. Clinical relapse in a patient with multiple myeloma presenting as an atrial plasmacytoma. J Clin Oncol 2011;29(3):e47-e49 PMID:20956627
Pinney JH, Lachmann HJ, Bansi L, Wechalekar AD, Gilbertson JA, Rowczenio D et al. Outcome in Renal AL Amyloidosis After Chemotherapy. J Clin Oncol 2011 PMID:21220614
Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011;86(1):57-65 PMID:21181954
Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011 PMID:21292775
Reed V, Shah J, Medeiros LJ, Ha CS, Mazloom A, Weber DM et al. Solitary plasmacytomas: Outcome and prognostic factors after definitive radiation therapy. Cancer 2011 PMID:21437886
Ronco P, Plaisier E, Aucouturier P. Monoclonal immunoglobulin light and heavy chain deposition diseases: molecular models of common renal diseases. Contrib Nephrol 2011;169:221-31 PMID:21252522
Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Loet XL et al. B-cell activation biomarkers as predictive factors of the response to rituximab in rheumatoid arthritis. Arthritis Rheum 2011;63(4):933-8 PMID:21225699
Sène D, Jallouli M, Lefaucheur J-P, Saadoun D, Costedoat-Chalumeau N, Maisonobe T et al. Peripheral neuropathies associated with primary Sjögren syndrome. Medicine 2011;90(2):133-8
Shah J, Blade J, Sonneveld P, Harousseau JL, Lantz K, Londhe A et al. Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression. Cancer 2011 PMID:21328327
Trotta MP, Lorenzini P, Bibas M, Galli M, Rizzardini G, Narciso P et al. Relative prognostic value of serum-free light chains and effective HAART in predicting HIV-associated lymphoma and mortality. Presented at CROI 2011
Uljon SN, Richardson PG, Schur PH, Anderson KC, Tanasijevic MJ, Lindeman NI. Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myeloma. Clin Chim Acta 2011;412(7-8):562-8 PMID:21144845
Vavrova J, Maisnar V, Tichy M, Friedecky B, Cermakova Z, Dastych M et al. Interlaboratory study of free monoclonal immunoglobulin light chain quantification. Clin Chem Lab Med 2011;49(1):89-92 PMID:21034251
Wirk B. Renal failure in multiple myeloma: a medical emergency. Bone Marrow Transplant 2011 PMID:21339749
Zangari M, Yaccoby S, Pappas L, Cavallo F, Kumar NS, Ranganathan S et al. A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica 2011;96(2):333-6 PMID:20952514
Zingone A, Kuehl WM. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma. Semin Hematol 2011;48(1):4-12 PMID:21232653

Chapter 30

Back to Contents Page

Chapter 32

Serum free light chain publications

From Wikilite

Contents

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

Views

Personal tools

Search

Toolbox